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Site-directed mutagenesis was used to characterize structural requirements for 
receptor-effector coupling of the pm2 muscarinic receptor (mAchR) expressed in Chinese 
hamster ovary (CHO) cells. Single amino acid substitutions in the third intracellular loop 
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alanine in amino acid position 212 of the third intracellular loop (i3) was replaced with 
glutamate, oxotremorine M-mediated coupling to phosphatidyl inositol (PI) hydrolysis 
resulted in responses similar to the partial agonist pilocarpine. This finding indicates that 
there are agonist specific conformations promoted by different ligands used to activate 
receptor coupling to effector systems. Mutation of a positively charged lysine in amino 
acid position 214 of i3 to alanine (K214A) resulted in a receptor that coupled to 
stimulation of PI metabolism via a G-protein insensitive to ADP-ribosylation by pertussis 
toxin (PTX). While 100 ng/ml PTX is sufficient to completely uncouple wild-type mAchR 
from effector systems, 1000 ng/ml failed to abolish coupling of K214A to stimulation of 
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For my grandparents, who gave of themselves to their families. Their example will 
not be forgotten. PREFACE 
I have always been interested in signal transduction. How does a cell gather 
information from its environment and convert it into useful information?  More 
importantly, once the information is gathered, how does a cell determine a meaningful 
response? Clearly, understanding these processes in a single cell is a daunting task. 
In order to better understand regulation of these events, reductionist approaches 
are often employed. This may mean that processes are studied in broken cell preparations, 
membrane preparations or with purified components, or that it  is studied in a cellular 
environment, intact living cells. Unfortunately, these cellular environments may introduce 
factors, that are not easily controlled and that reduce clarity when attempting to interpret 
experiments. Whatever the approach used, it is important to recognize the dependence of 
the experiments (and hence interpretation) on the context in which the experiment was 
conducted. 
The research conducted for this thesis focused on two areas. The first, was an 
attempt to relate structural changes in the pm2 muscarinic acetylcholine receptor (mAchR) 
with functional effects. Although it is relatively easy to make 'structural' changes in this 
receptor using site-directed mutagenesis, it is not easy to evaluate the effects of these 
changes. Few membrane bound proteins have been purified and crystallized, making 
interpretation of mutagenesis studies a very difficult task. In addition, with no direct 
measure of agonist-promoted conformational effects, in addition to the lack of structural 
information, analysis relies on expression and functional evaluation of the receptor in cells that do not normally express the mAchR. This approach has led to the second focus of 
this thesis research. 
Results obtained on functional coupling of the mutated receptor to effector 
systems are complicated by several factors. These include (1) receptor density achieved in 
the different clonal cell lines (2) dependence on the cell lines selected to express the 
mAchR (3) subtle differences in the clonal lines established and (4) the expression of 
endogenous factors that may modulate functional expression of the mutated receptors. 
These factors point out the importance of considering the context in which the receptors 
are expressed, and necessitates careful analysis of results obtained using these expression 
systems. MUSCARINIC RECEPTOR-EFFECTOR COUPLING IN CHINESE  
HAMSTER OVARY CELLS 
Chapter 1 
Introduction 
Historical Overview 
The concept of agonist-receptor interactions were implicit in the work of Claude 
Bernard and Paul Erlich in the second half of the 19th century, but it was J. N. Langley 
(1852-1926) of Cambridge University that coined the term "Receptor" or "receptive 
substance". (Limbird, 1986). Langley extended the concept that chemical signal 
transmission was responsible for the effects of curare and nicotine at the neuromuscular 
junction, and qualitatively described receptor selectivity, saturability, and mutual 
antagonism. In 1921, Loewi (Brown and McDonough, 1989) definitively showed that 
acetylcholine was transmitted chemically when fluid from the vagal endings of one 
stimulated frog heart was shown to have a physiological effect on a second, unstimulated 
heart. 
In the 1920's, A. J. Clark began to quantitatively describe the qualitative 
observations made by his predecessors. Clark postulated that ligand-receptor interactions 
obey the principles of mass action, and could therefore be described mathematically. 2 
These relationships are discussed below in greater detail within the context of the 
muscarinic acetylcholine receptor. 
Role of Receptors 
Receptors in general serve the simple purpose ofensuring that a specific signaling 
molecule is recognized and that its 'signal' is transduced in a relevant way (Siegel et al., 
1989). Membrane receptors serve the additional purpose of transducing the signal of an 
extracellular ligand into an intracellular physiological response.  This avoids the 
requirement that the ligand be capable of passing through a hydrophobic plasma 
membrane, and often results in an amplification of signals initiated by ligands at low 
concentrations. Some receptors interact with addition signal transduction machinery to 
effect their function. Specifically, seven-transmembrane receptors interact with G-proteins 
as well as effector proteins, providing three levels of interactions that can be modulated by 
the cellular environment (Gudermann et al., 1996). 
A number of mechanisms have evolved to ensure that cellular responsiveness is 
maintained under conditions of constant bombardment ofextracellular signals. Elevated 
expression of receptor ensures that cells maintain maximal sensitivity to chemical signals at 
low concentrations (Limbird, 1986). If these ligands are in excess, cells have evolved 
mechanisms of receptor desensitization and internalization to dampen the second 
messenger responses (Liggett, 1995). While these regulatory processes are elegant and 
far more complex than we have previously appreciated,  information can be gained about 3 
certain aspects of the signal transduction pathway via a reductionist approach (Cooper et 
al., 1986). 
Site-directed mutagenesis and receptor overexpression in exogenous cellular 
environments have been utilized to learn more about the molecular mechanisms of 
receptor-mediated signal transduction. Cells are capable of expressing receptors for 
numerous signal transduction pathways, including tyrosine kinase/growth factor receptors 
and ligand gated ion channels. We have focused on a single family ofmembrane bound 
receptors, those coupled to activation of effectors via guanine nucleotide binding proteins. 
More specifically, one member of this family, the m2 muscarinic acetylcholine receptor, 
has been studied in detail using site-directed mutagenesis and expression in Chinese 
hamster ovary cells in order to better understand the molecular properties of signal 
recognition and transduction. 
G-protein coupled receptors 
Muscarinic receptors are in the family of G-protein coupled receptors (Figure 1.1). 
Members of this family have several common features. They each have seven putative 
transmembrane domains with the N-terminus located extracellularly and the C-terminus 
located in the cytosol. Each serves to transduce the signal carried by an extracellular 
ligand, into a cellular response via a guanine-nucleotide binding protein, or G-protein 
(Gudermann et al., 1996). The ligands are diverse, and can be peptides such as 
neurokinin, angiotensin or endothelin, or small neurotransmitters such as epinephrine, 4 
acetylcholine and dopamine. Signal transduction is mediated via a common pathway 
though, through G-proteins. Figure 1.2 shows the agonist-promoted receptor activation 
of G-proteins, and possible effector systems that are activated. 5 
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Figure 1.1: Diagram of the G-protein coupled receptor. 
Common features of members of this family include seven transmembrane 
domains, alternating extracellular and cytosolic loops, an extracellular N-terminus and an 
intracellular C-terminus. 6 
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Figure 1.2: Receptor/G-protein activation cycle. 
Activation of G-proteins are mediated by agonist (L) binding to the membrane-
bound receptor. The activated G-proteins results in the dissociation of GDP and the 
binding of GTP. This exchange results in dissociation of the Gas subunit from 13y, allowing 
the GTP bound a subunit as well as the f3y subunit to activate effectors. 7 
Role of G-proteins 
G-proteins serve to transduce and amplify the signal carried by an extracellular 
ligand. After binding to the exposed surface of the receptor, the ligand presumably 
induces a change in receptor conformation which results in activation of a membrane 
delimited, heterotrimeric G-protein. It is not clear if the receptor is pre-coupledwith this 
G-protein, or if agonist binding promotes receptor interaction with the G-protein. It is 
clear that agonist binding results in activation of the G-protein by a receptor-mediated 
change in G-protein heterotrimer conformation (Birnbaumer, 1990). 
Once the activated or ligand bound receptor activates the G-protein, the 
heterotrimer dissociates into a and 13y subunits. The change in G-protein conformation 
alters the affinity of the a subunit for bound GDP. The GDP dissociates, and is replaced 
with GTP which is at higher concentration in the cytosol. In addition, the activated Ga 
subunit may have a higher affinity for GTP than GDP. This activated Ga is capable of 
activating effector enzymes such as adenylyl cyclase and phospholipase C. Intrinsic 
GTPase activity of the Ga subunit results in conversion of GTP to GDP, re-association 
with f3y subunits, and conversion of the active Ga subunit into the inactive form of the 
heterotrimer (Birnbaumer, 1990). The dissociated 13y subunits are also capable of 
activating effector systems, although their importance in cellular signaling has only 
recently been appreciated. 8 
Diversity of Ga subunits 
The Ga subunits of the G-protein heterotrimer have many functions in signal 
transduction and cellular signaling. There are at least 30 identified a-subunits to date 
(Simon et al., 1991), characterized by sequence similarity, their effect on effector enzymes 
and their sensitivity to bacterial toxins. The Gas family of Ga subunits activate adenylyl 
cyclase activity and are sensitive to ADP-ribosylation by cholera toxin, which functions to 
block GTP hydrolysis thereby activating members of this family in the absence of ligand 
activated receptor. Members of this family include transducin and two forms of Gas. 
The Gai subunits mediate inhibition of adenylyl cyclase, stimulation of 
phosphatidyl inositol metabolism and activation of inward rectifying K+ channels. In 
addition, this family is sensitive to ADP-ribosylation by pertussis toxin, which results in a 
Ga subunit that cannot be activated by liganded receptor. This family includes three 
primary subtypes, Gai 1, Gai2 and Goci3. Other members include PTX sensitive Gao, 
Gag (gustaducin) and Gat (transducin). In addition, transducin, which is found in retinal 
rods and cones, is also sensitive to ADP ribosylation by cholera toxin. Finally, Gaz, 
which is found primarily in brain is not sensitive to bacterial toxins. 
The Gaq subunit family is insensitive to ribosylation by bacterial toxins, and 
mediates activation of phospholipid metabolism, including phospholipase C, D and A2, 
although it is unclear if activation is via a direct or an indirect mechanism. Members of 
this family include Gaq, Gal 1, Ga14, Ga 15 and Ga16. A less well characterized family 
of Ga subunits include Ga.12 and Ga13, both of which are found ubiquitously, although 9 
their function is unclear. Table 1.1 summarizes all of the known Ga subunits identified to 
date. 
Since it is relatively easy to group these families of Ga subunits according to 
functional activation of effectors, it was always believed that G-protein specificity was 
conferred by the a subunits. Recent evidence indicates a larger role than previously 
appreciated, for the fry subunits. In addition, the specific combination of fry subunits 
appear to have large roles in determining the nature of the receptor-mediated activation of 
second messenger responses (Gudermann et al., 1996; Kleuss et al., 1991; Kleuss et al., 
1993). 10 
Table 1.1: Identified Got subunits. 
Family  Toxin Sensitivity  Receptors  Effectors 
Gail,2,3  PTX  m2/m4, a2AR, D2  a 
Gao  PTX  a2AR  a 
Gaz  none  m2  b 
Gag  PTX  taste receptors  c 
Gat  CTX/PTX  rhodopsin  d 
Gas  CTX  I3AR, TSH, D1, NK1  e 
Gaolf  CTX  olfactory receptor  f 
Gaq  none  ml, a1 AR  g 
Gall  none  g 
Ga14  none  g 
Ga15  none  g 
Ga16  none  g 
Ga12  none  g 
Ga13  none  g 
a K+ and Ca2+ channels, inhibition of adenylyl cyclase and stimulation of phospholipase C and A2 
b Inhibition of adenylyl cyclase 
c unknown 
d Stimulation of cGMP specific phosphodiesterase 
e Stimulation of adenylyl cyclase, Ca2+ and Na+ channels 
f Stimulation of adenylyl cyclase 
g Stimulation of phospholipase C 11 
13T subunits 
The fly subunits appear to have numerous direct functions as well as more subtle 
modulatory functions in the cell (Neer, 1994; Neer, 1995). There are at least five 
identified 0 and six identified y subunits (Neer, 1995). Table 1.2 summarizes the 3 and y 
subunits identified to date. The roles of these subunits have been much more difficult to 
characterize for a variety of reasons. First, there are no markers such as bacterial toxin 
sensitivity that would simplify assessing the role of the subunits. Secondly, the fry subunits 
associate very tightly, and it is difficult to purify and characterize them independently of 
one another. In addition, since they are found ubiquitously in mammalian cells, results 
obtained with expression systems may be difficult to interpret since endogenous subunits 
are uncharacterized. 
Second messenger systems 
The superfamily of G-protein coupled receptors consists of a large number of 
receptor families, each comprised of multiple subtypes, that converge on a limited number 
of known second messenger effector systems. The common features of each of these 
families of receptors are (1) they each span the plasma membrane seven times, with an 
extracellular N-terminus and a cytosolic C-terminus (2) they transduce and amplify 
signaling by extracellular ligands and (3) their actions are mediated through guanine-
nucleotide binding proteins or G-proteins. 12 
Interestingly, there is a large redundancy in functional coupling by each of the 
receptor families. In other words, numerous receptors, or receptor subtypes from multiple 
families of GPCRs converge on coupling to the same effector systems (Gudermann et al., 
1996). For example, members of the adrenergic, muscarinic, dopaminergic and 
serotoninergic families of GPCRs all couple to inhibition of adenylyl cyclase (Figure 1.3). 
Since the known G-protein a subunits are limited, the regulation of signaling pathways 
must be a complex cellular process, and may be dependent on simultaneous events that are 
competing with one another for resources (Neer, 1994; Neer, 1995). Alternatively, 
parsimony may dictate that cells regulate these complex signaling pathways by simply 
controlling expression of receptors, effectors, G-proteins or other necessary players in the 
signal transduction pathway. In addition, regulation may be made simpler by localizing the 
relevant players in the signaling pathways to delimited areas of the plasma membrane. 
Finally, the interactions of receptor with heterotrimeric G-proteins may be regulated to an 
extent by the expression and availability of specific combinations of 13y subunits. Although 
one or all of these alternatives are likely to play a role in the regulation of signal 
transduction (Gudermann et al., 1996), their importance has only recently been 
appreciated, and are now being explored in more detail (Neer, 1994; Neer, 1995). 
Before we can consider all of the possible interactions between receptor signaling 
and control of effector coupling, it is necessary to briefly outline the receptor families, 
their coupling specificity, and the G-protein heterotrimer requirements when known. 
Although it is impossible to provide all of the information known for GPCRs, the most 13 
commonly studied are presented with the assumption that within these families, all or most 
of the known signaling pathways will be discussed. 
Adrenerqic receptors 
There are two subfamilies of adrenergic receptors, the 13 and a adrenergic 
receptors ((3AR and aAR respectively). There are at least three subtypes of f3 631, (32, 
and (33) and at least two subtypes of a adrenergic receptors (al and a2). While the DAR 
receptors couple to stimulation of adenylyl cyclase, the aAR couple to either stimulation 
or inhibition of adenylyl cyclase or stimulation of PI metabolism depending on the subtype. 
Members of the adrenergic receptor family interact with both Gsa and Gia G-protein 
subunits. 
Muscarinic receptors 
The muscarinic receptors can be divided into five subtypes, ml through m5. In 
general, the odd numbered subtypes (ml, m3 and m5) couple to stimulation of PI 
metabolism through PTX insensitive G-proteins, presumably a member of the Gq family. 
On the other hand, m2 and m4 appears to couple through PTX-sensitive G-proteins, Gi or 
Go to inhibit adenylyl cyclase. In addition, when m2 is expressed in CHO cells, coupling 
to both an inhibition and a stimulation of adenylyl cyclase is observed (Ashkenazi et al., 
1989; Ashkenazi et al., 1987). The stimulatory phase is not sensitive to PTX, although the 
molecular mechanism mediating this response is not clear. Further details on the porcine 
m2 acetylcholine receptor are provided below. 14 
Dopamine receptors 
Dopamine is a catecholamine that is synthesized via the same pathway as 
epinephrine and norepinephrine. Dopaminergic cells express tyrosine hydroxylase and 
DOPA decarboxylase but lack the additional enzymes required to convert dopamine to 
norepinephrine and epinephrine. 
Receptors for dopamine are classified as D1 or D2, depending on whether or not 
coupling is to stimulation (D1) or inhibition (D2) of adenylyl cyclase. In addition, the D2 
receptor subtype has been shown to be expressed in either long (D2long) or short 
(D2short) forms. 
Serotoninerqic receptors 
Receptors that bind serotonin (5-HT) couple to inhibition (5-HT1, forms A, B, D, 
E and F) or stimulation (5-HT drosophilal) of adenylyl cyclase. In addition, serotonin 
receptor subtypes 5-HT2, 1C and 2F couple to stimulation of PI metabolism. 
Peptide G-protein coupled receptors 
There are several peptide receptors that are members of the GPCR family. These 
include receptors for endothelin, neurokinin, neuropeptide Y, cholecystokinin, thrombin, 
ACTH, and bradykinin (Birnbaumer, 1990). One common feature of the peptide 
receptors is a large N-terminus, which plays an important role in ligand binding (Strader et 
al., 1994). The peptide GPCR are capable of coupling to all effector systems discussed 
thus far. 15 
Basic Structure of G-protein coupled receptors 
Several domains of G-protein coupled receptors have been reported to be 
important in ligand binding. For peptide receptors, the large N-terminus as well several 
transmembrane domains play important roles. For G-protein coupled receptorsthat bind 
neurotransmitters, the second, third and seventh transmembrane domains are most 
important in determining ligand binding properties (Jackson, 1991; Strader et al., 1987; 
Strosberg, 1991). 
The important domains for receptor-effector coupling is reported to include the 
second and third intracellular loops as well as the C-terminus. Most studies localize the 
major determinants to the N- and C- termini of the third intracellular loop (i3) (Wess et al., 
1990; Wess et al., 1989). Large portions of the central part of this loop can be deleted 
without complete loss of functional coupling (Shapiro and Nathanson, 1989). In addition, 
replacement of an acidic amino acid residue in the second transmembrane domain results 
in complete loss of agonist-mediated activation of effectors. This residue is conserved 
across all families of G-protein coupled receptor as either an aspartic acid or glutamic 
acid. Conversion of this amino acid to asparagine or glutamine results in loss of coupling 
(Bihoreau et al., 1993; Fraser et al., 1989; Hu et al., 1992; Rose et al., 1995; Wang et al., 
1991; Wang et al., 1993). 16 
Cloning and Muscarinic receptor subtypes  
Muscarinic Receptor Subtypes 
Five subtypes of the muscarinic acetylcholine receptor have been cloned and 
characterized (Bonner et al., 1987; Kubo et al., 1986; Peralta et al., 1987). The odd 
numbered subtypes, ml, m3 and m5 couple to stimulation of PI metabolism while the even 
numbered subtypes, m2 and m4 couple to inhibition of adenylyl cyclase. In addition, the 
porcine m2 couples to stimulation of PI metabolism when expressed in Chinese hamster 
ovary cells (Ashkenazi et al., 1987). 
Functional Coupling of the subtypes 
The pm2 muscarinic acetylcholine receptor couples to inhibition of adenylyl 
cyclase via pertussis toxin (PTX) sensitive G-proteins. PTX functions to ADP ribosylate 
the a subunits of Gi and Go, leading to receptor/G-protein uncoupling. Treatment of cells 
with 100 ng/ml PTX results in complete loss of agonist-mediated activation of effector 
systems (Bulseco and Schimerlik, 1996). Chinese hamster ovary cells do not appear to 
express Go (Dr. Janet Robishaw, unpublished results), which limits the interaction of pm2 
to either Gai1,2 or 3. Others have shown that pm2 expressed in CHO cells preferentially 
interacts with Gai2 and Gai3 (Dell'Acqua et al., 1993). 
When m2 AchR is expressed in CHO cells, coupling to stimulation of adenylyl 
cyclase is also observed. The mechanism mediating this response is not clear, but it is not 17 
mediated by phospholipase C or Ca2+, or Gaq mediated events (Vogel et al., 1995). 
Others have proposed that this activation of adenylyl cyclase is due to coupling to Gas at 
high agonist concentrations (Eason et al., 1992). 
Structure-function studies of the muscarinic receptor 
Much of the structural information obtained for G-protein coupled receptors is 
inferred from experiments with site-directed mutants. Conclusions can be drawn about 
ligand binding properties once membranes are prepared from cell homogenates, but 
information obtained on receptor-effector coupling properties in whole cells may be 
difficult to interpret without taking into consideration the cell type used for receptor 
expression, and the receptor densities achieved in these systems. The following discussion 
will focus on information relating receptor structure to three basic propertiesligand 
binding, receptor-effector coupling and affects on desensitization/internalization 
properties. 
Ligand binding 
The ligand binding pocket appears to be formed by a ring-like arrangement of the 
seven transmembrane domain (Hulme et al., 1990). Several critical amino acid residues 
are proposed to interact with the ligand in this conserved hydrophilic cavity (Brann et al., 
1993; Wess, 1993). A critical aspartic acid residue in the third transmembrane domain has 
been shown to be important in ligand binding (Brann et al., 1993; Hulme et al., 1990; 18 
Wess, 1993). Affinity labeling with antagonist and agonist mustards indicate that this 
residue interacts with the ammonium headgroup of muscarinic ligands. Site-directed 
mutagenesis of the rat ml AchR implies that this aspartic acid residue is critical for proper 
ligand binding (Fraser et al., 1989). In addition, this residue has also been shown to be 
important for ligand binding in the (3-adrenergic receptor (Strader et al., 1987). 
Proline residues conserved in the fourth through seventh transmembrane domains 
are believed to introduce bends in the transmembrane helices (Hulme et al., 1990; Wess, 
1993). This combination of straight and kinked transmembrane domains may be important 
for the proper agonist-induced conformational changes. One proline in transmembrane 
VII of ml is believed to play an indirect role in agonist binding.  Mutating this proline to 
alanine resulted in a receptor with 80 to 400 times lowered affinity for agonists (Wess et 
al., 1993). Helix wheel models proposed places this proline facing the hydrophobic lipid 
environment rather than the ligand binding pocket, so any affect on ligand binding may be 
indirect, perhaps via an affect on receptor conformation. 
A series of conserved serine, threonine and tyrosine residues are located in the 
transmembrane domains of all muscarinic receptors. It has been proposed that the 
hydroxyl groups on these side chains function to interact with the acetylcholine ester 
moiety (Brann et al., 1993; Wess et al., 1991; Wess et al., 1992; Wess et al., 1993). 
Mutations of a threonine and tyrosine located in transmembrane domains V and VI 
respectively had the most dramatic effect on ligand binding affinities (Brann et al., 1993) 
but tyrosine residues of transmembrane III, VI and VII were also required for high affinity 
acetylcholine binding (Wess, 1993). 19 
Two conserved cysteine residues on the extracellular loops 1 and 2 appear to form 
a disulfide bridge that is important in receptor stabilization (Hulme et al., 1990). Although 
reduction of this disulfide results in receptor with reduced affinity for both agonists and 
antagonists, the effect appears to be at the level of protein stability and/or conformation 
rather than a direct interaction with muscarinic ligands. 
Receptor-effector coupling 
Ligand-mediated receptor activation of G-proteins appears to require several 
intracellular domains of GPCRs. The third intracellular loop (i3), or "loop 5-6" connects 
the fifth and sixth transmembrane domains. This loop is highly variable in size, and within 
a receptor family, is conserved among receptor subtypes. Specifically, the N-terminal and 
C-terminal portions of i3 appear to be important in determining coupling properties. 
The third intracellular loop of G-protein coupled receptors plays an important role 
in the regulation of receptor-effector coupling. Deletion analysis of i3 of the ml AchR 
indicates that the middle 126 amino acids are not necessary for agonist-mediated 
stimulation of PI metabolism (Shapiro and Nathanson, 1989). When the entire i3 along 
with part of the fifth transmembrane region were switched in ml/m2 chimeric receptors 
and expressed in oocytes, the chimera exhibited the cellular response properties of the 
subtype that contributed the loop (Kubo et al., 1988). 
The first 15-20 amino acid residues of the N-terminal region of i3 appear to 
determine G-protein specificity (Lechleiter et al., 1990; Wess et al., 1990; Wess et al., 
1990; Wess et al., 1989). Wess et al (1990) expressed m2 /m3 chimeric receptors in A9L 20 
cells where the first 16 residues of m2 or 17 residues of m3 were swapped. The m3 /m2-
16 residue chimera did not couple to PI hydrolysis but did weakly inhibit the formation of 
cAMP via a PTX sensitive G-protein. The m2/m3-17 residue chimera on the other hand, 
coupled to PI hydrolysis by a PTX insensitive G-protein while coupling to the inhibition of 
adenylyl cyclase occurred through a PTX sensitive G-protein (Wess et al., 1990). 
Although the N- and C- termini of i3 are rich in charged residues, the distribution 
of charge does not appear to be essential for efficient coupling to G-proteins. 
Replacement of residues conserved in the ml/m3 functional family with those conserved in 
the m2/m4 subtype family did not alter coupling of the human ml AchR to PI metabolism 
(Arden et al., 1992). The converse experiment (replacement of m2/m4 residues with 
ml/m3 conserved residues) supports this finding, but further suggests slight effects on G-
protein coupling with no apparent effect on cellular response (Bulseco and Schimerlik, 
1996). 
In addition to intracellular loops, one transmembrane mutant appears to have 
identified a critical amino acid residue involved in transducing a receptor conformation 
change upon ligand binding, into activation of G-proteins. Changing a single aspartic acid 
in the second transmembrane domain of GPCRs to asparagine consistently abolishes 
coupling of ligand activated receptor to effector systems, and presumably to activation of 
G-proteins. These mutations have been made in the ml and m2 muscarinic, the 132 
adrenergic, ct2 adrenergic, dopamine D2, 5-HT1 and 5-HT2A, endothelin, neurokinin -1 
and angiotensin II receptors (Bihoreau et al., 1993; Brodbeck et al., 1995; Ceresa and 
Limbird, 1994; Fraser et al., 1989; Hu et al., 1991; Neve et al., 1991; Strader et al., 1987; 21 
Strader et al., 1987; Wang et al., 1991). Antagonist binding is consistently unaffected. 
Agonist binding has been affected differently depending on the receptor system, and in 
some cases, specific agonists display an increase in affinity while others show a reduction. 
In addition, guanine nucleotide sensitivity is not consistently observed for the receptor 
systems in which this was studied. 
Desensitization and internalization 
Several domains of GPCRs appear to be important for agonist-mediated 
internalization and desensitization. Most of the site-directed mutagenesis has focused on 
regions of potential phosphorylation sites, with specific consensus sequences of specific 
kinases considered. Protein Kinase A, Protein Kinase C and G-protein coupled receptor 
kinase (GRK) appears to phosphorylate different regions of the a2A adrenergic receptor 
(Liggett, 1995). 
The C-terminal end of GPCRs appear to be important for phosphorylation by PKC 
and PKA. These kinases appear to affect slower processes of receptor downregulation 
and desensitization. Phosphorylation by the G-protein coupled receptor kinases appear to 
mediate a rapid uncoupling of the receptor from effector systems. 
The third intracellular loop appears to be the site of phosphorylation for the GRK 
family of kinases. These kinases include the 0-adrenergic receptor kinases ((SARK) as 
well as a number of G-protein receptor kinases that are numbered in order of discovery. 
GRK2 (or (3ARK1) appears to phosphorylate the m2 AchR in vivo, when expressed in 
COS cells (Tsuga et al., 1994). 22 
Summary 
Agonist binding to the muscarinic receptor is believed to trigger conformational 
changes in the transmembrane helices which are transmitted to the cytosolic loops that 
interact with G-proteins. While specific domains are often discussed, it is clear that 
changes in domains thought to be important in ligand binding (e.g. transmembrane 
domains) also participate in efficient coupling to effector systems. Likewise, mutations in 
the "G-protein coupling domain" are likely to also have effects on ligand binding while not 
affecting the ligand binding domain directly. These alterations may reflect modest changes 
in receptor conformation or alterations in agonist-induced conformation resulting in 
changes in receptor activation of G-proteins. Therefore, this implies that conformational 
changes of the receptor may involve the concerted contributions of several amino acid 
residues simultaneously making assignment of a specific G-protein coupling domain 
difficult. 
This premise is supported by the finding that an aspartic acid in the second 
transmembrane region, conserved in almost all G-protein coupled receptors (Probst et al., 
1992) is critical for the proper agonist-induced receptor conformation that is required to 
couple to G-proteins and effector systems. Mutating this aspartic acid in ml AchR 
adrenergic and dopamine receptors (Fraser et al., 1989; Neve et al., 1991; Strader et al., 
1989; Strader et al., 1987) as well as the pm2 AchR (Chapter 3) resulted in the elimination 
of coupling. 23 
The porcine m2 muscarinic acetylcholine receptor  
Expression in CHO cells 
Clones of wild-type and mutant pm2 mAchR were stably transfected into Chinese 
hamster ovary cells and expression amplified by increasing the concentration of 
methotrexate. Overexpression in CHO cells allowed the characterization of receptor-
effector coupling properties in intact cells, as well as isolation of large quantities of 
membranes enriched in muscarinic acetylcholine receptor. 
Expression of pm2 mAchR in CHO cells resulted in several experimental problems. 
It is not easy to isolate clonal cell lines expressing similar receptor densities. Since 
properties of functional coupling are dependent on receptor density (Vogel et al., 1995; 
Whaley et al., 1994), effective characterization relies on our ability to normalize responses 
for receptor density. This required that receptor density be reduced with the slowly 
dissociated antagonist, / -QNB. 
Coupling to second messenger systems 
The porcine m2 muscarinic acetylcholine receptor expressed in CHO cells couples 
to inhibition of adenylyl cyclase and stimulation of PI metabolism via pertussis toxin 
sensitive G-proteins (Ashkenazi et al., 1989; Ashkenazi et al., 1987). In addition the pm2 
mAchR also couples to stimulation of adenylyl cyclase at high agonist concentrations. 
The mechanism of adenylyl cyclase activation has not yet been determined, but does not 24 
appear to be mediated via Gocq or Ca2+ dependent processes (Vogel et al., 1995).  The 
pm2 mAchR also couples to other effector systems including modulation of ion channels 
(Hulme et al., 1990; Nathanson, 1987) and nitric oxide (NO) mediated elevation of cGMP 
(Bauer et al., 1994; Vila Echague et al., 1994). 25 
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Summary 
The N-terminus of the third cytoplasmic loop of the porcine m2 muscarinic 
receptor plays an important role in receptor-effector coupling. While large changes in 
coupling properties are easily detected, subtle changes are often overlooked. Three 
mutant receptors were characterized after expression in Chinese hamster ovary cells, and 
two of these exhibited subtle changes in coupling properties. Substitution of amino acids 
219-223 (KDKKE) with those conserved in the m1,3,5 receptor subtype family (ELAAL) 
had little effect on coupling to effector systems indicating that altering the charge 
distribution in this region did not affect receptor-G-protein interactions. Substitution of 
Ala with Glu at amino acid position 212 (A212E) or Lys with Ala in position 214 
(K214A) resulted in receptors with IC50 for inhibition of adenylyl cyclase that resembled 
wild-type although maximal percent inhibition was reduced. All mutants moderately 
decreased coupling to PI metabolism but mutant A212E caused oxotremorine-M to 
become a weak partial agonist compared to carbachol suggesting that receptor 
conformation is agonist-dependent even for ligands normally thought of as full agonists. 
K214A coupled to PI metabolism through both PTX-sensitive and PTX-insensitive G-
proteins. These results indicated that these mutants superficially possessed effector 
coupling characteristics similar to wildtype, but upon more detailed examination G-
protein-receptor interactions were altered. 27 
Introduction 
mAchRs' mediate intracellular responses through coupling to heterotrimeric 
guanine nucleotide-binding proteins. They are members of a large family of G-protein 
coupled receptors that possess seven hydrophobic transmembrane regions connected by 
alternating intracellular and extracellular loops with ligand binding domains located within 
the transmembrane regions. Five unique subtypes of mAchRs (ml-m5) have been cloned 
and characterized (Bonner et al., 1987; Kubo et al., 1986; Peralta et al., 1987). The odd 
numbered subtypes (ml, m3 and m5) stimulate phospholipid metabolism while the even 
numbered subtypes (m2 and m4) preferentially couple to inhibition of adenylyl cyclase 
(Hulme et al., 1990). The m2 subtype also couples to the inward rectifying K±-channel in 
the heart. The m2 muscarinic receptor subtype couples to both inhibition of adenylyl 
cyclase and stimulation of PI metabolism when expressed in CHO cells (Ashkenazi et al., 
1987). 
Guanine nucleotide-binding proteins that mediate the actions of mAchRs can be 
distinguished by their sensitivity to ADP ribosylation by PTX. The m2 mAchR couples to 
inhibition of adenylyl cyclase and stimulation of PI hydrolysis in CHO cells via G-proteins 
with differing PTX sensitivities (Ashkenazi et al., 1987). When ml and m3 receptor 
subtypes are expressed in CHO cells, they couple to stimulation of PI hydrolysis either 
through both PTX-sensitive and insensitive G-proteins or via a G-protein with 
intermediate sensitivity (Ashkenazi et al., 1989). These results indicate that different 
mAchR subtypes are capable of evoking similar physiological responses by coupling 
through different G-proteins in the same cell line. Chimeras of i3 or the N-terminal 28 
portion of i3 made with the radrenergic and m2 receptors indicate that promiscuous 
receptor G-protein coupling occurs with both PTX sensitive and PTX insensitive G-
proteins when the wrong i2 is included (Wong and Ross, 1994). 
The N-terminal and C-terminal regions of i3 have been shown to play important 
roles in regulation of receptor coupling to G-proteins and activation of effector systems 
for both the muscarinic (Lechleiter et al., 1990; Wess et al., 1990; Wess et al., 1989) 
(Bonner, 1992; Dixon et al., 1987) and p-adrenergic receptors .  For the mAchR, the first 
15-20 N-terminal residues of i3 are sufficient to determine selective coupling to G-
proteins. Wess et al. (Wess et al., 1990) used chimeric m2/m3 receptors stably expressed 
in A9 L cells to show that the first 17 N-terminal residues of i3 from the m3 mAchR 
rendered the m2 subtype PTX-insensitive for coupling to PI metabolism while PTX-
sensitive inhibition of adenylyl cyclase was retained. This finding suggests that the 
selectivity determinant for receptor-G-protein interaction lies within the first 17 N-terminal 
amino acid residues. This domain of i3 is proposed to have a-helical secondary structure 
and best correlates with the second messenger preferences exhibited by the odd and even 
numbered receptor subtypes in this region (Bonner, 1989; Hulme et al., 1990). Arden et 
al. (Arden et al., 1992) reported that substitution of three N-terminal i3 residues (the 5th, 
7th and 12th) from ml mAchRs (Glu, Lys and Glu) with residues found in the m2 subtype 
(Ala, Lys and Lys) did not alter the characteristics of carbachol-mediated m1 mAchR 
coupling to PI hydrolysis. In this mutant, the charge distribution was changed to that seen 
in the m2 mAchR which couples to inhibition of adenylyl cyclase by a PTX-sensitive G-
protein. Blum] et al (Bliiml et al., 1994a; Bliiml et al., 1994b) showed that a critical Tyr at 29 
the in the N-terminal of i3 was necessary for efficient coupling to PI hydrolysis. Carbachol 
was the only agonist utilized in these studies and PTX-sensitivity was not assessed. 
In the experiments presented below, pm2 mAchRs with mutations in charged 
residues at the N-terminus of i3 were characterized using carbachol as well as other full 
and partial agonists (Vogel et al., 1995). The results of these experiments suggest that 
even single amino acid mutations in this region may subtly affect ligand binding behavior 
as well as the manner in which mutant receptors interact with G-proteins. Alterations in 
G-protein specificity can be as dramatic as selectively changing the behavior of a full 
agonist to a partial agonist for PI stimulation but not inhibition of cAMP formation or as 
subtle as altering the sensitivity of a response to uncoupling by PTX, suggesting 
interaction with additional G protein(s). Taken together, these results emphasize the 
difficulty in assigning precise "structural" domains in i3 of the pm2 mAchR without 
thorough receptor characterization. 
Materials and Methods 
Materials 
[3H] / -QNB (43 Ci/nunol), [3H]NMS (79 Ci/mmol), and [31-I]myo-inositol (17.8 
Ci/nunol) were purchased from Du Pont-New England Nuclear. Carbachol and atropine 
were purchased from Aldrich Chemical Company and 1 -QNB, NMS, oxo M, 
acetylcholine and pilocarpine from Research Biochemicals International. Glass fiber filters 
were from Schleicher and Schuell (#32) or Whatman (GF/B). Restriction enzymes and T4 
DNA polymerase were from Promega, Gibco-Bethesda Research Laboratories or New 30 
England Biolabs. The mammalian expression vector (pSVE) and the clone for the wild-
type pm2 mAchR were gifts from Genentech, Inc. dhfr- CHO cells were obtained from 
America Type Culture Collection (Rockville, MD). Pertussis toxin was from List 
Biological Laboratories and Ro20-1724 from Bio Mol Research Labs. 
Site Directed Mutacienesis and Expression 
Site-directed mutagenesis was carried out as described by the mutagenesis 
procedure of BioRad. After cloning the gene for the pm2 mAchR into the Hind III-EcoRI 
sites of the polylinker region of ml3mp18, uracil containing single stranded DNA was 
annealed to mutagenic primers. The primers for A212E (5'-
CCTGCTCTTACTTTCCCGGGATATGTGC-3') and K214A (5'-
GTCCTTCTTAATTCTAGAGGCACTGGCTCGGGA-3') were designed to introduce a 
single amino acid change as well as new restriction enzyme sites to facilitate screening for 
mutants. The mutagenic oligonucleotide primer 5'-
CTCCTTAATCCTGCTCTCACTCTCCCGGGATATGTGCCA-3' was designed to 
replace five amino acids in position 219 through 223 (KDKKE(219-223)ELAAL). After 
mutant clones were identified, the mutations were confirmed by dideoxy DNA sequencing 
(Sanger et al., 1977). 
The Hind III-EcoRI fragment containing the pm2 mAchR coding region was 
isolated from ml3mpl8 Rf DNA by agarose gel electrophoresis and subcloned into the 
multiple cloning region of the expression vector, pSVE (Peralta et al., 1987). Mutant pm2 
mAchR-pSVE constructs were transfected into dhfr- CHO dhfr-cells by calcium 31 
phosphate precipitation. Cells expressing recombinant receptor were grown in selective 
media (modified D-MEM low in glycine and thymine) with 10% dialyzed calf serum, 100 
mg/ml insulin and methotrexate. Increasing concentrations of methotrexate resulted in 
amplification of receptor expression. 
Receptor expression was assessed in whole cells on tissue culture dishes by the 
addition of 10 nM [3H] l -QNB or [3H]NMS in the presence or absence of 100 mM 
atropine or 1 mM unlabeled l -QNB. Cells were incubated for 1.5 hours at 37°C, then 
washed twice with ice cold phosphate buffered saline, pH 7.4. Cells were solubilized with 
1 ml of 1% triton X-100 in PBS, then counted for tritium. Once receptors were 
expressed, membranes were prepared and binding of ligands assayed as described below. 
Membrane Preparation and Ligand Binding 
Suspension cultures were grown in MFD at 37°C in spinner culture flasks. Cells 
were harvested and the pellet resuspended in two volumes of homogenization buffer (250 
mM sucrose, 50 mM EDTA, 25 mM imidazole buffer, pH 7.4) containing benzamidine, 
soybean trypsin inhibitor, and pepstatin A at final concentrations of 1 mg/ml. The cell 
suspension was homogenized with a polytron homogenizer, PTA 10S probe, for 2x20 sec 
at 4°C under argon and cell membranes were prepared by sucrose gradient centrifugation 
as previously described (Peterson and Schimerlik, 1984). In some cases, 5 mM sodium 
butyrate was added 24 hours before harvesting cells to further enhance receptor 
expression. Untreated and butyrate-treated cultures resulted in membrane preparations 
with specific activities of 20 to 300 pmol NMS sites/mg protein. All ligand binding 
experiments were conducted in buffer containing 10 mM HEPES, 5 mM MgC12, 1 mM 32 
EDTA, 1 mM EGTA, pH 7.4 at 25°C by displacement of either [3H] l -QNB or [3H]NMS. 
Samples were filtered through glass fiber filters and washed with 3X 4 ml of ice cold 50 
mM Na phosphate buffer pH 7.4. When [3H]NMS was used, the glass fiber filters were 
treated with 0.1% (w/v) PEI before use. Nonspecific binding was determined in the 
presence of 10-4 M /-hyoscyamine and was less than 10% of the total radiolabel bound. 
Assays for Effector Coupling 
Stably transfected CHO cells expressing wild-type or mutant pm2 mAchRs were 
assayed in 24 well dishes for agonist-stimulated PI metabolism. Cells were plated at an 
initial density of 2.0 x 105 cells per well in Dulbecco's Modified Eagle Medium (D-MEM) 
with F-12 Nutrient Mixture (Gibco/Bethesda Research Laboratories), 10% calf serum 
(Sigma) and after addition of 0.5 ml of media containing 1 1.1.Ci/m1 [3H]- myo- inositol per 
well, incubated at 37°C for 24 hours. IP1 accumulation was measured as described by 
Lee et al. (Lee et al., 1990) thirty minutes after addition of ligands. To maximize fold 
stimulation of PI metabolism when constructing PTX dose-response curves (Figure 5), 
rpl accumulation was measured fifty minutes after carbachol addition. 
Assays for inhibition of forskolin-stimulated cAMP levels were conducted on CHO 
cells expressing wild-type or mutant receptors by a modification of the Salomon method 
(Salomon, 1979). Cells were plated on 35 mm tissue culture dishes and grown to a final 
density of 1.0 x 106 cells per plate. Prior to the assay for cAMP, cells were incubated with 
[311]-adenine (1 j.iCi/m1) for 2 hours in the presence of 0.5 mM Ro 20-1724 at 37°C in D-
MEM + F12 Nutrient Mixture. Total tritium labeled cAMP was separated with successive 
columns of AG50W-X4 resin (BioRad) and Alumina (Sigma). The cAMP was eluted 33 
from the alumina columns directly into scintillation vials with 4 ml of 0.1 M imidazole 
buffer, pH 7.4, and samples counted in a liquid scintillation counter. In specific 
experiments, PTX was added 6 to 12 hours prior to the assay to give the appropriate final 
concentration. 
Initial experiments indicated that in CHO cells expressing wild-type pm2 mAchR 
over the range of 105 to 2 x 106 receptors per cell the IC50, but not the maximal inhibition 
for cAMP formation and the maximal fold stimulation, but not the EC50, for PI stimulation 
were dependent on the number of receptors per cell (Vogel et al., 1995). Thus it was 
necessary to compare the IC50 for adenylyl cyclase inhibition and the maximal fold 
stimulation of PI metabolism of mutants with wild-type cell lines containing an 
approximately identical number of receptors per cell. After many attempts, it was not 
possible to isolate an appropriate distribution of cell lines nor was it possible to reduce 
wild-type receptor number sufficiently with the alkylating agent benzilylcholine mustard, 
which was able to maximally remove about 90% of the surface sites from wild-type pm2 
mAchR cell lines expressing 1-2 x 106 sites/cell. An alternative approach in which 
receptor number was reduced by addition of various amounts of the slowly dissociating 
antagonist /-QNB was utilized.  After an hour, the plates were rinsed twice with media to 
remove any free l -QNB. The physiological assays were then initiated with the appropriate 
agonists and the average numbers of surface receptors per cell determined by addition of 
[3H]NMS in the presence or absence of 10-4M l- hyoscyamine. Plots of IC50 (for 
inhibition of cAMP formation) and fold maximal response (for PI stimulation) versus pm2 
receptors/cell were made and the appropriate wild-type parameter determined from the 34 
standard curves and used for comparison with the values for mutants expressing receptors 
at the same receptor number per cell. Parameters for mutant receptors were compared to 
wild-type pmt mAchR expressed at the appropriate receptor density (Tables 2 and 3). 
Data Analysis 
Functional assays and agonist ligand binding data were analyzed using non-linear 
least squares curve-fitting in Origin (Micro Cal Software, Inc.). Data from effector 
coupling assays were either fit to the logistic equation (1) for PI assays or equation (2) for 
cAMP assays. 
(B-A)
Y = A +  (1)
1 + (C/[x])D  
(B-A)  (E-A) 
Y = A +  +  (2)
1 + (C/[x])D  1 + ([x]/F)G 
For each of these equations, [x] is the ligand concentration, A and B (or E) the 
minimum and maximum plateaus of the curve, C the EC50 for PI or adenylyl cyclase 
stimulation, F the IC50 for adenylyl cyclase inhibition and D (or G) the Hill coefficient or 
slope factor. The logistic equation is customarily used to evaluate dose-response curves 
(Barlow and Blake, 1989). Competition displacement curves were fit according to a mass 
action model for receptor-ligand interactions at three independent classes of sites 
(equation 3, below) as described in Tota et al. (Tota et al., 1987). 
(F1)  (F2)  (1 - Fl - F2)  1 
Y = ( 11 ) r K - ,  1 + [L]/K + [I]/Ki  1 + [L]/K + [I]/K2  1 + [L]/K + [I]/K3 i 35 
In equation 3, Y is the fractional saturation of the receptor and [L] is the free 
concentration of antagonist used in the experiment with dissociation constant K. [I] is the 
total concentration (assumed to equal the free concentration since significant displacement 
does not occur until [I total] >> [total receptor]) of the competing agonist with 
dissociation constants K1, K2, and K3. F1, F2 and F3 are the corresponding fractions of 
total binding sites where F3 = I - Fi - F2. Antagonist binding was analyzed using 
Scatchard plots (Scatchard, 1949). 
Results 
Expression of pm2 AchR in CHO cells 
The pm2 mAchR constructs in pSVE were stably transfected into dhfr- CHO cells 
and amplified by growing in the presence of increasing concentrations of methotrexate. 
The wild-type pm2 cell line expressed 1.2 x 106 total receptors per cell, while A212E, 
K214A and KDKKE(219-223)ELAAL expressed 3.0 x 105, 3.8 x 105, and 1.0 x 106 
receptors/cell respectively. Comparison of specific [3H]NMS versus [3H] /-QNB binding 
indicated that wild-type and KDKKE(219-223)ELAAL expressed 100% of their receptors 
on the cell surface and A212E and K214A about 70% to 80%. 
Ligand binding characteristics 
The ligand binding properties of pm2 mutants and wild-type receptor are 
summarized in Table 2.1. The affinity of [3H] /-QNB was within a factor of two for the 
mutants compared to wild-type while [3H]NMS binding was weaker to the mutants by 36 
three to five fold. Thus the antagonist binding properties of the mutants for these two 
ligands were affected in the mutant pm2 receptors, but not very strongly. 
Agonist binding data for wild-type pm2 mAchR for carbachol, acetylcholine and 
oxo M were consistent with fits to three independent classes of sites (K1, K2 and K3) while 
pilocarpine data were best fit by assuming two classes of sites (i.e. K2 = K3). Agonist 
binding properties were affected in a selective manner by specific mutations. The 
mutation A212E appears to reduce the affinity of the pm2 mAchR for acetylcholine but 
not carbachol, and slightly increased the affinity for oxo M. The mutation K214A 
increased the affinity for oxo M by five to 27 fold. The mutation KDKKE(219-
223)ELAAL also increased the affinity for oxo M at the low and intermediate affinity sites 
and for carbachol at the high affinity site by factors of eight to 10 fold. The binding 
properties of the partial agonist pilocarpine were essentially unaffected for the three 
mutants. 37 
Table 2.1 Ligand Binding Properties of Mutant pm2 mAchRsa 
Antagonists 
/-QNB  NMS 
PKa (M)  n  PKa (M)  n 
wildtype 
A212E 
K214A 
KDKKE(219-223)ELAAL 
4.68 ± 0.04 
4.5 1 0.1 
4.6 ± 0.1 
*4.33 ± 0.04 
3 
6 
3 
6 
8.9 ± 0.1 
*8.1 ± 0.1 
*8.4 ± 0.1 
*8.3 ± 0.1 
3 
4 
3 
2 
Agonists 
PK1 (M)  PK2 (M)  PK3 (M)  F1  F2 
Carbachol 
wildtype 
A212E 
K214A 
KDKKE(219- 223)ELAAL 
8.110.2 
8.310.1 
*8.4210.02 
*9.010.2 
5.610.3 
5.310.1 
6.010.1 
5.710.2 
4.310.1 
4.410.2 
*5.10.1 
*4.511 
0.2010.05 
0.2110.02 
0.3110.02 
0.2510.04 
0.5210.10 
0.3110.14 
0.4810.03 
0.5010.07 
4 
3 
4 
4 
Acetylcholine 
wildtype 
A212E 
K214A 
KDKKE(219- 223)ELAAL 
9.310.1 
*8.010.2 
8.910.2 
9.511.1 
6.610.2 
*5.30.1 
6.710.1 
*7.210.3 
5.210.1 
*4.4±0.2 
5.910.2 
5.410.3 
0.3610.02 
0.2510.09 
0.3710.08 
0.1210.06 
0.5210.03 
0.5410.25 
0.3210.08 
0.3910.07 
2 
4 
2 
5 
Oxotremorine-M 
wildtype 
A212E 
K214A 
KDKKE(219- 223)ELAAL 
8.310.1 
8.310.3 
*9.010.1 
8.2±0.1 
6.110.1 
6.710.6 
*6.7610.03 
*7.7±0.1 
4.710.2 
*5.210.1 
*6.210.2 
*5.7±0.1 
0.1710.05 
0.2310.01 
0.1510.01 
0.25±0.02 
0.1310.08 
0.5010.02 
0.57±0.08 
0.4±0.03 
3 
4 
4 
2 
Pilocarpine 
wildtype 
A212E 
K214A 
KDKKE(219- 223)ELAAL 
6.610.2 
6.810.1 
6.610.2 
6.510.2 
4.910.3 
5.610.1 
5.210.2 
5.610.2 
0.29 ± 0.11 
0.53 ± 0.12 
0.52 ± 0.05 
0.20 ± 0.04 
0.71 ± 0.11 
0.47 ± 0.10 
0.48 ± 0.09 
0.80 ± 0.10 
3 
2 
2 
2 
a Values represent the mean ± S.D. of 2-4 experiments. 
* Significantly differs (p50.05) from pm2 wild-type mAchR. 38 
Stimulation of PI metabolism 
Data comparing the coupling of wild-type and mutant pm2 mAchRs to stimulation 
of PI is summarized in Figures 2.1, 2.2 and Table 2.2. Carbachol, acetylcholine and oxo 
M stimulated accumulation of IP1 up to 2 fold over basal levels in cells expressing wild -
type pm2 mAchRs. EC50s for these agonists were 1.7 1.1.M, 0.4 1.1.M and 0.30 1AM 
respectively. The maximal fold stimulation values reported for wild-type pm2 mAchRs are 
those estimated from the standard curve at 3.0 x 105, 3.8 x 105 and 1.0 x 106 receptors per 
cell respectively and mutant pm2 mAchRs at their respective receptor densities. 
Compared to wildtype, the mutant pm2 mAchRs stimulated PI hydrolysis with 
EC50s that are selectively altered, depending on the ligand and mutant. Wild-type 
receptor, A212E, K214A and KDKKE(219-223)ELAAL display EC50s of 1.7 p.M, 2.6 11 
M, 4.2 I.LM and 6.6 AI respectively when carbachol is the agonist, with maximal percent 
stimulation of 60-72%, 66%, 85% and 98%. These findings indicate that these mutants 
have little or no effect on carbachol mediated coupling to PI metabolism. 
Acetylcholine and oxo M appear to have different effects on the coupling of 
mutants to stimulation of PI metabolism than carbachol. While K214A coupled to PI 
metabolism with an EC50 approximately 10 fold higher than wild-type for acetylcholine, 
the EC50 for oxo M did not significantly differ. This is also observed for KDKKE(219-
223)ELAAL but not A212E. 39 
Although A212E shows high affinity binding to both carbachol and oxo M (Table 
2.1), oxo M does not stimulate PI hydrolysis in the same manner as other ligands. 
Carbachol gave maximal fold stimulation of 1P1 formation at levels similar to wild-type 
with an EC50 of 2.6 1.J.M. On the other hand, both acetylcholine and oxo M behaved like 
partial agonists for PI stimulation (Figures 2.1, 2.2, 2.3 and 2.4), although maximal 
inhibition of cAMP formation was similar to carbachol (Table 2.3; Figures 2.4, 2.5 and 
2.6). Maximum fold stimulation significantly differed from wild-type for both of these 
agonists (Table 2.2) and the EC50 significantly increased for acetylcholine. The response 
for oxo M was consistently too low to determine this parameter accurately. 40 
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Figure 2.1: Agonist stimulation of PI hydrolysis by wild-type pm2 mAChR 
Experiments were conducted as described in Experimental Procedures. Data are 
presented as fold stimulation of PI hydrolysis over basal levels of released inositol 
monophosphates. The data shown are representative of 3-6 experiments with each agonist 
concentration done in duplicate. Curves were derived from a least squares fit to equation 
1 and average values for EC50 and maximal fold stimulation are summarized in Table 2.2 
Wild-type pm2 mAchR, were expressing 1.2x106 receptors/cell. The fitted parameters 
were: EC50 = 4.9 ± 1.4  1.6 fold; EC50 = 0.59 ± 0.09 gM, 1.6 fold; EC50 = 0.24 ± 
0.02 AM, 1.7 fold; and EC50 = 1.4 ± 1.9 ;AM, 1.2 fold for carbachol, oxo M, acetylcholine 
and pilocarpine respectively. Slope factors used were 1.0 for carbachol, and 0.5 for oxo 
M, acetylcholine and pilocarpine. 41 
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Figure 2.2: Agonist stimulation of PI hydrolysis by A212E mutant mAchR. 
Experiments were conducted as described in Experimental Procedures. Data are 
presented as fold stimulation of PI hydrolysis over basal levels of released inositol 
monophosphates. The data shown are representative of 3-6 experiments with each agonist 
concentration done in duplicate. Curves were derived from a least squares fit to equation 1 
and average values for EC50 and maximal fold stimulation are summarized in Table 2.2. 
A212E m2 mAchR mutant, 3x105 receptors/cell with fitted parameters: EC50 = 7.1 ± 3.9 
1AM, 1.7 fold; EC50 = 2.0 ± 0.3712M, 1.3 fold; EC50 = 0.17 ± 0.07 uM, 1.4 fold; and ECso 
= 24.0 ± 16.1 piM, 1.2 fold for carbachol, oxo M, acetylcholine and pilocarpine 
respectively. Slope factors were 1.0 for carbachol and acetylcholine and 0.5 for oxo M and 
pilocarpine. 42 
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Figure 2.3: Normalized agonist-mediated maximum stimulation of PI hydrolysis for 
wild-type and mutant mAchRs. 
Experiments were conducted as described in Experimental Procedures.  Data are 
presented as the ratio of agonist-mediated maximal response relative to carbachol for each 
receptor mutant. Expression levels are 1.2x106 receptors/cell for pmt mAchR, and 
3.0x105, 3.8x105 and 1.0x106 receptors/cell for A212E, K214A and KDKKE(219-
223)ELAAL respectively. The data shown are 2-10 experiments done in duplicate (± 
SD). Pilocarpine stimulated PI hydrolysis between 64% and 83% of carbachol stimulated 
levels, while oxo M and acetylcholine stimulated 90% to 110%. The one exception was 
oxo M for A212E which maximally stimulated PI hydrolysis at 79% of carbachol 
0.05) are marked with *. stimulated levels. Statistically significant differences (p 5_ 43 
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Figure 2.4: Normalized agonist-mediated maximum stimulation of PI hydrolysis and 
maximum inhibition of adenylyl cyclase. 
Experiments were conducted as described in Experimental Procedures. Data are 
presented as the ratio of agonist-mediated maximal response relative to carbachol for each 
receptor mutant. Expression levels are 1.2x106 receptors/cell for pmt mAchR, and 
3.0x105, 3.8x105 and 1.0x106 receptors/cell for A212E, K214A and KDKKE(219-
223)ELAAL respectively. The data shown are 2-9 experiments done in duplicate (± SD). 
All agonists inhibited cAMP formation between 75% to 100% of carbachol inhibition. 
Statistically significant differences (p 5 0.05) are marked with *. 44 
To compare the relative efficacy of each agonist for mutant receptors, maximal 
stimulation offP1 accumulation and maximal inhibition of adenylyl cyclase were 
normalized to values obtained for carbachol (Figures 2.3 and 2.4). Pilocarpine stimulated 
PI hydrolysis between 64% and 83% of carbachol stimulated levels, while oxo M and 
acetylcholine stimulated 90% to 110% compared to carbachol for all receptors 
characterized. The one exception was oxo M for A212E which maximally stimulated PI 
hydrolysis at 79% of carbachol stimulated levels. While the observed maximal stimulation 
by acetylcholine significantly differed from wild-type for A212E (Table 2.2, Figures 2.1 
and 2.2), it did not appear to differ significantly from carbachol stimulated levels for this 
mutant (Figure 2.3). 45 
Table 2.2 Mutant pm2 mAchR Coupling to Stimulation of Inositol Phospholipid 
Metabolism 
A2onists 
log EC50 (M)  Maximal Fold Stimulation  n 
Carbachol 
a wildtype  5.8 ± 0.2  (1.60, 1.63, 1.72)b 
A212E  5.6 ± 0.3  1.6 ± 0.1  7 
K214A  *5.4 ± 0.3  1.9 ± 0.2  5 
KDKKE(219- 223)ELAAL  *5.3 ± 0.3  2.0 ± 0.3  7 
Acetylcholine 
a wildtype  6.6 ± 0.4  (1.65, 1.70, 1.82)b 
A212E  *6.1 ± 0.1  *1.43 ± 0.04  6 
K214A  *5.6 ± 0.5  1.7 ± 0.5  11 
KDKKE(219-223)ELAAL  *5.4 ± 0.2  1.8 ± 0.2  4 
Oxotremorine-M 
a wildtype  7.1 ± 0.9  (1.50, 1.52, 1.62)b 
A212E  c  *1.3 ± 0.1  6 
K214A  6.5 ± 0.9  1.8 ± 0.1  7 
KDKKE(219- 223)ELAAL  6.3 ± 0.3  1.8 ± 0.2  5 
Pilocarpine 
a wildtype  4.6 ± 0.7  (1.25, 1.30, 1.58)b 
A212E  c  1.2 ± 0.1  2 
K214A  c  *1.10 ± 0.01  2 
KDKKE(219- 223)ELAAL  4.9 ± 0.1  1.4 ± 0.1  2 
a Values represent the mean ± S.D. of 3-12 experiments. 
b Wild-type % maximal stimulation at 3x105, 3.8x105, 1.0x106 pm2 mAchR/cell. 
EC50 is not well determined due to small observed response to agonist treatment. 
* Significantly differs (p0.05) from pm2 wild-type mAchR expressed at comparable receptor densities 46 
Inhibition of cAMP formation 
Data describing the coupling of wild-type and mutant pm2 mAchRs to the 
inhibition of cAMP formation in CHO cells is summarized in Figure 2.4 and Table 2.3. 
Reduced maximal percent inhibition was observed for all agonists for each of the mutant 
receptors characterized although IC50 values for carbachol were similar to wild-type pm2 
mAchRs expressed at the same level (Table 2.3). It is unclear if this finding reflects any 
specific changes in receptor-G-protein interaction or if a general reduction in coupling 
efficiency is observed due to the slight modifications of i3. This explanation is consistent 
with the observation that most chimeric receptors couple to effector systems with lower 
efficiency than the wild-type receptor (Bonner, 1992). Unlike the results for stimulation 
of PI metabolism, maximal inhibition of adenylyl cyclase relative to carbachol was the 
same for all mutants (Figure 2.4). Increased IC50 values were observed for acetylcholine 
and oxo M for both A212E and K214A, although no significant deviation from wild-type 
was observed for carbachol. KDKKE(219-223)ELAAL did not exhibit any agonist-
dependent increase in IC50. 
The data in Figures 2.5 and 2.6 showed that muscarinic agonists caused both 
inhibitory and stimulatory effects on cAMP levels. At high concentrations, all agonists 
appeared to mediate stimulation of adenylyl cyclase. The EC50 of stimulation for the pm2 
mAchR was variable and highly dependent on receptor number with values ranging from 
10 to 1000 p.M. 47 
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Figure 2.5: Inhibition of cAMP formation by wild-type pm2 mAChR 
Experiments were conducted as described in Experimental Procedures. Data are 
presented as levels of cAMP generated relative to forskolin-stimulated levels. The data 
shown are representative of 3-4 experiments with duplicate data points. Curves were 
derived from a least squares fit to equation 2 and average values for IC50 and % maximal 
inhibition are summarized in Table 2.3. Wild-type pm2 mAchR expressed 1.2x106 
receptors/cell. The fitted parameters were: IC50 = 0.11 ± 0.03 pM, 75% inhibition for 
carbachol; IC50 = 0.3 ± 0.06 1.1.M, 80% inhibition for oxo M. 48 
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Figure 2.6: Inhibition of cAMP formation by A212E mAchR 
Experiments were conducted as described in Experimental Procedures. Data are 
presented as levels of cAMP generated relative to forskolin stimulated levels. The data 
shown are representative of 3-4 experiments with duplicate data points. Curves were 
derived from a least squares fit to equation 2 and average values for IC50 and % maximal 
inhibition are summarized in Table 2.3. A212E 1;012 mAchR mutant expressed 3x105 
receptors/cell, with fitted parameters: IC50 = 0.7 ± 0.3  40% inhibition for carbachol; 
IC50= 0.3 ± 0.11.1M, 35% inhibition for oxo M. Slope factor = 1.0 for both agonists in 
wild-type and A212E. 49 
Table 2.3 Mutant pm2 mAchR Coupling to Inhibition of cAMP Formation 
A2onists 
log IC50 (M)  % Maximal Inhibition  n 
Carbachol 
wildtype  (6.5, 6.6, 7.0)b  74 ± 7  a 
A212E  *6.1 ± 0.3  *48 ± 9  6 
K214A  6.8 ± 0.9  *47 ± 4  6 
KDKKE(219-223)ELAAL  7.2 ± 0.5  *48 ± 4  9 
Acetylcholine 
a wildtype  (7.4, 7.5, 8.0)b  74  ± 7 
A212E  *6.8  ± 0.3  *36  ± 7  3 
K214A  *7.0  ± 0.1  *42  ± 7  4 
KDKKE(219-223)ELAAL  7.6  ± 0.4  *45  ± 7  3 
Oxotremorine-M 
a wildtype  (6.9, 7.0, 7.4)b  73  ± 6 
A212E  6.4  ± 0.4  *39  ± 4  3 
K214A  6.7  ± 0.4  *42  ± 3  3 
KDKKE(219-223)ELAAL  *7.96  ± 0.04  *48  ± 2  2 
a Values represent the mean ± S.D. of 3-4 experiments.  
b Wild-type EC50 values at 3.0x105, 3.8x105 and 1.0x106 pm2 mAchRs/cell.  
* Significantly differs (pS0.05) from pm2 wild-type mAchR expressed at comparable receptor densities. 50 
PTX Sensitivity 
Selectivity of G-protein coupling appeared to be affected by removal of a positive 
charge at the seventh N-terminal residue of i3 in the mutant K214A. Inhibition of cAMP 
formation was mediated by a PTX-sensitive G-protein for K214A (data not shown) while 
coupling to PI metabolism occurred through G-proteins with different PTX sensitivity 
than wild-type pm2 mAchRs (Figures 2.7, 2.8, 2.9 and 2.10). Wild-type receptor, 
KDKKE(219-223)ELAAL (Figure 2.9) and A212E (data not shown) coupled to PI 
metabolism by a G-protein that was PTX sensitive since treatment with 100 ng/ml 
pertussis toxin for 12 hours resulted in complete uncoupling. For K214A, treatment with 
100 ng/ml PTX failed to significantly reduce the measured accumulation of lP1 (Figure 
2.8) although the EC50 for carbachol was left-shifted by about 20 fold. 
The PTX concentration dependence on maximal fold IP1 accumulation was 
assessed for K214A and wild-type receptor (Figure 2.10). While PTX treatment reduced 
the fold accumulation of IP1 for K214A there was a 100 fold right-shift in PTX sensitivity 
compared to wildtype. In addition, treatment with 1000 ng/ml PTX failed to completely 
abolish the response to carbachol. To maximize the carbachol-stimulated increase in PI 
hydrolysis, these experiments were allowed to proceed for 50 minutes instead of 30. 
While this may explain the greater fold accumulation of IP1 for both wild-type pm2 
receptor and K214A, it does not account for the apparent difference in PTX sensitivity. 51 
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Figure 2.7: Effect of PTX on PI hydrolysis by wild-type m2 mAchR. 
Cells expressing wild-type or mutant pm2 mAchRs were treated with 100 ng/ml 
PTX for 12 hours in the presence of 1 p,Ci/m1 [31I]myo-inositol prior to the assay. Data 
are presented as fold stimulation of PI metabolism over basal levels for each experiment.
The data shown are from representative experiments. Curves through the data were 
derived from a least squares fit to equation 1. Wild-type pm2 mAchR (n=2) expressing 
1.2x106 receptors/cell. Fitted parameters for the control were: EC50 = 2.9 ± 0.711M, 2 
fold. 52 
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Figure 2.8: Effect of PTX on PI hydrolysis by K214A mutant mAchR. 
Cells expressing wild-type or mutant pmt mAchRs were treated with 100 ng/ml 
PTX for 12 hours in the presence of 1 pei/ml [3H]myo- inositol prior to the assay. Data 
are presented as fold stimulation of PI metabolism over basal levels for each experiment. 
The data shown are from representative experiments. Curves through the data were 
derived from a least squares fit to equation 1. K214A pmt mAchR mutant (n=4) 
expressed 3.8x105 receptors/cell with fitted parameters EC50 = 1.3 ± 0.7 11M, 1.7 fold; 
EC50 = 0.08 ± 0.04 ixM, 1.5 fold for control and PTX treated respectively. 53 
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Figure 2.9: Effect of PTX on PI hydrolysis by KDICICE mutant mAchR. 
Cells expressing wild-type or mutant pm2 mAchRs were treated with 100 ng/ml 
PTX for 12 hours in the presence of 1 tiCi/m1 [3H]myo- inositol prior to the assay. Data 
are presented as fold stimulation of PI metabolism over basal levels for each experiment. 
The data shown are from representative experiments. Curves through the data were 
derived from a least squares fit to equation 1. KDKKE(219- 223)ELAAL pm2 mAchR 
mutant (n=2) expressed 1.0x106 receptors/cell with fitted parameters for the control: EC50 
= 15 ± 10 gM, 2.5 fold. 54 
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Figure 2.10: Effect of PTX concentration on IN accumulation by wild-type and 
1(214A mAchR. 
Cells were treated with various concentrations of PTX for 12 hours prior to 
conducting the PI assay and assayed for inositol monophosphate accumulation 50 minutes 
after addition of 1 mM carbachol. Data are presented as maximal fold increase in IPI 
accumulation over basal levels for PTX-treated as well as control cells. Data shown are 
the means of triplicate determinations (±SD) from one representative experiment (n=2). 
The curves through the data have no theoretical basis. 55 
Discussion 
Specificity of coupling 
The i3 loop of G-protein-coupled receptors plays an important role in regulating 
receptor-effector coupling. Deletion mutants of the 132-adrenergic receptor indicated that 
the N- and C-terminal regions are necessary for coupling to stimulation of adenylyl cyclase 
(Dixon et al., 1987; Strader et al., 1987). Deletion analysis of the third intracellular loop 
for ml mAchR also indicated that the middle 126 amino acids are not necessary for 
agonist-mediated stimulation of PI metabolism (Shapiro and Nathanson, 1989). The entire 
third intracellular loop and part of the fifth transmembrane region were switched in ml /m2 
chimeric receptors. When expressed in oocytes, the ml /m2 chimera exhibited the 
physiological response characteristics of the receptor that contributed the loop (Kubo et 
al., 1988) also implying a role in specificity. 
Other studies indicate that effector specificity is conferred by the first 15 to 20 N-
terminal amino acids of i3 (Lechleiter et al., 1990; Wess et al., 1990). Wess et al. 
expressed m2/m3 chimeras in A9 L cells where the first 16 (of m2) or 17 (of m3) N-
terminal residues were swapped between the muscarinic receptor subtypes. The m3 /m2-
16 residue chimera did not couple to PI hydrolysis, but did weakly inhibit formation of 
cAMP via a PTX-sensitive G-protein. The m2/m3-17 residue chimera on the other hand, 
coupled to PI metabolism through a PTX-insensitive G-protein while maintaining PTX-
sensitive inhibition of cAMP formation (Wess et al., 1990). This implies that the N-
terminal region of i3 plays an important role in determining coupling selectivity but may 56 
not be the only determinant. To characterize important residues in this region, single and 
multiple mutations were introduced in the fifth, seventh and 12th-16th N-terminal amino 
acids of i3 in the porcine m2 mAchR. Our findings indicate that subtle changes in G-
protein coupling characteristics and ligand binding parameters can occur with little or no 
change in observed physiological responses. 
Effect on Liaand binding 
At this time a detailed interpretation of the effects of mutations on agonist binding 
properties is difficult. This laboratory has analyzed agonist competition data assuming 
models for three classes of noninteracting sites or a two state model plus a third receptor 
state that does not couple to G-proteins (Vogel et al., 1995). Both approaches allow 
calculation of values for K1, the agonist dissociation constant from RG, and K2, the 
dissociation constant for agonist binding to the free receptor, as well as K3, the agonist 
dissociation constant from a molecularly undefined receptor state which does not couple 
to G-proteins. The assignment of K1 and K2 is based on the conversion of F1 to F2 by 
guanine nucleotides (Vogel et al., 1995). However, both analyses show multiple local 
minima and appear to be ill-conditioned. In addition, models based on equilibrium 
(Chidiac and Wells, 1992) or kinetic data (Hirschberg and Schimerlik, 1994) have been 
proposed that evoke receptor-receptor interactions. Nevertheless, the data in Table 2.1 
do indicate that even single amino acid mutations in a region of the m2 mAchR thought to 
be involved in coupling to G-proteins also affect the ligand binding properties of the 
protein. 57 
Effect on receptor- effector coupling 
The effects of the mutations on receptor-effector coupling were more straight 
forward. Replacing a positively charged residue with a neutral one (K214A) resulted in a 
receptor that coupled to effector systems through a different G-protein(s). The difference 
in PTX sensitivity for agonist stimulation of PI metabolism has previously been reported 
for receptors expressed in CHO cells (Ashkenazi et al., 1989; Ashkenazi et al., 1987). 
Three classes of responses were described for both transfected and endogenous receptors. 
Endogenous receptors for thrombin and transfected porcine m2 mAchRs coupled to PI 
metabolism by PTX-sensitive G-proteins while transfected ml and m3 receptors were only 
partially sensitive to PTX suggesting both PTX-sensitive and insensitive G-proteins 
mediated the response. On the other hand, endogenous cholecystokinin receptors coupled 
to PI metabolism through a completely PTX-insensitive G-protein (Ashkenazi et al., 
1989). 
K214A appeared to couple to both inhibition of cAMP formation and stimulation 
of PI metabolism in a manner similar to wild-type pm2 receptor. Since inhibition of cAMP 
formation is mediated by a PTX-sensitive G-protein for K214A, it is clear that this mutant 
still efficiently couples to Gi. It has been demonstrated that wild-type m2 mAchR couples 
to PI metabolism through the PTX-sensitive 0-proteins Gai2 and Gai3 in CHO cells (24). 
This suggests that for K214A, coupling to PI metabolism could occur through Gi as well 
as some other PTX-insensitive G-protein, perhaps Gq or Gil. Gq and G11 which mediate 
coupling to PI metabolism in a PTX-insensitive manner are expressed in our Chinese 
hamster ovary cell line as are Gai2 and Gai3, while Gail and Gao are not expressed 58 
(Dell'Acqua et al., 1993)`. After exposure to 100 ng/ml PTX, a concentration sufficient to 
eliminate coupling to PI stimulation for wild-type, A212E and KDKKE(219-223)ELAAL, 
K214A still appeared to couple to this response with an EC50 for carbachol left-shifted by 
about 20 fold compared to the non-PTX treated control. This suggested that the major 
pathway for IP1 formation was through a different G-protein after PTX treatment than in 
non- PTX treated controls, and that this response appeared more tightly coupled in the 
presence of carbachol. When cells expressing K214A were treated with high 
concentrations of PTX, the dose-response curve was right-shifted and complete 
uncoupling did not occur even at high PTX concentrations (Figure 2.10). Taken together 
these results indicate that K214A must be coupling to PI stimulation through both PTX-
sensitive and insensitive G-proteins. Whether the rightward shift of the PTX dose-
response curve is due to K214A coupling to a different PTX-sensitive G-protein than 
wild-type receptor or to an increase in coupling through the PTX-insensitive pathway as 
the levels of PTX-sensitive G-protein are reduced is not yet known. When chimeric 
ml/m2 receptors with i3 or the N-terminal portion of i3 were reconstituted with specific 
G-proteins (Gi, Go, Gz, Gq and Gs), receptor G-protein interactions occurred with both 
PTX sensitive and PTX-insensitive G-proteins (Wong and Ross, 1994). An alternative 
explanation also compatible with this result is that the K214A mutation stabilizes the 
receptor-G protein complex, reducing the availability of the G-protein to PTX. 
* J. Robishaw, unpublished results. 59 
Lysine is conserved at amino acid position 214 in the m2/m4 mAchR family while 
the ml/m3/m5 family has a conserved Glu in that position. Perhaps the positively charged 
side chain of Lys is important in determining the nature of G-protein coupling interactions 
for the m2 /m4 mAchRs. Replacing this Lys with a neutral Ala may remove a constraint 
which allows the receptor to interact with multiple G-proteins. For the human m3 
mAchR, several charged residues near the N-terminal of i3 were required for normal signal 
transduction (Kunkel and Peralta, 1993). 
The N-terminal region of i3 is predicted to form an amphipathic a-helical structure 
in all G-protein coupled receptors. Studies on chimeric m2/m3 mAchRs suggest that 
receptors with similar function utilize regions of conserved charge and secondary structure 
without complete sequence identity (Lechleiter et al., 1990). While this motif may 
represent a structural requirement in receptor-G-protein interactions in general, the 
individual charged residues within this region may play a role in determining the nature of 
the protein-protein interaction. When the amino acid sequences of the third intracellular 
loop are aligned, the N-terminal regions are most conserved among the functional families 
(e.g. m2/m4 vs. m 1/m3/m5). Replacing Lys with Glu at position 214 (K214E), which 
swaps residues conserved at that position between the functional families resulted in a 
receptor that was not properly processed. All receptor sites detected (3 x 105 sites/cell) 
were internalized with no expression on the cell surface (data not shown). 
Replacement of a non-polar amino acid with an acidic one (A212E) resulted in 
ligand binding and effector coupling properties similar to wild-type receptor. The notable 
exceptions were the weaker binding of acetylcholine and that oxo M appears to be less 60 
effective at stimulating PI hydrolysis than other agonists, although it bound with high 
affinity. Acetylcholine also appeared to be less effective at stimulating PI hydrolysis and is 
significantly different (p  0.05) than wild-type pm2 (Table 2.2). When normalized to 
carbachol stimulated levels of IP I, this reduced efficacy is less striking and does not 
significantly differ from the full agonist carbachol, while oxo M does (Figure 2.3). It is 
not clear whether oxo M promoted a receptor conformation that was in general less 
efficient at coupling to Gi or if changes in Gia subtype selectivity were altered reducing the 
efficiency of effector activation. Regardless of the mechanism of action, it is significant to 
note that this finding implies that the agonists oxo M, and to a lesser extent, acetylcholine 
behaved differently than carbachol. 
Agonist-mediated physiological responses for A212E in CHO cells occur through 
PTX-sensitive G-proteins, making it difficult to ascertain whether or not subtle changes in 
coupling result. At pm2 mAchR numbers greater than 105 per cell, maximal stimulation of 
PI metabolism appeared to be limited by receptor expression, while maximal inhibition of 
cAMP formation was not. Most investigations of receptor mutants are carried out on cell 
lines that are overexpressing receptor. Under these conditions, inefficient coupling of 
receptor to G, may go unnoticed in assays of cellular cAMP levels since the receptor is in 
excess. Although oxo M mediated inhibition of cAMP formation for A212E resembles 
wild-type receptor, it is possible that this agonist promotes a receptor conformation that is 
less efficient at activating the G-proteins expressed in CHO cells. 
All of the mutant receptors assayed as well as wild-type pm2 mAchR exhibit both 
an inhibition and stimulation of cAMP formation. While the stimulatory phase is not 61 
dependent on Ca2+ or activation of protein kinase-C (Baumgold, 1992), the mechanism by 
which this effect occurs is not known. For the ca-adrenergic receptor which also couples 
to both inhibition and stimulation of cAMP formation, the stimulatory phase has been 
reported to be mediated by a direct interaction with Gs (Eason et al., 1992). m4 mAchRs 
have also been shown to activate Gs directly in HEK 293 cells (Dittman et al., 1994). 
These observations implicate an indirect pathway in the stimulation of cAMP formation, 
possibly mediated by G-protein py subunits. 
The KDKKE(219- 223)ELAAL pm2 receptor mutant replaced the 12th through 
the 16th N-terminal residues conserved in the m2/m4 functional family with those 
conserved in the ml/m3/m5 family. While this change introduces alterations in the charge 
distribution within this domain of i3, it does not affect the predicted secondary structure of 
this portion of the loop. Binding of carbachol and oxo M was affected, but not effector 
coupling characteristics. Coupling to effector systems occurred via PTX-sensitive G-
proteins as seen in wild-type receptor (Figure 2.7). Fold simulation of PI hydrolysis 
resembled wild-type pm2 receptor while human ml mAchRs expressed in CHO cells 
elicited a 13 fold increase in IP1 accumulation (data not shown). The EC50 values for 
acetylcholine and carbachol significantly differed from wild-type while the EC50 for oxo M 
did not. Although residues 219-223 are within the region of i3 reportedly responsible for 
switching effector coupling characteristics between m2 and m3 mAchRs (Wens et al., 
1990), this finding suggests that charge distribution in this domain of the loop does not 
play a large role in G-protein selectivity. This finding is supported by the converse 62 
mutation made in the human ml mAchR (Arden et al., 1992) where change in charge 
distribution played a minor role in G-protein coupling to PI metabolism. 
The N-terminal domain of the third intracellular loop of the mAchR appears to 
play a role in G-protein coupling, but it is clearly not the only determinant. Chimeric 
muscarinic (Bonner, 1992; Lechleiter et al., 1990; Wess et al., 1990), and al-adrenergic 
(Cotecchia et al., 1992) receptors gain the coupling selectivity of the introduced loop 
while characteristics of the wild-type receptor are retained to some degree. The rat m3 
mAChR N-terminal domain of i3 was studied by replacing residues with corresponding 
amino acids found in the m2/m4 receptor family (Bliiml et al., 1994b). The authors 
concluded that a critical Tyr residue in rat m3 was necessary for efficient coupling to PI 
hydrolysis, although substitution of Tyr for Ser in the corresponding position of Hm2 did 
not result in an enhanced PI response (Bli.iml et al., 1994a). flogger et al (Bigger et al., 
1995) studied Hml N- and C- terminal junctions of i3. They proposed that these domains 
of i3 could function as a crucial hinge region allowing exposure of specific binding pockets 
upon agonist binding as well as a specific recognition substrate, and cautioned against the 
definition of precise coupling domains in these regions of the muscarinic receptor. In 
addition, the G-protein selectivity of chimeric receptors (Wong and Ross, 1994) appears 
to depend on specific contributions by both i2 and i3, and promiscuous receptor G-protein 
interactions occur in the absence of the correct i2. 
Since all members of the seven transmembrane receptor family interact with 0-
proteins, it is possible that portions of the transmembrane region (the most well conserved 
domains) are also important in determining G-protein recognition characteristics. A 63 
mutation in the second transmembrane region (D69N) results in a pm2 receptor that binds 
agonists but does not efficiently couple to effectors. The role of intracellular loops may be 
to modulate coupling to G-proteins and characteristics observed for each receptor system 
studied may be dependent on the context in which they are expressed. Coupling 
selectivity and efficiency may in fact be dependent on the interaction of intracellular loops 
with other structural domains of the receptor as well as those of the specific G-proteins 
expressed in the cells being examined. Mouse ml AChRs when expressed in Y1 adrenal 
carcinoma cells, CHO cells and Rat-2 fibroblasts, coupled to multiple G-proteins (as 
determined by PTX sensitivity) in a cell line specific manner (Shapiro et al., 1993). 
Summary 
In summary, we have shown that single amino acid changes in the N-terminal 
domain of i3 can lead to subtle changes in G-protein coupling characteristics. This finding 
suggests that analysis of mutants designed to assess coupling selectivity may require more 
detailed examination before conclusions can be drawn. Although it appears that coupling 
is affected by N-terminal residues of i3, the nature of these interactions may be determined 
by several structural domains simultaneously rather than by the i3 alone as well as the 
context in which the receptor is expressed. It is imperative that careful evaluation of all 
data pertaining to coupling characteristics be considered before conclusions be drawn on 
structural domains. Elucidation of explicit roles of the structural domains important in G-
protein coupling by site-directed mutagenesis requires that high resolution assessment of 
selectivity be utilized. 64 
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Abstract 
Agonist-stimulated internalization and desensitization of effector coupling were 
studied in Chinese hamster ovary cells stably transfected with wild-type and mutant m2 
muscarinic acetylcholine receptors. Site-directed mutagenesis was used to mutate an 
aspartic acid conserved in the putative second transmembrane domain of all muscarinic 
receptors to asparagine (D69N). Antagonist binding was unchanged by this mutation 
while agonist binding was slightly altered. Affinities for carbachol, acetylcholine and 
pilocarpine were similar to wild-type receptor, while oxo M affinity was reduced by 25 
fold. Consistent with studies of other G-protein coupled receptors, the D69N mutation 
had a dramatic effect on receptor-effector coupling properties. Agonist-mediated 
inhibition of adenylyl cyclase and stimulation of PI hydrolysis was abolished for all 
agonists examined except oxo M. Receptor internalization and desensitization of D69N 
did not require coupling to second messenger systems. Agonists incapable of activating 
effector systems stimulated receptor internalization at rates similar to wild-type receptor. 
Desensitization of oxo M-stimulated receptor-effector coupling was observed for full 
agonists but not the partial agonist pilocarpine. Pertussis toxin, which uncouples receptor 
from endogenous G-proteins, failed to prevent carbachol-stimulated internalization of 
surface receptor sites. Cells treated with sodium nitroprusside and 8-bromo-cGMP 
exhibited a loss of surface receptor sites with no change in effector coupling properties 
while dibutyryl-cAMP and thapsigargin had no effect on receptor sites or coupling. These 
findings suggest that different agonists promote unique receptor conformations which can 66 
affect G-protein coupling properties. In addition, receptor-effector coupling is not 
necessary for agonist-promoted internalization and that internalization and desensitization 
are mediated by separate mechanisms in the CHO cell heterologous expression system. 67 
Introduction 
Overview 
Receptor desensitization is a common cellular response to persistent stimulation by 
agonists (Liggett, 1995). GPCRs are regulated by several processes in response to 
persistent agonist treatment including, internalization, recycling, sequestration and down-
regulation  It is suggested that the net effect of these processes are to uncouple the 
receptor from second messenger effector systems. In addition, receptor internalization 
and recycling may play an important role in resensitization of 02 adrenergic receptor 
responses (Pippig et al., 1995; Yu et al., 1993), although the molecular mechanisms 
underlying these observations are still unclear. 
Internalization and desensitization 
Receptor internalization, down-regulation and desensitization appear to be 
regulated by separate mechanisms. Agonist-induced movement of receptors to localized 
invaginations of the plasma membrane can be separated from endocytosis for the f32 
adrenergic receptor expressed in 293 human kidney fibroblasts. Agonists may function to 
promote receptor movement to the appropriate cellular location where passive 
endocytosis can occur (von Zastrow and Kobilka, 1994). Internalized receptors are stored 
in endosomes and can be recycled to the plasma membrane or degraded (Koenig and 
Edwardson, 1994). Treatment of cells with colchicine, to prevent receptor down-
regulation had no effect on rapid internalization of mAchRs in cultured neuronal cells 68 
(Maloteaux and Hermans, 1994). Furthermore, when cells expressing dopamine D1 
receptors were treated with concanavalin A or sucrose, agonist-induced receptor 
internalization was prevented without affecting desensitization properties (Ng et al., 
1995). Human embryonic kidney cells expressing a dominant-negative allele of G-protein 
coupled receptor kinase 2 (GRK2) reduced agonist-dependent phosphorylation of m2 
mAchR and prevented desensitization. In addition, mutations in the third intracellular 
loop of m2 mAchR produced receptors that were not phosphorylated in an agonist-
dependent manner, yet receptor internalization was not affected (Pals Rylaarsdam et al., 
1995). These results suggest that internalization, down-regulation and desensitization are 
regulated in an agonist-dependent manner by independent mechanisms. 
Mutation of second transmembrane aspartic acid 
Several aspartic acids are conserved in the second and third transmembrane 
domains of G-protein coupled receptors (Strader et al., 1987; Wang et al., 1991). The 
aspartic acid located in the putative second transmembrane of G protein-coupled receptors 
play an important role in mediating agonist-stimulated coupling to G-proteins (Fraser et 
al., 1989).  Mutations analogous to aspartic acid 69 of the pm2 mAchR were made in ml 
mAchR (Fraser et al., 1989; Lameh et al., 1992), in (32 adrenergic (Strader et al., 1987), a 
2 adrenergic (Ceresa and Limbird, 1994; Wang et al., 1991), serotonin (Ho et al., 1992; 
Wang et al., 1993), dopamine D2 (Neve et al., 1991), lutropin (Ji and Ji, 1991), 
angiotensin H (Bihoreau et al., 1993), neurokinin-1 (Brodbeck et al., 1995), and 
endothelin A receptors (Rose et al., 1995). Antagonist binding was consistently 
unaffected by this mutation while the effect on agonist binding varied from a reduction 69 
(Strader et al., 1987) to an increase in agonist affinity (Fraser et al., 1989; Wang et al., 
1991). Coupling to effector systems was consistently abolished by this mutation, leading 
to the conclusion that this acidic residue is important for agonist-mediated activation of G-
proteins. 
Focus of this chapter 
Receptor-effector coupling does not appear to be necessary for agonist-dependent 
internalization and sequestration. 02 adrenergic receptor mutants unable to stimulate 
effector activation undergo agonist-promoted internalization (Campbell et al., 1991; 
Goldman et al., 1996; Mahan et al., 1985). Contrary to these results, when the second 
transmembrane aspartic acid of the ml mAchR was mutated to asparagine (D71N) and 
expressed in a transient transfection system, both agonist-mediated coupling and 
internalization were abolished (Lameh et al., 1992). 
We have mutated the conserved aspartic acid to asparagine (D69N) in the second 
transmembrane domain of the pmt mAchR to evaluate the role of full and partial agonists 
in receptor internalization and effector coupling. Coupling to inhibition of adenylyl 
cyclase and stimulation of PI hydrolysis is abolished by this mutation for all agonists 
except oxo M, which elicits maximal responses for both effector systems with about half 
the efficacy and a lower potency than wild-type receptor. This mutant offers a unique 
opportunity to evaluate the effect of agonists that promote activation of G-proteins as well 
as those that do not, on receptor internalization and desensitization. Internalization of 
D69N is observed in response to treatment with full agonists carbachol, acetylcholine and 70 
oxo M as well as the partial agonist pilocarpine even though receptor-effector coupling is 
only stimulated by oxo M. Desensitization of oxo M mediated stimulation of PI hydrolysis 
and inhibition of forskolin-stimulated adenylyl cyclase activity was observed for all full 
agonists, but not the partial agonist pilocarpine. Treatment of cells expressing wild-type 
or D69N mAchRs with PTX does not prevent carbachol-mediated internalization of 
receptor. In addition, receptor internalization is not mediated by increases in Ca2+ or 
cAMP, although elevated cGMP may play a role. These results confirm that effector 
activation is not required for receptor internalization, and that desensitization and 
internalization are mediated by separate mechanisms. In addition, oxo M appears to 
promote a unique conformation in D69N pmt mAchR capable of activating G-proteins 
and effector systems. 71 
Materials and Methods 
Abbreviations Used 
mAchR, muscarinic acetylcholine receptor; pm2, porcine m2 subtype of the 
muscarinic acetylcholine receptor; CHO, Chinese hamster ovary cells; DMEM, Dulbecco's 
modified Eagle's medium plus F12 nutrient mixture; G-protein, Guanine nucleotide-
binding protein; GPCR, G-protein coupled receptors; Gpp(NH)p, guanyl 
imidodiphosphate; 1P1, inositol monophosphate; IBMX, 4-(3-butoxy-4-methoxybenzy1)-2-
imidazolidinone; PI, phosphatidylinositol; PTX, pertussis toxin; oxo M, oxotremorine M; 
l -QNB, R-(-)-quinuclidinylbenzilate; NMS, N-methyl scopolamine; and SNP, Sodium 
nitroprusside. 
Materials 
Radioactive ligands ([3H] /-QNB, 52.3 Ci/mmol; and [3H]NMS, 84 Ci/mmol ) 
were purchased from New England Nuclear. Radioactive compounds for second 
messenger assays were purchased from New England Nuclear (myo-[3H] inositol, 24.4 
Ci/mmol; [3H]adenine, 25.8 Ci/mmol; and [14C]cAMP, 52.3 Ci/mmol) or American 
Radiochemical (myo- [3H]inositol, 20 Ci/mmol; and [3H]adenine, 15 Ci/mmol). Carbachol 
was purchased from Aldrich Chemical Company, pertussis toxin from List Biological 
Laboratories, forskolin, IBMX, l -QNB, NMS, oxo M, acetylcholine and pilocarpine were 72 
from Research Biochemicals International, and dibu  1-cAMP, 8-bromo-cGMP and 
thapsigargin from BIOMOL Research Laboratories. All other reagents were either from 
GIBCO-Bethesda Research Laboratories (cell culture media and supplements) or Sigma. 
Restriction enzymes and T4 DNA polymerase were from Promega, GIBCO-Bethesda 
Research Laboratories or New England Biolabs. The mammalian expression vector 
(pSVE) and the clone for the wild-type pmt mAchR were gifts from Genentech, Inc. The 
dhfr CHO cells were obtained from America Type Culture Collection. 
Cloning and mutagenesis 
Cloning and expression of mutant and wild-type mAchR-pSVE constructs are 
described elsewhere (Bulseco and Schimerlik, 1996; Vogel et al., 1995)*. The site-
directed mutant, D69N was constructed using the oligonucleotide, 5'-
GATGAGGTTAGCACAGGC-3', confirmed by dideoxy DNA sequencing (Sanger et al., 
1977), and the construct stably transfected in dhfr- CHO cells by calcium phosphate 
precipitation. Wild-type receptor was overexpressed in CHO cells after removing 75 
bases from the 5' untranslated region and replacing the weak 5' upstream Kozak sequence 
(CAAA) with a 'strong' Kozak sequence (CACC) (Kozak, 1987), to obtain receptor 
expression levels equivalent to those seen in the D69N mutant. 
* Bulseco, D.A. and M.I. Schimerlik, in preparation. 73 
Receptor expression 
Receptor expression was assessed in whole cells on 24-well tissue culture dishes 
by the addition of 10 nM [3H] l -QNB in the presence or absence of saturating 
concentrations of unlabeled antagonists, NMS or l -QNB in DMEM. Cells were incubated 
for 1.5 to 2 hours, then washed twice with ice cold phosphate buffered saline (pH 7.4), 
solubilized with 0.5 ml 1% Triton X-100 in PBS, and counted for tritium. Surface 
receptor sites were determined by competition of [3H] l -QNB with the unlabeled 
hydrophilic antagonist, NMS while total receptor was determined in the presence of 
unlabeled hydrophobic antagonist, l -QNB. Determination of surface receptor sites using 
this approach gave results within 10% of [3H]NMS binding. 
Receptor internalization assays were conducted after treating cells for various 
times in FD supplemented with 10% calf serum (Sigma). Time course of internalization 
was studied by incubating cells with 1 mM agonist for various times. Assays for 
desensitization of second messenger responses were determined after cells were incubated 
with 1 mM agonist for 3 to 4 hours while other treatments were for 1 (1 mM sodium 
nitroprusside) or 2 hours (1 I_IM and 1 mM dibutyryl-cAMP; 1 pi.M and 1 mM 8-bromo-
cGMP; 100 IAM thapsigargin). 
Receptor ligand binding studies were performed on intact cells in 24-well dishes in 
DMEM. Direct binding of [3H]NMS and agonist competition of [3H]NMS binding for 
wild-type and D69N mAchR were characterized. For saturation binding isotherms, non-
specific binding was determined in the presence of 100 IiM /-hyoscyamine. Competition 74 
binding experiments were conducted in the presence of 2.5 nM [3H]NMS in the presence 
of unlabeled agonists (0.1 nM to 10 mM). 
Assays for effector coupling and data analysis. 
Assays for receptor-effector coupling are described elsewhere (Bulseco and 
Schimerlik, 1996). CHO cells expressing wild-type or mutant pm2 mAchRs were assayed 
in 24-well dishes for agonist-stimulated PI hydrolysis (Lee et al., 1990) or inhibition of 
forskolin-stimulated adenylyl cyclase (Salomon, 1979). Data were analyzed using 
nonlinear least-squares curve fitting in Origin (MicroCal Software) as described in 
(Bulseco and Schimerlik, 1996) for functional assays and (Vogel et al., 1995) for ligand 
binding experiments. 
Data from effector coupling assays were fit to the logistic equation. Equation 1 
was used for PI assays, with a third term added (Eq. 2) to account for a stimulatory phase 
observed in the cAMP assays (Bulseco and Schimerlik, 1996). 
.  (max min) Y=  (Eq. 1) (EC50/ v, /[x]i 
(max 1 min)  (max 2  min)
Y = min+  +  (Eq. 2)
pl  1+ (EC50s/  p2 
1 + (LX-IEC50i)  AX.11 
In each of these equations [x] is the agonist concentration used; max or maxl,2 
and min are the maximum and minimum plateaus of the curves; and p or p1,2 the 
respective slope factors. 75 
Agonist binding data were fit assuming three non-interacting classes of sites using 
the equation below (Vogel et al, 1995). 
[Roi]([Lo] [RL])
[fe] =E
3  (Eq. 3)
Kd + (Kdt Ki)[1]+[Lo][RI] 
[Roi] is the total receptor concentration for each receptor site; [Lo], the total 
concentration of radiolabeled tracer used in the experiment with dissociation constant Kd; 
and [I], the total unlabeled competing agonist with dissociation constant Ki. 
Receptor internalization kinetic experiments were fit to Equation 4. Parameters 
are y(t), the amount of surface receptor at time t; yO, the surface sites that remained after 
treatments for receptor internalization; Al, the amplitude, and k, the apparent rate 
constant for receptor internalization. 
Y(t) = YO + Alexp(kt)  (Eq. 4) 76 
Results 
Receptor expression levels 
Wild-type and D69N mAchRs were expressed at high levels in the plasma 
membrane of CHO cells. Receptor densities of 2.0-4.0 x 106 receptors per cell were 
observed for both mutant and wild type, with 88-92% of the sites expressed at the cell 
surface. Modification of the 5' untranslated region of the wild-type receptor clone 
(pSVE-pm2 short c1.1) was necessary to increase receptor expression to levels observed 
with the D69N mutant mAchR. A wild-type clone without these 5' upstream changes 
maximally expressed 0.8-1.2 x 106 receptors per cell, although approximately 90% of 
these sites were localized to the plasma membrane (data not shown). All data for wild-
type presented in this report refers to the high expression (pSVE-pmt short c1.1) clone. 
D69N mAchR mutant couples poorly to effectors 
Coupling of D69N to inhibition of adenylyl cyclase (Figure 3.1) and stimulation of 
PI metabolism (Figure 3.3) is dependent on the agonist used. oxo M is the only agonist to 
elicit a measurable response for inhibition of adenylyl cyclase and stimulation of PI 
hydrolysis, although at reduced maximal responses and with lower potency. Carbachol 
(n=3), acetylcholine (n=3) and pilocarpine (n=1) did not elicit inhibitory responses while 
maximal inhibition of adenylyl cyclase was 41 ± 6 % for oxo M with an IC50 of 8.4 ± 0.5 77 
gM (Table 3.1). This represents a 2 fold lower maximal response for oxo M and an 80 
fold increase in 1050 when compared to wild-type receptor. 78 
Table 3.1: D69N and wild-type pm2 mAchR coupling to inhibition of adenylyl 
cyclase and stimulation of PI hydrolysis. 
Assays were conducted as described in "Materials and Methods", and analyzed as 
described in (Bulseco and Schimerlik, 1996). Values represent the mean ± SD of n 
experiments, each done in duplicate. 
AC Inhibition  PI Hydrolysis 
IC50  Max  n  EC50  Max  n 
(gM)  Inhibition  (PM)  Stimulation 
(%)  (Fold) 
Wild-type 
Carbachol  0.6 ± 0.3  61.5 ± 5.5  2  1.5 ± 0.3  1.6 ± 0.1  4 
Acetylcholine  0.05 ± 0.01  61.5 ± 2.5  2  5.5 ± 2.0  1.9 ± 0.2  3 
oxo M  0.10±0.05  75 ±3  2  5.1 ± 0.4  1.8 ± 0.2  2 
Pilocarpine  7.9 ± 2.1  49.5 ± 3.5  2  5.6 ± 2.1  1.43 ± 0.09  3 
D69N 
oxo-M  8.4 ± 0.5  41 ± 6  3  10.6± 1.1  1.46 ± .02  3 79 
Data describing the coupling of wild-type pm2 mAchR to the inhibition of adenylyl 
cyclase and stimulation of PI hydrolysis are summarized in Figures 3.2, 3.4 and Table 3.1. 
Wild-type pm2 exhibits both inhibition and stimulation of adenylyl cyclase activity (Figure 
3.2) for all agonists. The stimulation of adenylyl cyclase is reproducible, but with poorly 
characterized EC50s. A range of 15 pt.M to 2 mM was observed for carbachol, 
acetylcholine, oxo M and pilocarpine. For clarity, these parameters have been omitted 
from Table 3.1. Wild-type IC50 for oxo M is 0.10 ± 0.05 µM with a maximal inhibition 
of 75 ± 3 % at receptor densities similar to the D69N mutant. 
Oxo M was the only agonist to elicit a stimulation of PI hydrolysis in CHO cells 
expressing the D69N mutant, with an EC50 of 10.6 ± 1.1 11M and maximum fold 
stimulation of 1.46 ± 0.02. These values are only slightly different from wild-type 
receptor; 5.1 ± 0.4 gM, 1.8 ± 0.2 maximum fold stimulation. 80 
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Figure 3.1: Inhibition of forskolin-stimulated cAMP formation for D69N. 
Data are presented as cAMP generated relative to forskolin stimulated levels and 
are from representative experiments. Curves were derived from a least-squares fit as 
described in Bulseco and Schimerlik, (1996). Average values are summarized in Table 
3.1.  The fitted parameters for the D69N are 1050 = 9.0 ± 3.3 iiM, 32.5 ± 1.7 % 
inhibition for oxo M (), with slope fixed at 1. Data for carbachol (0), acetylcholine (U) 
and pilocarpine (0) were fit, but parameters are undetermined due to small measurable 
responses. 81 
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Figure 3.2: Inhibition of forskolin-stimulated cAMP formation for wild-type 
mAchR. 
Data are presented as cAMP generated relative to forskolin stimulated levels and 
are from representative experiments. Curves were derived from a least-squares fit as 
described in Bulseco and Schimerlik, (1996). Fitted parameters for wild-type are 1050 = 
0.11 ± 0.02 JIM, maximal inhibition 73.2 ± 5.9 %, 1050 = 0.8 ± 0.5 IIM, maximal 
inhibition 65.8 ± 7.8 %, 1050 = 0.06 ± 0.01 ptM, maximal inhibition 64.6 ± 5.9 %, and 
1050 = 1.6 ± 0.9 WI, maximal inhibition 59.8 ± 17.1 % for oxo M (9), carbachol (0), 
acetylcholine (II) and pilocarpine (0) respectively 82 
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Figure 3.3: Stimulation of PI hydrolysis for D69N mutant mAchR. 
The data are presented as fold stimulation of PI hydrolysis over basal levels of 
inositol monophosphate. Curves were derived from a least squares fit. Fitted parameters 
for D69N are EC50 = 12.4 ± 2.3 1AM, maximal stimulation 1.50 ± 0.01 with slope factor 
fixed at 1 for oxo M (). Response was too low to obtain reliable fitted values for 
carbachol (0), acetylcholine () and pilocarpine (). 83 
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Figure 3.4: Stimulation of PI hydrolysis for wild-type mAchR. 
The data are presented as fold stimulation of PI hydrolysis over basal levels of 
inositol monophosphate. Curves were derived from a least squares fit to a logistic 
equation. Fitted parameters for wild type; EC50 9.2 ± 3.8 gM, 2.2 ± 0.8 pM, 9.9 ± 5.0 
pM and 6.7 ± 3.0 gM for oxo M (, dotted line), carbachol (0, solid line), acetylcholine 
(MI, dashed line) and pilocarpine (, dashed-dotted line), with maximal fold stimulation of 
1.75 ± 0.03, 1.83 ± 0.02, 1.90 ± 0.03, and 1.51 ± 0.02 fold respectively 84 
Ligand binding properties of D69N are similar to wild type 
Ligand binding properties of D69N were similar to wild-type pmt AchR for all 
agonists except oxo M (Table 3.2). Direct binding studies of the antagonist, [3H]NMS, 
gave dissociation constants of 0.39 ± 0.1 nM (n=10) for D69N and 0.2 ± 0.1 nM (n=6) for 
wild-type receptor. Agonist binding data in whole cells for D69N and wild-type pm2 
mAchR for oxo M, carbachol and acetylcholine were consistent with fits to two 
independent classes of sites (KH and KO while pilocarpine was best fit by assuming a 
single class of sites (KH). The superhigh affinity state (KsH) observed in membrane 
preparations of wild-type pm2 mAchR is not detectable in assays using intact cells, 
possibly due to high concentrations of endogenous guanine-nucleotides or the high 
expression levels achieved in these CHO cell clones. Carbachol and acetylcholine 
exhibited affinities similar to wild-type receptor while oxo M exhibited a 25 fold reduction 
in affinity. Pilocarpine bound D69N with 3 fold higher affinity than wild-type receptor, 
but was still best fit to a single site (Table 3.2). 85 
Table 3.2: D69N and wild-type pmt mAchR ligand binding properties. 
Whole cell agonist competition experiments were done as described in "Materials 
and Methods". Data were analyzed as described in (Vogel et al., 1995) using nonlinear 
least-squares curve fitting. Values represent the mean ± SD of n experiments. 
Wild type  D69N 
KH  KL  n  KH  KL  n 
Carbachol8  (0) 
1.7 ± 0.8 
(11M) 
37.6 ± 10.3  5 
(PM) 
2.0 ± 0.7  47.5 ± 0.3  6 
Acetylcholine  0.4 ± 0.2  87.4 ± 6.7  4  0.4 ± 0.1  23.5 ± 4.0  4 
oxo M  0.4 ± 0.2  43.5 ± 16.5  4  10.6 ± 3.0  254.2 ± 79.7  5 
Pilocarpine  17.4 ± 9.0  3  26.6 ± 10.1  b  4 
% receptor sites in the high affinity state (Ku) is 25, 26, 33, and 100% for carbachol, acetylcholine, oxo 
M and pilocarpine respectively for wild-type mAchR and 31, 22, 67 and 100% for D69N. 
b Pilocarpine is best fit to a single class of binding site. 86 
Desensitization of oxo M-activated coupling 
Desensitization of oxo M-activated coupling to inhibition of adenylyl cyclase 
(Figure 3.5) and stimulation of PI hydrolysis (Figure 3.7) in D69N was observed for 
carbachol and oxo M but not pilocarpine. Coupling properties of pm2 mAchR are 
dependent on receptor density (Vogel et al., 1995; Whaley et al., 1995; Whaley et al., 
1994). Desensitization is therefore measured as a rightward shift in IC50 for inhibition of 
adenylyl cyclase activity as well as reduction in maximal inhibition, and as a reduction in 
maximal stimulation of PI hydrolysis with no change in EC50. Pretreating cells with 
acetylcholine led to inconsistent results (data not shown), presumably due to agonist 
degradation during the incubation period. The fitted parameters for D69N were IC50 = 
3.5 ± 1.0 AM, 36.4 ± 4.1 % maximal inhibition for untreated cells, IC50 = 66.7 ± 49.0 
AM, 28.2 ± 4.2 % maximal inhibition, IC50 = 71.3 ± 32.5 p.M, 28.0 ± 2.1 % maximal 
inhibition, and IC50 = 3.0 ± 0.9 AM, 32.8 ± 2.1 % maximal inhibition for cells treated with 
carbachol, oxo M and pilocarpine respectively. Desensitization to PI metabolism resulted 
in loss of measurable response for cells treated with carbachol and oxo M, while treatment 
with pilocarpine resulted in a response similar to untreated cells. The fitted parameters for 
D69N were EC50 = 11.3 ± 3.4 AM, 1.51 ± 0.01 fold maximal stimulation, and EC50 = 
4.5 ± 1.6 AM, 1.65 ± 0.02 fold maximal stimulation for control and pilocarpine treated 
cells respectively. 87 
Similar results were observed for wild-type pmt (Figures 3.6, 3.8) after treatment 
with various agonists. Pretreatment with both carbachol and oxo M led to desensitization 
of carbachol-mediated responses, but preincubation with pilocarpine did not. Fitted 
parameters for wild-type were IC50 = 0.38 ± 0.13 AI, maximal inhibition 72.2 ± 3.6 %, 
IC50 = 2.5 ± 0.21.1M, maximal inhibition 33.7 ± 4.1 %, IC50 = 3.1 ± 1.8 1.1M, maximal 
inhibition 39.9 ± 3.3 %, and IC50 = 2.7 ± 0.8 AM, maximal inhibition 53.6 ± 18.5 % for 
control, carbachol, oxo M and pilocarpine treated cells respectively. Carbachol and oxo 
M abolished measurable coupling to PI metabolism, while pilocarpine resulted in a 
response similar to untreated cells. Fitted parameters for wild-type are EC50 = 1.7 ± 1.2 
1.1M, and 0.5 ± 0.2 gM, for control and pilocarpine treated cells, with maximal fold 
stimulation of 1.50 ± 0.04, and 1.63 ± 0.02 fold respectively. Although receptor 
desensitization was always accompanied by receptor internalization, a reduction in surface 
receptor density was not sufficient to lead to desensitization. 88 
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Figure 3.5: Desensitization of forskolin-stimulated inhibition of cAMP formation for 
D69N. 
Data are presented as cAMP generated relative to forskolin-stimulated levels and 
are from representative experiments. Cells were pretreated with the agonists indicated (1 
mM) for 4 hours, followed by second messenger assays with oxo M for D69N. Curves 
were derived from a least-squares fit as described in (Bulseco and Schimerlik, 1996). The 
fitted parameters for the D69N are 1050 = 3.5 ± 1.0 gM, 36.4 ± 4.1 % inhibition, slope 
0.8 for control (D, dashed line), ICSO = 66.7 ± 49.0 JAM, 28.2 ± 4.2 % inhibition for 
carbachol (0, solid line), 1050 = 71.3 ± 32.5 pM, 28.0 ± 2.1 % inhibition for oxo M (E, 
dotted line) and 1050 = 3.0 ± 0.9 LtM, 32.8 ± 2.1 % inhibition for pilocarpine (0, dashed-
dotted line) treated cells respectively (slope factors fixed at 1). 89 
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Figure 3.6: Desensitization of forskolin-stimulated inhibition of adenytyl cyclase for 
wild-type mAchR. 
Data are presented as cAMP generated relative to forskolin-stimulated levels and 
are from representative experiments. Cells were pretreated with the agonists indicated (1 
mM) for 4 hours, followed by second messenger assays with carbachol for wild type. 
Curves were derived from a least-squares fit as described in (Bulseco and Schimerlik, 
1996). Fitted parameters for wild-type are 1050 = 0.38 ± 0.13 pM, maximal inhibition 
72.2 ± 3.6 %, 1050 = 2.5 ± 0.2 gM, maximal inhibition 33.7 ± 4.1 %, 1050 = 3.1 ± 1.8 
tiM, maximal inhibition 39.9 ± 3.3 %, and 1050 = 2.7 ± 0.8 p.M, maximal inhibition 53.6 ± 
18.5 % for control (, dashed line), carbachol (0, solid line), oxo M (, dotted line) and 
pilocarpine (0, dashed-dotted line) treated cells respectively. Slope factors were fixed at 
1. 90 
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Figure 3.7: Desensitization of PI Hydrolysis for D69N mutant AchR. 
The data are presented as fold stimulation of PI hydrolysis over basal levels of 
inositol monophosphate for control cells or after pretreatment of cells as described above. 
Curves were derived from a least squares fit. Fitted parameters for D69N are EC50 = 
11.3 ± 3.4  1.51 ± 0.01 fold, and EC50 = 4.5 ± 1.6 04, 1.65 ± 0.02 fold for control 
() and pilocarpine (0) treated cells. Treatment with carbachol (0) and oxo M () 
resulted in small responses and poorly determined fits. 91 
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Figure 3.8: Desensitization of PI Hydrolysis by wild-type mAch1R. 
The data are presented as fold stimulation of PI hydrolysis over basal levels of 
inositol monophosphate for control cells or after pretreatment of cells as described above. 
Curves were derived from a least squares fit. Fitted parameters for wild-type are EC50 = 
1.7 ± 1.2 I.AM, and 0.5 ± 0.2 piM, for control () and pilocarpine (0) treated cells, with 
maximal fold stimulation of 1.50 ± 0.04, and 1.63 ± 0.02 fold respectively. Treatment 
with carbachol (0) and oxo M () resulted in small responses and poorly determined fits. 92 
Internalization of D69N does not require coupling 
The time course of receptor internalization was similar for all agonists. The partial 
agonist, pilocarpine as well as full agonists carbachol, acetylcholine and oxo M, induced 
internalization of wild-type and D69N mAchR surface sites (Figures 3.9, 3.10). 
Approximately 50% of the surface sites were internalized within 30-60 minutes. Total 
cellular receptor was reduced maximally to 40-50%, with no further reduction after 
agonist treatment for up to 24 hours (data not shown). The apparent rate constants 
obtained for carbachol, oxo M, acetylcholine and pilocarpine were 0.04 ± 0.02, 0.05 ± 
0.03, 0.06 ± 0.03 and 0.1 ± 0.08 % receptors/cell/min respectively for wild-type receptor, 
and 0.10 ± 0.03, 0.03 ± 0.02, 0.01 ± 0.01 and 0.11 ± 0.13 % receptors/cell/min 
respectively for D69N. Agonist treatment for 2 hours reduced surface receptor numbers 
by 40 to 70% for wild-type receptor, and by 50 to 60% for D69N. Although 
internalization of cell surface sites was promoted by pilocarpine, desensitization of oxo M-
activated stimulation of PI hydrolysis and inhibition of forskolin-stimulated adenylyl 
cyclase activity was only observed after treatment with full agonists (Figures 3.5, 3.7). 93 
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Figure 3.9: Agonist-promoted receptor internalization rates for wild-type mAchR. 
CHO cells expressing wild-type pmt mAchR were treated with 1 mM carbachol, 
oxo M, acetylcholine or pilocarpine in FD media supplemented with 10% calf serum for 
the times indicated. Fitted lines were obtained by fitting the data with equation 4, and 
resulted in an apparent rate estimate, k (in % receptor/cell/minute) an amplitude, Al, and 
the surface sites that remained after treatments, Y0. Rates obtained were 0.04 ± 0.02, 
0.05 ± 0.03, 0.06 ± 0.03 and 0.1 ± 0.08 % receptors/cell/min for carbachol (solid line), 
oxo M (dotted line), acetylcholine (dashed line) and pilocarpine (dashed-dotted line) 
respectively, with amplitudes of 54.6 ± 17.7, 71.0 ± 18.4, 69.7 ± 18.6 and 39.1 ± 13.6. 
The sites that remained after agonist treatment were 41.3 ± 14.4, 32.9 ± 12.3, 35.2 ± 13.1, 
and 59.6 ± 6.7 % receptors/cell for carbachol, oxo M, acetylcholine and pilocarpine 
respectively. 94 
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Figure 3.10: Agonist-promoted receptor internalization rates for D69N mAchR. 
CHO cells expressing D69N mAchR were treated with 1 mM carbachol, oxo M, 
acetylcholine or pilocarpine in FD media supplemented with 10% calf serum for the times 
indicated. Fitted lines were obtained by fitting the data with equation 4, and resulted in an 
apparent rate estimate, k (in % receptor /cell/minute) an amplitude, Al, and the surface 
sites that remained after treatments, Y0. Rates obtained were 0.10 ± 0.03, 0.03 ± 0.02, 
0.01 ± 0.01 and 0.11 ± 0.13 % receptors/cell/min for carbachol (solid line), oxo M (dotted 
line), acetylcholine (dashed line) and pilocarpine (dashed-dotted line) respectively, with 
amplitudes of 59.3 ± 4.0, 54.3 ± 18.7, 59.3 ± 14.2 and 52.9 ± 13.8. The sites that 
remained after agonist treatment were 40.7 ± 2.1, 49.8 ± 15.9, 41.0 ± 14.7, and 47.2 ± 7.2 
% receptors/cell for carbachol, oxo M, acetylcholine and pilocarpine respectively. 95 
Cells expressing wild-type or mutant receptor were treated with 100 ng/ml PTX 
for 12 hours prior to assays for receptor internalization. This concentration is sufficient to 
completely abolish receptor-effector coupling (Bulseco and Schimerlik, 1996), but did not 
prevent carbachol mediated internalization of surface receptor sites (Table 3.3). 
cGMP induces receptor internalization while Ca2+ and cAMP do not 
The effects of other second messengers were studied to determine the role of 
receptor-effector coupling in receptor internalization. Release of internal Ca2+ was 
stimulated with 1 mM thapsigargin. The cyclic nucleotide analog dibutyryl-cAMP was 
used at concentrations of 11.1M and 1 mM. None of these treatments significantly affected 
cell surface pm2 mAchR expression. Thapsigargin, liAM and 1 mM dibutyryl-cAMP 
resulted in 105.8 ± 14.5, 86.8 ± 3.3 and 88.9 ± 2.1% of control receptor surface sites 
respectively. Treating cells with 50 1.1M forskolin, a concentration sufficient to elevate 
cAMP levels in CHO cells had no effect on receptor expression levels (Table 3.3). 
Sodium nitroprusside (SNP) induces internalization of ml AchR expressed in CHO 
cells (Maggio et al., 1995), presumably via a nitric oxide mediated increase in cGMP 
levels. Treatment with 1 mM SNP, as well as the cGMP analog 8-bromo-cGMP resulted 
in a significant reduction of cell surface mAchR sites. Although 1 11.M 8-bromo-cGMP did 
not significantly reduce surface receptor sites (83.6 ± 9.4%; p = 0.27, Student's t-test), 1 
mM 8-bromo-cGMP and sodium nitroprusside did significantly (p .._ 0.01, Student's t-test) 
reduce expression of surface receptor sites to 73 ± 0.9% and 51.3 ± 0.06% respectively. 96 
Results for D69N were similar to those obtained for wild-type pm2 mAchR for sodium 
nitroprusside (59.1 ± 0.5%, n=4) and 1 mM cGMP (70 ± 1.1%, n=2) treatments. 
Membranes prepared from CHO cells expressing wild-type pm2 AchR were treated with 1 
mM SNP for 1 hour, washed, then resuspended in binding buffer followed by receptor 
binding assays with 10 nM antagonist [3H] /-QNB. This treatment had no affect on total 
receptor sites. Specific activities were 55.7 and 52.9 pmol/mg protein for control and 
SNP-treated membranes respectively, indicating that SNP requires a functioning cell to 
have its affect, and cannot directly reduce m2 mAchR binding sites. 
Loss of surface receptor sites did not always coincide with desensitization. Figures 
3.11 and 3.12 show that treatments which resulted in loss of receptor sites did not affect 
coupling to inhibition of adenylyl cyclase (Figure 3.11) or stimulation of PI metabolism 
(3.12). 97 
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Figure 3.11: Effect of second messenger treatments on mAchR desensitization of 
forskolin-stimulated inhibition of adenylyl cyclase activity. 
CHO cells expressing wild-type receptor were exposed to 1 mM 8-bromo-cGMP, 
1 mM dibutyryl cAMP, 100 }.LM thapsigargin and 1 mM sodium nitroprusside and assays 
for accumulation of cAMP conducted as described in "Material and Methods". The lines 
through the data were obtained by least squares fit to equation 2. IC5Os obtained for 
control (), cAMP (0), cGMP (s), thapsigargin () and sodium nitroprusside (+) 
treated cells were 0.09± 0.0711M, 0.1 ± 0.1 gM, 0.13 ± 0.07 gM, 0.02 ± 0.02 11M and 
0.17 ± 0.09 ptM respectively, with maximal inhibition of 68.3 ± 11.5%, 65.7 ± 11.6%, 
65.9 ± 11.8%, 58.0 ± 12.0% and 70.2 ± 11.6%. EC50 for stimulation of adenylyl cyclase 
was 6.7 ± 4.1 giM, 14.7 ± 9.6  18.6 ± 7.3  11.7 ± 7.6 p.M and 5.8 ± 3.9 ptM for 
control, cAMP, cGMP, thapsigargin and sodium nitroprusside treated cells respectively. 98 
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Figure 3.12: Effect of second messenger treatments on mAchR desensitization of PI 
hydrolysis. 
CHO cells expressing wild-type receptor were exposed to 1 mM 8-bromo-cGMP, 
1 mM dibutyryl cAMP, 10012M thapsigargin and 1 mM sodium nitroprusside and PI 
metabolism assays conducted as described in "Material and Methods". The lines through 
the data were obtained by least squares fit to equation 1. EC5Os obtained for control (), 
cAMP (0), cGMP (s), thapsigargin () and sodium nitroprusside (+) treated cells were 
6.7 ± 4.0 pM, 3.4 ± 1.7 tiM, 1.8 ± 0.9 gM, 1.8 ± 1.4 µM and 2.8 ± 2.71AM respectively, 
with maximal fold stimulation of 1.40 ± 0.06, 1.32 ± 0.04, 1.28 ± 0.04%, 1.30 ± 0.05 and 
1.28 ± 0.07. 99 
Table 3.3: Effect of other treatments on receptor internalization. 
CHO cells expressing wild-type receptor were exposed to treatments as described 
in "Materials and Methods". Results are presented as the percent surface sites remaining 
(of control) after indicated treatments, and are mean ± SEM of two to seven experiments 
(n) each done in duplicate or triplicate. 
Treatment  % Surface Binding  n 
Sites 
Control  100  3 
1 mM Carbachol  69.5 ± 1.0b  7 
1 mM Pilocarpine  69.7 ± 5.6b  6 
1 mM Oxotremorine M  72.3 ± 1.9b  2 
1 IIM dibutyryl-cAMP  86.8 ± 3.3  3 
1 mM dibutyryl-cAMP  88.9 ± 2.1  3 
111M 8-bromo-cGMP  83.6 ± 9.4  3 
1 mM 8 -bromo -cGMP  73.0 ± 0.9b  3 
100 RM Thapsigargin  105.8 ± 14.5  3 
50 !AM Forskolin  97.1 ± 4.4  2 
1 mM Sodium nitroprusside  51.3 ±0.6b  3 
100 ng/m1PTX  98.2 ± 2.1  2 
100 ng/m1PTX +  71.7 ± 1.7"  2 
1 mM carbachol 
a Values represent the mean ± SEM of n determinations, each done in duplicate or  
triplicate.  
b Significantly different from controls (p  0.01, Student's t-test).  100 
Discussion 
Desensitization 
Desensitization is broadly defined as the attenuation of agonist-mediated responses 
after prolonged agonist exposure. The mechanisms involved in receptor desensitization 
often include receptor phosphorylation by protein kinase A (PICA), protein kinase C 
(PKC) or one of a family of G-protein coupled receptor kinases (GRK) (reviewed in 
(Premont et al., 1995)). Rapid uncoupling of the 02 adrenergic receptor from effectors is 
mediated by a member of the GRK family, 0ARK1 (0 adrenergic receptor kinase 1 or 
GRK2), which rapidly phosphorylates receptors. Receptor phosphorylation is not 
sufficient to uncouple receptor from effector systems, and requires that 0-arrestin binds 
the GRK2 phosphorylated receptor, before uncoupling from G-protein activation occurs 
(Lohse et al., 1992). 
The pm2 mAchR is not rapidly uncoupled from effector systems when expressed in 
CHO cells. Cells must be treated for at least two hours with agonist before any 
appreciable change in receptor-effector coupling occurs. GRK2 can phosphorylate the m2 
mAchR in vivo, and receptor internalization appears to depend on GRK2-mediated 
phosphorylation (Tsuga et al., 1994), but rapid uncoupling does not occur. Data for the 
02 adrenergic receptor is more complicated. It is clear that agonist-stimulated 
phosphorylation is important in 02 adrenergic receptor sequestration and desensitization 
(Liggett et al., 1993), but f3-arrestin is also important. Recent evidence indicates that 101 
GRK2 phosphorylation may have a larger role than initially envisioned. Ferguson et al 
(1995) have recently reported that GRK2 phosphorylation facilitates 02 adrenergic 
receptor sequestration and that binding of 0-arrestin to GRK2-phosphorylated receptor 
mediates both agonist-promoted receptor internalization (Ferguson et al., 1996) and rapid 
uncoupling of receptor from G-proteins. pm2 mAchR expressed in CHO cells may not 
rapidly uncouple due to the lack of GRK or 0-arrestin like proteins that would mediate 
rapid uncoupling of the pm2 AchR. Alternatively, these proteins may be expressed at 
levels too low to be effective when mAchR is overexpressed. Since coupling to inhibition 
of adenylyl cyclase is receptor density dependent (Vogel et al., 1995), relatively small 
changes in receptor-effector coupling may be masked by high receptor expression. 
Internalization 
The pm2 mAchR is rapidly internalized when cells are exposed to agonist. Cell 
surface receptor sites of both wild-type and D69N mutant mAchR are reduced to about 
50% of control cells when exposed to agonist for 30 to 60 minutes. Recent evidence 
indicates that different mechanisms mediate internalization and desensitization (Ng et al., 
1995; Pals Rylaarsdam et al., 1995). In addition, steps involved in receptor internalization 
may be separated into an agonist-promoted localization of receptors and an agonist-
independent endocytosis event (von Zastrow and Kobilka, 1994). Internalization of 
receptor will "uncouple" the receptor from both the signaling ligand as well as G-proteins 
located in the plasma membrane. Our results indicate that desensitization as induced by 
full agonists is always accompanied by a reduction in receptor sites, but receptor 
internalization does not necessarily indicate that desensitization will be observed. 102 
Although some of the reduction in effector coupling can be attributed to receptor 
internalization, our results with pilocarpine, a partial agonist, as well as cGMP and SNP 
treatment, emphasizes that internalization alone cannot account for receptor 
desensitization. 
A reduced rate of desensitization for partial agonists has been reported for ml and 
m3 AchR expressed in CHO cells (Hu et al., 1991). Pilocarpine, a partial agonist, affects 
receptor internalization and recycling properties differently than the full agonist carbachol, 
for pm2 mAchR expressed in CHO cellst. While both full and partial agonists resulted in 
surface receptor internalization, desensitization was observed only for the full agonists. 
The unique receptor internalization and recycling properties induced by full and partial 
agonists may indicate that the precise pathway taken by these internalized receptors are 
agonist-dependent and may impact desensitization properties. 
Second messenger analogs  
Other possible mechanisms of receptor internalization and desensitization were 
studied with the use of second messenger analogs. The permeable cyclic nucleotide 
analogs, dibutyryl- cAMP and 8-bromo-cGMP had different effects on cell surface 
expression of pm2 mAchR. 8-bromo-cGMP significantly reduced cell surface receptor 
expression of pm2 mAchR while dibutyryl-cAMP had no effect (Table 3.3). Coupling 
properties were not significantly affected by these analogs, although the slight increase in 
IC50 for inhibition of adenylyl cyclase and reduction in PI maximal response for 8-bromo-
t Bulseco, D.A. and M.I. Schimerlik, in preparation. 103 
cGMP and sodium nitroprusside treatments are consistent with a reduction in surface 
receptor sites. These findings suggest that cAMP-dependent PKA is not involved in 
receptor internalization or desensitization of the pm2 mAchR expressed in CHO cells. 
Alternatively, the effect of phosphorylation may be masked by the high receptor 
expression achieved in these clonal cell lines. 
cGMP may mediate receptor internalization but not desensitization. Sodium 
nitroprusside has been shown to promote receptor internalization of ml AchR expressed 
in CHO cells (Maggio et al., 1995). Our results support these findings. Sodium 
nitroprusside (presumably via an increase in cGMP) and 8-bromo-cGMP reduce surface 
receptor sites to 51% and 73% of control cells respectively.  Muscarinic receptor 
activation of guanylate cyclase may occur indirectly through activation of phospholipase 
C. Metabolism of phosphatidylinositol produces inositol monophosphates and 
diacylglycerol, which may subsequently activate phospholipase A2 resulting in the release 
of arachidonic acid or its lipoxygenase metabolites, which in turn can activate cGMP 
production (McKinney and Richelson, 1989). Although receptor sites are reduced, 
coupling to inhibition of adenylyl cyclase and stimulation of PI hydrolysis is not 
significantly affected by sodium nitroprusside or 8-bromo-cGMP (Figures 3.11 and 3.12). 
Since we did not characterize pm2 mAchR coupling to activation of guanylate cyclase in 
CHO cells, it is possible that this response is desensitized by these treatments while 
coupling to other effectors are not. These findings suggest that guanylate cyclase 
activation, or the action of cGMP phosphodiesterases are not involved in mediating 104 
desensitization of pm2 mAchR to the effector systems studied, and that mechanisms 
mediating receptor internalization and desensitization are distinct. 
Thapsigargin, which increases intracellular Ca2+ concentrations (Dell'Acqua et al., 
1993) had no effect on expression of pm2 mAchR (Table 3.3) or the coupling properties 
of pm2 mAchR to second messenger responses (Figures 3.11 and 3.12). In addition, 
inclusion of EGTA-AM, a cell permeable chelater of divalent cations, did not prevent 
carbachol-induced loss of surface mAchR. Cells pre-treated with 100 1.1M EGTA-AM and 
untreated cells were exposed to 1 mM carbachol resulting in a reduction of cell surface 
receptor sites to 21.6 ± 2.3% and 37.0 ± 5.5% of control cells respectively. EGTA-AM 
alone reduced surface receptor sites to 68.1 ± 8.1% of untreated cells, indicating that the 
effects of this treatment may not be limited to chelation of internal Ca2+ or that chelation 
of Ca2+ results in loss of surface receptor sites. These findings suggest that Ca2+ is not 
directly involved in receptor internalization and desensitization. Since the pm2 mAchR 
couples to PI hydrolysis, it is assumed that intracellular Ca2+ concentration is elevated 
upon agonist stimulation, but further experiments are necessary to determine if this plays a 
role in receptor internalization and desensitization. 
D69N Mutant 
Coupling of the D69N mAchR mutant to effector systems is agonist dependent. 
oxo M is capable of activating both inhibition of adenylyl cyclase and stimulation of PI 
hydrolysis while the other agonists are not. Acetylcholine appears to elicit a slight 
stimulation of adenylyl cyclase, but the response is modest and difficult to characterize. 105 
These results imply that different agonists promote different receptor conformations, 
which can differentially affect the interaction of receptor and G-protein. When the 
analogous mutation was made in the a2-adrenergic receptor (D79N), coupling to 
potassium channels was abolished while inhibition of adenylyl cyclase and Ca2+ currents 
were unaffected (Surprenant et al., 1992). This implies that agonists can promote distinct 
conformations of the receptor that differentially interact with G-proteins, or different G-
protein heterotrimers consisting of different combinations of a and f3y subunits. Finally, 
we have previously shown that oxo M, and to a lesser extent acetylcholine, stimulates PI 
hydrolysis of the mAchR mutant A212E with reduced efficacy relative to carbachol, 
implying agonist specific properties of G-protein activation (Bulseco and Schimerlik, 
1996). 
Coupling is not necessary for internalization and desensitization 
Receptor-effector coupling is not necessary to promote receptor internalization 
(Campbell et al., 1991; Mahan et al., 1985). When D69N was stably expressed in CHO 
cells, agonists that failed to elicit coupling to inhibition of adenylyl cyclase and stimulation 
of PI hydrolysis promoted pm2 mAchR internalization with a time course similar CHO 
cells expressing wild-type receptor at similar densities. This finding is supported by results 
obtained after treating cells with PTX. Cells were incubated with 100 ng/ml prior to 
experiments for receptor internalization. Although this concentration of PTX is sufficient 
to abolish agonist-induced effector activation (Bulseco and Schimerlik, 1996), it did not 
prevent carbachol stimulated internalization of surface receptor sites (Table 3.3). 106 
Contrary to our results, Lameh et al (Lameh et al., 1992) reported that an 
analogous mutation in hml mAchR (D71N) resulted in complete loss of carbachol induced 
receptor internalization, although this finding may be explained by the expression system 
used to characterize the mutant receptor. Experiments with wild-type receptor were 
conducted on stably transfected human kidney cells, while mutant receptors were 
characterized after transient transfection of these cells (Lameh et al., 1992). Although 
both stable and transient transfections yielded cells expressing similar receptor levels (792 
± 347 and 676 ± 34 fmol/mg protein for wild-type and D71N respectively), the 
distribution of expression in the transiently transfected cell lines may play a role in 
determining mAchR internalization properties. While the average receptor levels are 
known in a transiently transfected system, the distribution of expression in these cells 
cannot be characterized. Our experiments conducted on D69N were in a stably 
transfected clonal cell line and our findings suggest that receptor density plays an 
important role in receptor internalization and recycling rates:. 
High affinity binding of oxo M to membranes prepared from CHO cells expressing 
D69N mAchR is sensitive to guanine nucleotides. When membranes were pre-incubated 
with 100 pM GppNHp, a small but detectable reduction in agonist high affinity binding 
was observed when [3H] -NMS competition experiments were done with oxo M, but not 
with carbachol, acetylcholine or pilocarpine. Addition of GppNHp to membranes, also 
results in an increase in [3H] -NMS binding sites, similar to that seen with wild-type pm2 
: Bulseco, D.A. and M.I. Schimerlik, in preparation. 107 
mAchR expressed at similar receptor levels. In addition, preliminary experiments with 
direct binding of [3H] -oxo M also exposes a small but detectable fraction of high affinity 
sites that are sensitive to guanine nucleotides§. These findings indicate that the agonist 
bound D69N receptor/G-protein complex may be stabilized by oxo M but not the other 
agonists, in support of our findings that oxo M uniquely promotes coupling to inhibition of 
adenylyl cyclase and stimulation of PI hydrolysis. One alternative, explanation is that the 
D69N tightly associates with G-proteins and agonist-promoted activation and dissociation 
of G-protein and receptor does not occur. Since D69N is expressed at high receptor 
densities in CHO cells, and receptor is in large excess over available G-proteins, it is 
difficult to distinguish between these two possibilities. 
Effect of partial agonists 
One of the primary objectives of this study was to evaluate the effect of a partial 
agonist on receptor internalization and desensitization for wild-type mAchR and D69N, a 
mutant that couples poorly to effector systems. The use of a partial agonist can provide 
information on internalization and desensitization properties that relates agonist efficacy, 
agonist affinity and receptor-effector coupling. Surprisingly, the results for internalization 
and desensitization were the same for both wild-type and D69N. Carbachol, oxo M, 
acetylcholine and pilocarpine promoted receptor internalization while desensitization was 
only observed with full agonists. Although pilocarpine promoted receptor internalization 
with the same time course for wild-type and D69N, it did not lead to desensitization. 
§ Vogel, W.K., D.J. Broderick, V.A. Mosser, G.L. Peterson, and M.I. Schimerlik, in 
preparation. 108 
Although it is possible that the time course of desensitization is slower for partial agonists 
(Hu et al., 1991), our results are similar when cells are pretreated with pilocarpine for 3 or 
12 hours. In addition, pilocarpine appears to affect receptor internalization and recycling 
properties in a receptor density dependent fashion different from that of carbachol". It is 
likely that agonist-dependent conformational changes of the liganded receptor affects the 
fate of that receptor. This suggestion is supported by observations that oxo M uniquely 
activates effector systems for the D69N mutant, and becomes a partial agonist for an i3 
mutant of the pm2 AchR (Bulseco and Schimerlik, 1996). 
Summary 
These results support the idea that agonist occupancy is sufficient to promote 
receptor internalization. Desensitization appears to be mediated by a distinct mechanism 
from internalization and although we observe a reduction in coupling potency and efficacy 
after prolonged treatment with agonists, some but not all of the observed changes can 
simply be attributed to a reduction in surface receptor sites. Although the partial agonist 
pilocarpine effectively promotes receptor internalization, only the full agonists carbachol, 
acetylcholine and oxo M were able to desensitize second messenger responses. Results 
obtained with the D69N mutant AchR support the conclusion that these responses do not 
require receptor-effector coupling. These findings emphasize the importance of 
considering both the context in which these receptors are expressed (i.e. the cell line) as 
well as the receptor densities achieved in these overexpression systems. Partial agonists 
" Bulseco, D.A. and M.I. Schimerlik, in preparation 109 
may be useful tools to help distinguish the molecular mechanisms of receptor 
internalization and desensitization of G-protein coupled receptors. 110 
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Abstract 
The porcine m2 muscarinic acetylcholine receptor (mAchR) expressed in Chinese 
hamster ovary cells undergoes rapid internalization and recycling upon persistent 
treatment with agonists. The effects of full and partial agonists were dependent on 
receptor densities, as were the final estimated rates of internalization (k3) and recycling 
(k2). When a high expression clonal cell line, pSVE short pm2 c1.1, was treated with 
pilocarpine or carbachol, the receptor recycling rate (k2) was increased two and four fold 
respectively, while the rate of internalization (k3) was increased 14 to 20 fold. Treatment 
of a low expression clonal cell line, pSVE pm2 c1.5, with carbachol also resulted in 
increased recycling (four fold) and internalization (28 fold) rates. The partial agonist, 
pilocarpine, had a modest affect on these rates (about 2 fold). These agonist-dependent 
changes in receptor recycling and internalization rates did not depend on effector-
coupling. A single point mutation in the putative second transmembrane domain of the 
pm2 AchR, D69N resulted in a receptor that does not couple to second messenger 
effector systems, yet internalized and recycled at rates similar to wild-type receptor 
expressed at similar densities. Agonist-promoted rates of receptor degradation (k4) were 
affected by this mutant though. Carbachol did not increase the rate of receptor 
degradation for the mutant D69N, but increased this rate nine and 27 fold for wild-type 
mAchR expressed at low and high receptor densities respectively. These findings suggest 
that receptor internalization and recycling properties are not dependent on effector 
coupling, but are dependent on both receptor expression levels and the agonist used. 112 
Furthermore, receptor degradation appears to be dependent on agonist as well as 
receptor-effector coupling. 
Introduction 
Overview 
The porcine m2 mAchR activates cellular effector systems by coupling through G-
proteins. In Chinese hamster ovary cells, the pmt mAchR couples to both inhibition of 
adenylyl cyclase and stimulation of PI metabolism through the PTX-sensitive Gi isotypes 
(Ashkenazi et al., 1987). Regulation of receptor desensitization is a common cellular 
response to prolonged exposure to agonists (Liggett, 1995). The m2 mAchR is 
phosphorylated (Haga et al., 1990; Haga et al., 1993; Richardson and Hosey, 1990; 
Richardson and Hosey, 1992; Tsuga et al., 1994), internalized and down-regulated in 
response to persistent agonist treatment. It has been suggested that the net effect of these 
processes are to effectively uncouple the receptor from second messenger effectors. In 
addition, receptor internalization and recycling may play an important role in 
resensitization of the m2 mAchR response (Giannini and Boulay, 1995; Hein et al., 1994; 
Hishinuma et al., 1993; Pippig et al., 1995; Yu et al., 1993), although the mechanisms 
underlying these observations are still uncharacterized. 113 
Receptor internalization and desensitization 
Agonist-promoted internalization of the mAchR has been shown to occur in a 
variety of cell types. The rates of receptor internalization and subsequent recycling appear 
to be cell line and receptor subtype (Koenig and Edwardson, 1996; Koenig and 
Edwardson, 1994) dependent. Rapid receptor turnover appears to occur within minutes 
of exposure to agonist, even if the net surface receptor numbers are unchanged (Koenig 
and Edwardson, 1994; von Zastrow and Kobilka, 1994). 
It has been proposed that receptor internalization and recycling functions to 
resensitize receptors following prolonged exposure to agonists (Yu et al., 1993). 
Phosphatases may lead to resensitization by dephosphorylating receptors that are 
internalized (Maloteaux and Hermans, 1994; Roettger et al., 1995). Data suggests that 
internalized receptors are recycled to the plasma membrane with a time course consistent 
with the kinetics of dephosphorylation (Giannini and Boulay, 1995). When cells 
expressing 132 adrenergic receptors were pre-treated with sucrose or concanavalin A, 
which prevents receptor internalization and sequestration, resensitization was also blocked 
(Yu et al., 1993). 
Receptor distribution is altered after agonist treatment. 132-adrenergic receptors 
are rapidly redistributed to pits in the plasma membrane after exposure to agonists, from 
which passive receptor endocytosis can occur (von Zastrow and Kobilka, 1994). Dual 
pathways for agonist-promoted receptor internalization appear to exist for the 
cholecystokinin receptor, a G-protein coupled receptor for a peptide ligand (Roettger et 
al., 1995). Exposure to agonists promotes receptor internalization by both clathrin-coated 114 
and smooth endocytotic pits. Receptors endocytosed via coated pits appear destined for 
degradation while those internalized via smooth endocytotic vesicles remain near the 
plasma membrane and appear to be rapidly dephosphorylated and recycled (Roettger et 
al., 1995). To date, the role of agonist efficacy on regulation of receptor trafficking has 
not been well characterized. Furthermore, receptor density may determine initial receptor 
distribution in the plasma membrane, which may affect properties of agonist-promoted 
receptor trafficking. 
Focus of this study 
In this study, we have characterized the agonist-promoted rates of receptor 
internalization and recycling with full (carbachol) and partial (pilocarpine) agonists at two 
receptor densities. At receptor densities greater than 2.0e6 receptors per cell, both 
carbachol and pilocarpine promoted receptor internalization similarly, while lower 
receptor densities (-1.0e6 receptors per cell) resulted in differences in internalization 
properties for the full and partial agonist. In addition, agonist-promoted internalization of 
a mAchR point mutant (D69N) was characterized. This mutant is expressed at high 
receptor densities, couples poorly to inhibition of adenylyl cyclase and stimulation of PI 
hydrolysis with all agonists except oxo M, yet receptor internalization is similarly 
promoted by carbachol, pilocarpine, oxo M and acetylcholine (Chapter 3). Our results 
indicate that agonist-dependent m2 mAchR internalization is receptor density dependent, 
and does not require receptor-effector coupling. 117 
Receptor expression in Chinese hamster ovary cells 
The mutant pm2 mAchR constructs in pSVE were stably transfected into Chinese 
hamster ovary cells deficient in the gene dihydrofolate reductase (dhfr), and amplified 
with increasing concentrations of methotrexate. High expression wild-type pm2 mAchR 
was overexpressed in CHO cells after removing 75 bases from the 5' untranslated region 
and replacing the weak 5' upstream Kozak sequence (CAAA) with a 'strong' Kozak 
sequence (CACC) (Kozak, 1987)*, to obtain elevated receptor expression. This construct 
resulted in very high receptor expression (2.0 to 4.0 x 106 receptors per cell) in dhfr CHO 
cells, and was necessary to achieve expression levels similar to the D69N mutant AchR. 
Wild-type and mutant receptor cell lines were cloned prior to characterization. The low 
expression clonal cell line (pSVE pm2 c1.5), the high expression clone (pSVE short pm2 
c1.1) as well as the D69N (pSVE D69N c1.1/2) were characterized for internalization and 
desensitization properties. 
Lioand binding 
Receptor expression was assessed in whole cells on 24 well tissue culture dishes by 
the addition of 10 nM [3H] / -QNB in the presence or absence of saturating concentrations 
of the unlabeled antagonists NMS or 1 -QNB in FD media. Cells were incubated for 1.5 to 
2 hours, then washed twice with ice cold phosphate buffered saline (pH 7.4). Cells were 
solubilized with 0.5 ml 1% Triton X-100 in PBS, transferred to scintillation vials then 
counted for tritium. Surface receptor sites were determined by competition of [3H] l -QNB 
with the unlabeled hydrophilic antagonist, NMS, while total receptor was determined in 118 
the presence of unlabeled hydrophobic antagonist, / -QNB. Determination of surface 
receptor sites using this approach gave results within 10% of [3H] -NMS binding. 
Second messenger assays 
Chinese hamster ovary cells expressing wild-type or mutant muscarinic receptors 
were assayed for coupling to second messenger effector systems. Inhibition of forskolin-
stimulated adenylyl cyclase assays were conducted on either 35 mm or 24 well culture 
dishes. All assays for agonist-stimulated phosphatidyl inositol metabolism were conducted 
on 24 well dishes. Surface receptor expression as well as total receptor expressed was 
assessed for each second messenger assay conducted. Wild-type receptor was expressed 
at approximately 1.0 x 106 (pSVE c1.5) or 2.0 x 106 (pSVE short c1.1) surface sites per 
cell, while the D69N AchR mutant cell line expressed approximately 2.0 x 106 surface 
sites per cell. 
Stably transfected CHO cells expressing wild-type or mutant pm2 were assayed for 
agonist-stimulated metabolism of phosphatidyl inositol as described (Bulseco and 
Schimerlik, 1996). Cells were plated in 24 well dishes at an initial density of 1.0 to 2.0 x 
105 cells per well in Dulbecco's Modified Eagle Medium (FD) supplemented with 10% calf 
serum (Sigma).  1 ptCi/m1 [3H]- myo- inositol was added and cells incubated at 37° C for 24 
hours. Prior to the assay, cells were treated for 30 minutes with 10 mM lithium chloride in 
FD at 37° C. After addition of agonists, cells were incubated for an additional 30 minutes 
at 37° C and reactions stopped with 5% trichloroacetic acid. Extracts were diluted with 
distilled water, then neutralized with 1 N sodium hydroxide. Samples were applied to 
columns containing 0.6 ml of AG 1-X8 anion exchange resin (BioRad), washed with 10 ml 119 
of distilled water followed by 2 ml of 5 mM sodium tetraborate, 60 mM sodium formate. 
Inositol monophosphates (IP1) were eluted with 2 ml of 0.2 M ammonium formate, 0.1 M 
formic acid. 
Assays for cAMP levels were conducted on CHO cells expressing wild-type or 
mutant receptors plated on 35 mm or 24 well tissue culture dishes as described (Bulseco 
and Schimerlik, 1996). Cells were incubated with [3H]-adenine (1 or 2 tiCi/m1) for two to 
four hours at 37° C in FD supplemented with 10% calf serum. Cells were washed twice 
with 1 ml FD media, and assayed for inhibition of forskolin-stimulated adenylyl cyclase 
activity in the presence of phosphodiesterase inhibitors 0.5 mM Ro 20-1724 and 100 gM 
B3MX. The reaction was stopped by aspiration of the media, followed by addition of 0.3 
ml 2% SDS, 1.3 mM cAMP. [14C]-cAMP was added to each plate to correct for cAMP 
recovery, followed by 0.75 ml distilled water and 0.1 ml perchloric acid. The extract was 
transferred to 1.5 ml microcentrifuge tubes containing 0.1 ml potassium hydroxide at a 
concentration sufficient to neutralize an equivalent volume of perchloric acid (usually 
11.5 M). The tubes were vortexed, then centrifuged at 4° C for 10 minutes at 12,000 rpm. 
The supernatant from each tube was transferred to columns containing 2 ml of AG 50W-
X4 Dowex (BioRad) resin. After washing with 6 ml distilled water, the samples were 
eluted onto columns made with 0.5 g dry Alumina resin (Sigma) with an additional 6 ml of 
water. The cAMP was eluted from the alumina columns directly into scintillation vials 
with 4 ml of 0.1 M imidazole buffer (pH 7.3), and samples counted for both [14C] -cAMP 
and [3H] -cAMP. 120 
Assays for receptor desensitization were conducted as described above after 
exposing CHO cells to the appropriate treatments. All agonists were used at a 
concentration of 1 mM, in FD supplemented with 10% calf serum, and cells exposed for 
three or 12 hours. 
Assays for receptor internalization and recycling 
Agonist-promoted pmt mAchR internalization and recycling rates were estimated 
as described (Koenig and Edwardson, 1996; Koenig and Edwardson, 1994). Receptor 
recycling rates were determined after blocking surface receptor binding sites with 
benzilylcholine mustard (BCM). Stock BCM was diluted to 10 RM in 10 mM NaPO4, 1 
mM EDTA, pH 7.5 and cyclized for 30 minutes at room temperature. A final 
concentration of 0.1 gM BCM was used to block surface receptor sites on untreated cells, 
cells treated with 20 µM cycloheximide for 1 hour, and cells treated with cycloheximide 
followed by 1 mM carbachol or pilocarpine. Cells were allowed to recover in FD media 
supplemented with 10% calf serum over a period of 120 minutes. At the specified times, 
cells were washed twice with FD media and ligand binding conducted as described above. 
Rate of receptor internalization was determined by following the time course of agonist-
promoted loss of surface receptor sites in cells treated with carbachol or pilocarpine in FD 
media + 10% calf serum. 121 
Data analysis 
Data from effector coupling assays were fit to the logistic equation. Equation 1 
was used for PI assays, with a third term added (Eq. 2) to account for a stimulatory phase 
observed in the cAMP assays (Bulseco and Schimerlik, 1996). 
(max min)
Y = min+  (Eq. 1)
1+ (EC50/ )p /[xy 
(max 1 min)  (max 2  min)
Y  (Eq. 2) 
1+ (EC50,,Xx3)pl 
1+ ([xYEC50i) P 
In each of these equations [x] is the agonist concentration used; max, maxi or 
max2 and min are the maximum and minimum plateaus of the curves; and p or pl the 
respective slope factors. 
Data from receptor internalization and recycling experiments were fit to Equation 
3 (Koenig and Edwardson, 1994) where k1 is the rate of new receptor synthesis; k2 is the 
rate of receptor recycling from endosomes to the plasma membrane; k3 the rate of receptor 
internalization; k4 the rate of receptor degradation; Rs, the surface (plasma membrane) 
receptor sites with initial value of Rs0 at t=0; Re, the internal (endosomal) receptor sites 
with an initial value of Re0 at tom. 
(Eq. 3) 
(kl+k2Re0+k2(k4k1))( e(k2+1c3)t )+ Rs0(k2 +k3e-{k2143)t )  k2(k4 kOt Rs (Xk2+k3)) 
1 
(k2+k3 
Equation 3 can be simplified by manipulation of experimental conditions. 
Rs = Re0*(1e-k2`)+kit  (Eq. 4) 122 
In the absence of agonist, it is assumed that k3 and k4 are negligible. When cells 
are treated with BCM, all surface sites are blocked and Rs0 can be fixed at 0 resulting in 
Eq. 4. Treatment with cycloheximide prevents new synthesis, allowing k1 to be fixed at 0 
which eliminates the linear term (k11) in Eq. 4. BCM experiments (n=4) done in the 
presence or absence of cycloheximide (in duplicate or triplicate) were pooled and the 
recycling rate constant (k2), the rate of new synthesis (k1) and the endosomal pool of 
mAchR (Re0) estimated by fitting the data to equation 4. These values were used in 
equation 3 to estimate receptor internalization rate (k3) and rate of receptor degradation 
(k4). 
Agonist binding data were fit assuming three non-interacting classes of sites using 
the equation below (Vogel et al., 1995). 
[Roi]([Lo][RL1)
[Rii= E  (Eq. 5) 
Kd + K / Ki 
[Roi] is the total receptor concentration for each receptor site; [Lo], the total 
concentration of radiolabeled tracer used in the experiment with dissociation constant Kd; 
and [I], the total unlabeled competing agonist with dissociation constant Ki. 123 
Results 
Expression in Chinese hamster ovary cells 
Clonal CHO cell lines expressing wild-type pm2 mAchR were selected at both low 
and high expression levels. The low expression cell line (pSVE pm2 c1.5) displayed 
between 0.8 to 1.2 x 106 receptors per cell, while the high expression wild-type cell line 
(pSVE pm2 short c1.1) expressed between 2.0 and 4.0 x 106 receptors per cell. In both 
cases, approximately 90% of the receptors expressed were present in the plasma 
membrane and accessible to the hydrophilic antagonist NMS. D69N mutant mAchR was 
also expressed at high levels in CHO cells. Between 2.0 and 2.8 x 106 receptors per cell 
were regularly expressed throughout these experiments, with at least 90% of the receptors 
localized to the plasma membrane. 
Time course of receptor internalization 
The time course of receptor internalization in response to prolonged agonist 
treatment is dependent on receptor density and the agonist used. Figures 4.1 and 4.2 
show surface and total receptor remaining after treatment with the full agonist, carbachol, 
and the partial agonist, pilocarpine, for CHO cells expressing low (c1.5) and high (c1.1) 
pm2 mAchR levels. Carbachol significantly (p  0.01, Student's t-test) reduced surface 
receptor sites to 41 ± 12 % and 37 ± 1 % of control for cells expressing both low (Figure 
4.1) and high (Figure 4.2) receptor levels respectively. Pilocarpine on the other hand, 
significantly (p  0.01, Student's t-test) reduced surface receptor number to 49 ± 3 % of 124 
control only for the c1.1 CHO cell line which expresses the mAchR at high density. Cells 
expressing low mAchR densities were not affected by prolonged exposure to pilocarpine. 
To further characterize these observations, agonist-dependent rates of receptor 
internalization were studied as previously described (Koenig and Edwardson, 1996; 
Koenig and Edwardson, 1994), in CHO cell lines expressing low or high receptor 
numbers. Cycloheximide did not appear to significantly affect carbachol-stimulated 
internalization of receptor sites for the first 120 minutes of treatment (Figure 4.3). Both 
surface and total receptor numbers were similar to results obtained in the absence of 
cycloheximide. Cycloheximide did appear to prevent the degradation of internalized 
receptor during longer exposure to carbachol. This resulted in greater total receptor 
numbers at four to six hours of carbachol treatment, than is observed in the absence of 
cycloheximide. Since the experiments described were conducted within 120 minutes, it is 
assumed that cycloheximide does not have a significant affect on the observed rates. 
The time course of agonist-promoted receptor internalization was used to obtain 
estimates of k3 and k4, the rates of receptor internalization and degradation respectively. 
Figure 4.4 shows the effects of carbachol and pilocarpine on surface receptor number for 
c1.5. Carbachol treatment resulted in about 50% loss of surface receptor sites, while 
pilocarpine had no affect. The estimated rates of receptor recycling (k2) for carbachol and 
pilocarpine treated cells were 0.054 and 0.019 % receptor/cell/minute respectively while 
untreated cells displayed a recycling rate of 0.012 % receptor/cell/minute (Figures 4.7 and 
4.11). Carbachol treatment resulted in a 28 fold increase in rate of receptor 
internalization. The estimated rates of receptor internalization (k3) were 0.0026 ± 0.0005, 125 
0.074 ± 0.005 and 0.005 ± 0.001 % receptor/cell/minute for untreated, carbachol and 
pilocarpine treated cells respectively. Similarly, carbachol increased the rate of receptor 
degradation about 9 fold, with k4 = 0.28 ± 0.09 % receptor/cell/minute compared to 
0.031 ± 0.069 and 0.05 ± 0.01 % receptor/cell/minute for control and pilocarpine treated 
cells respectively (Table 4.1). 
The results observed for the partial agonist, pilocarpine, were different for the 
CHO cell line expressing high receptor densities. Figure 4.5 shows that both carbachol 
and pilocarpine exposure resulted in a 50% loss of surface receptor sites. The estimated 
rates of receptor recycling (k2) for carbachol and pilocarpine treated cells were 0.043 and 
0.027 % receptor/cell/minute respectively while untreated cells displayed a recycling rate 
of 0.011 % receptor/cell/minute (Figures 4.8 and 4.12). Carbachol treatment resulted in a 
22 fold increase in rate of receptor internalization while pilocarpine increased 
internalization rate about 16 fold. The estimated rates of receptor internalization (k3) were 
0.0027 ± 0.0005, 0.059 ± 0.011 and 0.043 ± 0.008 % receptor/cell/minute for untreated, 
carbachol and pilocarpine treated cells respectively. Receptor degradation was also 
affected by agonist treatment, with a 26 fold increase for carbachol treated cells (0.37 ± 
0.24 % receptor/cell/minute) and a six fold increase for pilocarpine treated cells (0.090 ± 
0.029 % receptor/cell/minute), while untreated cells displayed a degradation rate constant 
of 0.014 ± 0.066 % receptor/cell/minute (Table 4.1). 
Agonist-promoted internalization of the pm2 mAchR is independent of receptor-
effector coupling. The D69N mutant fails to couple to second messenger systems for all 
agonists studied except oxo M. Figure 4.6 shows that both carbachol and pilocarpine 126 
treatments resulted in about 60% loss of surface receptor sites. The estimated rates of 
receptor recycling (k2) for cells treated with carbachol and pilocarpine were 0.044 and 
0.042 % receptor/cell/minute respectively while untreated cells displayed a recycling rate 
of 0.060 % receptor/cell/minute (Figures 4.8 and 4.12). Carbachol treatment resulted in a 
15 fold increase in rate of receptor internalization while pilocarpine increased 
internalization rate about 14 fold. The estimated rates of receptor internalization (k3) were 
0.0072 ± 0.0011, 0.109 ± 0.011 and 0.100 ± 0.019 % receptor/cell/minute for untreated, 
carbachol- and pilocarpine-treated cells respectively. The results for receptor degradation 
were different than those seen for CHO cells expressing wild-type receptor. Carbachol 
had no affect on apparent rate of receptor degradation, and pilocarpine reduced the 
degradation rate by 80 fold. The estimated rates (k4) were 0.081 ± 0.034, 0.090 ± 0.020 
and 0.001 ± 0.003 % receptors/cell/minute for untreated, carbachol-treated and 
pilocarpine-treated cells respectively (Table 4.1). 
Time course of receptor recycling 
The rates of m2 mAchR recycling when expressed in CHO cells were affected by 
agonist exposure. Carbachol increased the rate of receptor recycling at low receptor 
densities, while both pilocarpine and carbachol increased recycling rate when receptor was 
expressed at high densities. In order to characterize these rates, it was necessary to 
eliminate receptors at the cell surface and follow the time course of receptor appearance in 
the absence of new protein synthesis. Cells expressing m2 mAchR were exposed to 
cycloheximide (20 iiM, 1 hour) before agonist treatments. Benzilylcholine mustard 
(BCM) was then used to covalently block all surface receptor sites and the time course of 127 
receptor recovery at the cell surface followed for 120 minutes.  The treatment maximally 
resulted in 90% loss of surface receptor sites, although as little as 75% loss of sites were 
observed for some experiments. Experiments in which BCM treatment failed to reduce 
the surface receptor sites by at least 85% were not used in the analysis presented in this 
report. In each case, the residual binding after BCM treatment was subtracted prior to 
data analysis. 
The time course of receptor appearance on the cell surface was dependent on 
agonist used as well as receptor density. For the low expressing cell line, the full agonist 
carbachol resulted in a four fold increase in recycling rate (k2) while pilocarpine had little 
effect. Figures 4.7 and 4.11 show recovery of surface receptor after carbachol and 
pilocarpine treatments respectively. The recycling rates estimated from the analysis were 
0.054 ± 0.014 % receptor/cell/minute for carbachol and 0.019 ± 0.008 % 
receptor/cell/minute for pilocarpine-treated cells, while cells treated with cycloheximide 
alone displayed a recycling rate of 0.012 ± 0.003 % receptors/cell/minute. 
For the high expressing clonal cell line, carbachol and pilocarpine had similar 
effects on the rates of receptor recycling, increasing k2 by four and two fold respectively. 
Figures 4.8 and 4.12 show recovery of surface receptor after carbachol and pilocarpine 
treatments. The recycling rates estimated from the analysis were 0.043 ± 0.013 % 
receptor/cell/minute for carbachol and 0.027 ± 0.009 % receptor/cell/minute for 
pilocarpine treated cells, while cells treated with cycloheximide alone displayed a recycling 
rate of 0.011 ± 0.004 % receptors/cell/minute. 128 
The rate of receptor recycling for the D69N mutant AchR was unaffected by 
carbachol or pilocarpine treatment, although high receptor densities are expressed and 
both agonists promote net receptor internalization. Figures 4.9 and 4.13 show recovery of 
surface receptor after carbachol and pilocarpine treatments. The recycling rates estimated 
from this analysis were 0.044 ± 0.007, 0.043 ± 0.007 and 0.027 ± 0.011 % 
receptors/cell/minute for carbachol, pilocarpine and cycloheximide treated cells 
respectively. 129 
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Figure 4.1: Low expression (c1.5) total and surface receptor sites remaining after 
agonist treatments. 
Cells were treated with carbachol or pilocarpine in FD + 10% calf serum for the 
indicated times. [3H] d -QNB was displaced with unlabeled / -QNB to determine total 
receptor binding sites and unlabeled NMS for determination of surface receptor sites. 
Data are presented as percent sites of control remaining after specified treatments (n---2 or 
3, each done in triplicate). Carbachol treatments resulted in significant reduction in 
surface receptor sites (*, p  0.01, Student's t-test). 130 
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Figure 4.2: High expression (c1.1) total and surface receptor expression after agonist 
treatments 
Cells were treated with carbachol or pilocarpine in FD + 10% calf serum for the 
indicated times. [3H] / -QNB was displaced with unlabeled / -QNB to determine total 
receptor binding sites and unlabeled NMS for determination of surface receptor sites. 
Data are presented as percent sites of control remaining after specified treatments (n=2, 
each done in triplicate). Both carbachol and pilocarpine treatments resulted in differences 
significant from untreated c1.1 cells (*, p 5 0.01, Student's t-test). 131 
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Figure 4.3: Effect of cycloheiimide on c1.5 receptor down regulation. 
Cycloheximide treated cells were exposed to 1 mM carbachol in FD + 10% calf 
serum for the times indicated. [3FI] / -QNB was displaced with unlabeled / -QNB to 
determine total receptor binding sites and unlabeled NMS for determination of surface 
receptor sites. Data are presented as percent sites of control remaining after carbachol 
treatment for the specified times (n=3, each done in triplicate). 132 
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Figure 4.4: Low expression (c1.5) time course of receptor internalization after 
treatment with carbachol or pilocarpine. 
CHO cells expressing approximately 1 e6 wild-type mAchRs per cell were treated 
with 1 mM carbachol or pilocarpine in FD media supplemented with 10% calf serum for 
the times indicated. Data are reported as the mean (n=4, each done in duplicate or 
triplicate) of the percent surface sites of control. Error bars were omitted for clarity. 
Values were determined with errors of less than 10%. Fitted lines were obtained by 
nonlinear least squares curve fitting to equation 3. Rates are reported as % receptors/cell 
per minute and Re0 as % of initial surface receptor density. Values used for k1, k2, Re0 
and Rs0 were determined in experiments utilizing BCM treatments, and fixed at the 
following values. k1 was fixed at 0.00153 and Rs0 at 100 for all treatments while control, 
carbachol and pilocarpine treated cells were fixed at, k2 = 0.012, Re0 = 23.42; k2 = 0.054, 
Re0 = 47.15; and k2 = 0.019, Re0 = 39.79 respectively. k3 and k4 for control, carbachol 
and pilocarpine treated cells were k3 = 0.0026 ± 0.0005, Ica = 0.031 ± 0.069 k3 = 0.074 ± 
0.005, k4 = 0.28 ± 0.09 ,  and k3 = 0.005 ± 0.001, Ica = 0.05 ± 0.01 respectively. 133 
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Figure 4.5: High expression (c1.1) time course of receptor internalization after 
treatment with carbachol or pilocarpine. 
CHO cells expressing greater than 2e6 wild-type mAchRs per cell were treated 
with 1 mM carbachol or pilocarpine in FD media supplemented with 10% calf serum for 
the times indicated. Data are reported as the mean (n=4, each done in duplicate or 
triplicate) of the percent surface sites of control. Error bars were omitted for clarity. 
Values were determined with errors of less than 10%. Fitted lines were obtained by 
nonlinear least squares curve fitting to equation 3. Rates are reported as % receptors/cell 
per minute and Re0 as % of initial surface receptor density. Values used for k1, k2, Re0 
and Rs0 were determined in experiments utilizing BCM treatments, and fixed at the 
following values. k1 was fixed at 0.00285 and Rs0 at 100 for all treatments while control, 
carbachol and pilocarpine treated cells were fixed at, k2 = 0.011, Re0 = 21.34; k2 = 0.043, 
Re0 = 26.84; and k2 = 0.027, Re0 = 29.55 respectively. k3 and k4 for control, carbachol 
and pilocarpine treated cells were k3 = 0.0027 ± 0.0005, k4 = 0.014 ± 0.066 ; k3 = 0.059 ± 
0.011 k4 = 0.37 ± 0.24 , and k3 = 0.043 ± 0.008, k4 = 0.090 ± 0.029 respectively. 134 
110 
1 0 0 - + 
+ 
+ 
+ 
-I-
9 0 -
Carbachol 
8 0 - o  Pilocarpine 
7 0 -
e:o 
0 
+  Control 
6 0 -
.... 
5 0 -
4 0 - '  '- ......... 0  0.  0 
0 
30-
20  .  I  .  I  -.  I  I  I 
0  25  50  75  100  125 
Time (min) 
Figure 4.6: D69N mutant AchR time course of receptor internalization after 
treatment with carbachol or pilocarpine. 
CHO cells expressing greater than 2e6 D69N mutant mAchRs per cell were 
treated with 1 mM carbachol or pilocarpine in FD media supplemented with 10% calf 
serum for the times indicated. Data are reported as the mean (n=4, each done in duplicate 
or triplicate) of the percent surface sites of control. Error bars were omitted for clarity. 
Values were determined with errors of less than 10%. Fitted lines were obtained by 
nonlinear least squares curve fitting to equation 3. Rates are reported as % receptors/cell 
per minute and Re0 as % of initial surface receptor density. Values used for k1, k2, Re0 
and Rs0 were determined in experiments utilizing BCM treatments, and fixed at the 
following values. k1 was fixed at 0.0684 and Rs0 at 100 for all treatments while control, 
carbachol and pilocarpine treated cells were fixed at, k2 = 0.0595, Re0 = 10.37; k2 = 
0.0435, Re0 = 28.72; and k2 = 0.0424, Re0 = 30.39 respectively. k3 and k4 for control, 
carbachol and pilocarpine treated cells were k3 = 0.0072 ± 0.0011, ka = 0.081 ± 0.034 ; k3 
= 0.109 ± 0.011, k4= 0.090 ± 0.020 , and k3 = 0.100 ± 0.019, kt = 0.001 ± 0.003 
respectively. 135 
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Figure 4.7: Low expression: recovery/recycling of receptor after BCM treatment. 
CHO cells expressing about 1e6 wild-type mAchRs per cell were left untreated, or 
treated with cycloheximide alone, or 1 mM carbachol + cycloheximide in FD media 
supplemented with 10% calf serum for the times indicated. BCM was added to all cells 
and recovery of surface expression levels determined at the times specified. Data are 
reported as the mean ± S.E.M. (n=4 each done in duplicate or triplicate) of the percent 
surface sites of control. Fitted lines were obtained by nonlinear least squares curve fitting 
to equation 4. Rates are reported as % receptors/cell/min and Re0 as % of initial surface 
receptor density. Values obtained for untreated cells were k1 = 0.002 ± 0.001, k2 fixed at 
0.012, Re0 = 23.41 ± 1.94, for cycloheximide treated cells, k1 fixed at 0, k2 = 0.012 ± 
0.003, Re0 = 35.67 ± 5.30 and for carbachol + cycloheximide treated cells, k1 fixed at 0, 
k2 = 0.054 ± 0.014 and Re0 = 47.15 ± 3.86. 136 
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Figure 4.8: High expression: carbachol stimulated recovery/recycling of receptor 
after BCM treatment. 
CHO cells expressing greater than 2e6 wild-type mAchRs per cell were left 
untreated, or treated with cycloheximide alone, or 1 mM carbachol + cycloheximide in FD 
media supplemented with 10% calf serum for the times indicated. BCM was added to all 
cells and recovery of surface expression levels was determined at the times specified. Data 
are reported as the mean ± S.E.M. (n=4 each done in duplicate or triplicate) of the percent 
surface sites of control. Fitted lines were obtained by nonlinear least squares curve fitting 
to equation 4. Rates are reported as % receptors/cell/min and Re0 as % of initial surface 
receptor density. Values obtained for untreated cells were k1= 0.003 ± 0.001, k2 fixed at 
0.01, Re0 = 21.34 ± 1.26, for cycloheximide treated cells, k1 fixed at 0, k2 = 0.011 ± 
0.004, Re0 = 28.93 ± 6.13 and for carbachol + cycloheximide treated cells, k1 fixed at 0, 
k2 = 0.043 ± 0.013 and Re0 = 26.83 ± 2.72. 137 
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Figure 4.9: D69N: carbachol stimulated recovery/recycling of receptor after BCM 
treatment. 
CHO cells expressing greater than 2e6 D69N mutant mAchRs per cell were left 
untreated, or treated with cycloheximide alone, or 1 mM carbachol + cycloheximide in FD 
media supplemented with 10% calf serum for the times indicated. BCM was added to all 
cells and recovery of surface expression levels was determined at the times specified. Data 
are reported as percent surface sites of control from a representative experiment. Fitted 
lines were obtained by nonlinear least squares curve fitting to equation 4. Rates are 
reported as % receptors/cell/min and Re0 as % of initial surface receptor density. Values 
obtained for untreated cells were k1 = 0.069 ± 0.026, k2 fixed at 0.059, Re0 = 10.37 ± 2.5, 
for cycloheximide treated cells, k1 fixed at 0, k2 = 0.027 ± 0.011, Re0 = 16.90 ± 2.69 and 
for carbachol + cycloheximide treated cells, k1 fixed at 0, k2 = 0.0438 ± 0.007 and Re0 = 
28.72 ± 1.60. 138 
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Figure 4.10: Calf serum is required for receptor internalization and down 
regulation. 
CHO cells expressing approximately 1.2e6 wild-type mAchRs per cell were 
exposed to 1 mM carbachol in serum free FD media for the times indicated. [3H] / -QNB 
was displaced with unlabeled 1 -QNB to determine total receptor binding sites and 
unlabeled NMS for determination of surface receptor sites. 139 
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Figure 4.11: Low expression: pilocarpine stimulated recovery/recycling of receptor 
after BCM treatment 
CHO cells expressing about 1 e6 wild-type mAchRs per cell were left untreated, or 
treated with cycloheximide alone, or 1 mM pilocarpine + cycloheximide in FD media 
supplemented with 10% calf serum for the times indicated. BCM was added to all cells 
and recovery of surface expression levels determined at the times specified. Data are 
reported as the mean ± S.E.M. (n=4 each done in duplicate or triplicate) of the percent 
surface sites of control. Fitted lines were obtained by nonlinear least squares curve fitting 
to equation 4. Rates are reported as % receptors/cell/min and Re0 as % of initial surface 
receptor density. Values obtained for untreated cells were k1 = 0.002 ± 0.001, k2 fixed at 
0.012, Re0 = 23.41 ± 1.94, for cycloheximide treated cells, k1 fixed at 0, k2 = 0.012 ± 
0.003, Re0 = 35.67 ± 5.30 and for pilocarpine + cycloheximide treated cells, k1 fixed at 0, 
k2 = 0.019 ± 0.008 and Re0 = 39.79 ± 7.45. 140 
0  50  100  150 
Time (min) 
Figure 4.12: High expression: pilocarpine stimulated recovery/recycling of receptor 
after BCM treatment 
CHO cells expressing greater than 2e6 wild-type mAchRs per cell were left 
untreated, or treated with cycloheximide alone, or 1 mM pilocarpine + cycloheximide in 
FD media supplemented with 10% calf serum for the times indicated. BCM was added to 
all cells and recovery of surface expression levels was determined at the times specified. 
Data are reported as the mean ± S.E.M. (n=4 each done in duplicate or triplicate) of the 
percent surface sites of control. Fitted lines were obtained by nonlinear least squares 
curve fitting to equation 4. Rates are reported as % receptors/cell/min and Re0 as % of 
initial surface receptor density. Values obtained for untreated cells were k1 = 0.003 ± 
0.001, k2 fixed at 0.01, Re0 = 21.34 ± 1.26, for cycloheximide treated cells, k1 fixed at 0, 
k2 = 0.011 ± 0.004, Re0 = 28.93 ± 6.13 and for pilocarpine + cycloheximide treated cells, 
k1 fixed at 0, k2 = 0.027 ± 0.009 and Re0 = 29.55 ± 4.10. 141 
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Figure 4.13: D69N: pilocarpine stimulated recovery/recycling of receptor after BCM 
treatment 
CHO cells expressing greater than 2e6 D69N mutant mAchRs per cell were left 
untreated, or treated with cycloheximide alone, or 1 mM pilocarpine + cycloheximide in 
FD media supplemented with 10% calf serum for the times indicated. BCM was added to 
all cells and recovery of surface expression levels was determined at the times specified. 
Data are reported as percent surface sites of control from a representative experiment. 
Fitted lines were obtained by nonlinear least squares curve fitting to equation 4. Rates are 
reported as % receptors/cell/min and Re0 as % of initial surface receptor density. Values 
obtained for untreated cells were k1 = 0.069 ± 0.026, k2 fixed at 0.059, Re0 = 10.37 ± 2.5, 
for cycloheximide treated cells, k1 fixed at 0, k2 = 0.027 ± 0.011, Re0 = 16.90 ± 2.69 and 
for pilocarpine + cycloheximide treated cells, k1 fixed at 0, k2 = 0.043 ± 0.007 and Re0 = 
30.39 ± 1.63. 142 
Auonist- promoted increase in endosomal receptor stores 
Initial number of endosomal receptors may be increased by exposure to agonists. 
Determination of Re0, or receptor stored in endosomes at t = 0, shows that both full and 
partial agonists increased the estimated parameter Re0 independent of receptor density. 
Analysis of surface receptor recovery after cycloheximide and BCM treatment depend on 
recycling rate constant (k2) and initial endosomal receptor number (Re0) after agonist 
treatment. Figures 4.7 and 4.11 show the time course of surface receptor recovery for 
CHO cells expressing wild-type pm2 mAchR at low receptor densities. Estimated values 
for Re0 were 23.41 ± 1.94, 47.15 ± 3.86 and 39.79 ± 7.45 % receptors for untreated, 
carbachol-treated and pilocarpine-treated cells respectively. For CHO cells expressing 
wild-type pmt mAchR at high densities (Figures 4.8 and 4.12), these values were 
estimated to be 21.34 ± 1.26, 26.83 ± 2.72 and 29.55 ± 4.10 % receptors for untreated, 
carbachol- and pilocarpine- treated cells. Figures 4.9 and 4.13 show the time course of 
surface receptor recovery for D69N mutant mAchR. Re0 for this mutant was estimated to 
be 10.37 ± 2.5, 28.72 ± 1.60 and 30.39 ± 1.63 % receptors for untreated, carbachol- and 
pilocarpine-treated cells respectively. 
Although Re0 is increased after treatment with agonists, cycloheximide in the 
absence of agonists appears to contribute to this increase. Re0 was estimated to be 35.67 
± 5.30, 28.93 ± 6.13 and 16.90 ± 2.69 % receptors for low expression wild type, high 
expression wild-type and D69N mutant AchR respectively. When this result is considered, 143 
it appears that agonist treatment only affects endosomal receptor number for the low 
expression wild-type cell line and the CHO cell line expressing D69N mutant AchR. 
Monist-promoted receptor degradation 
Prolonged exposure to agonists increased the apparent receptor degradation rate 
(k4). For wild-type receptors, carbachol had a large affect on k4, while pilocarpine's affect 
was modest (Table 4.1). CHO cells expressing low (c1.5) wild-type pm2 mAchR levels 
displayed estimated values for k4 of 0.03, 0.28 and 0.05 % receptors/cell/minute for 
untreated, carbachol and pilocarpine-treated cells respectively. CHO cells expressing high 
receptor numbers, displayed estimated rates of 0.01, 0.38 and 0.09 % 
receptors/cell/minute for untreated, carbachol and pilocarpine-treated cells. Receptor-
effector coupling may be necessary for agonist-promoted receptor degradation. When the 
D69N mutant AchR was exposed to carbachol, k4 was unchanged, while pilocarpine 
treatment led to a reduction in degradation rate. 
Time course of desensitization 
Uncoupling of the pm2 AchR from second messenger effector systems did not 
follow the same time course as receptor internalization and was observed only after 
treatment with the full agonist carbachol. Although treatment with the partial agonist, 
pilocarpine reduced surface receptor numbers in CHO cells expressing greater than 2.0 x 
106 wild-type m2 AchR, it did not lead to desensitization. In addition, cells treated with 
carbachol in the absence of calf serum displayed an attenuation of effector coupling with 
less than 10% reduction in surface receptor sites. 144 
When CHO cells expressing wild-type mAchRs were exposed to carbachol for 
three or 12 hours, desensitization was observed for coupling to inhibition of adenylyl 
cyclase (Figures 4.14, 4.15) and stimulation of PI metabolism (Figures 4.16 and 4.17). 
Exposing these cells to pilocarpine for three or 12 hours did not lead to significant 
changes in coupling properties, although surface receptor number is reduced (Figures 4.1 
and 4.2). Tables 4.3 and 4.4 summarize the results obtained for desensitization of wild-
type receptor. Carbachol treatment resulted in an 18 fold and a 6 fold increase in IC50 for 
CHO cells expressing low and high pm2 mAchR numbers respectively, accompanied by a 
35% and 12% reduction in maximal response when inhibition of adenylyl cyclase was 
measured. Carbachol exposure effectively eliminated measurable coupling to stimulation 
of PI metabolism. Pilocarpine treatment had a modest effect on IC50 for coupling to 
inhibition of adenylyl cyclase. CHO cells expressing low pm2 mAchR numbers displayed 
a two fold increase in IC50, while CHO cells expressing high receptor numbers showed 
roughly a two fold decrease in IC50. In each case, maximum % inhibition was unchanged 
when compared to control cells. Similar results were obtained for D69N when exposed to 
1 mM carbachol or pilocarpine for 4 (See Figures 3.5 and 3.7) or 8 hours (n=1, data not 
shown) prior to second messenger assays. 
Rapid receptor internalization and desensitization of CHO cells expressing pm2 
mAchR requires that agonist treatment be conducted in the presence of 10% calf serum. 
When calf serum is omitted, the time course of carbachol promoted receptor 
internalization is altered (Figure 4.10), and less than 10% of the surface receptor sites are 
lost after 3 hours of treatment. Although very little surface receptor sites are lost, there is 145 
a reduction in maximum percent inhibition of forskolin-stimulated inhibition of adenylyl 
cyclase from 71% to 57%, and a modest 4 fold increase in 1050 from 0.3711M to  1.54 
1AM (Figure 4.18). EC50 for stimulation of adenylyl cyclase activity is not changed by 
carbachol treatment. 146 
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Figure 4.14: Desensitization of forskolin-stimulated inhibition of cAMP formation 
for low expression wild-type mAchR. 
Data are presented as cAMP generated relative to forskolin-stimulated levels and 
are from representative experiments for pretreatment with carbachol for 3 (n=10) or 12 
hours (n=2), or with pilocarpine for 3 (n=4) or 12 hours (n=2). Cells were pretreated with 
the agonists indicated (1 mM) for the specified times in FD + 10% calf serum, followed by 
second messenger assays using the agonist carbachol. Curves were derived from a least-
squares fit as described in (Bulseco and Schimerlik, 1996). Average values are 
summarized in Table 4.3. The fitted parameters were estimated to be IC50 = 0.35 ± 0.09 
EC50 = 14 ± 3  68.8 ± 3.9 % inhibition; IC50 = 4.97 ± 1.52 1AM, EC50 = 93.0 ± 
29.3 1..tM, 35.7 ± 7.9 % inhibition; IC50 = 3.96 ± 1.81 µM , EC50 = 24.6 ± 15.4 pM, 39.3 
± 17.2 % inhibition; IC50 = 1.24 ± 0.56 pM, EC50 = 16.0 ± 10.0 1.tM, 69.4 ± 9.4 % 
inhibition and IC50 = 0.92 ± 0.37 1,tM, EC50 = 14.1 ± 8.3 gM, 75.7 ± 8.4 % inhibition for 
control, 3 hour carbachol treatment, 12 hour carbachol treatment, 3 hour pilocarpine 
treatment and 12 hour pilocarpine treatment respectively. 147 
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Figure 4.15: Desensitization of forskolin-stimulated inhibition of cAMP formation 
for high expression wild-type mAchR. 
Data are presented as cAMP generated relative to forskolin-stimulated levels and 
are from representative experiments for pretreatment with carbachol for 3 (n=4) or 12 
hours (n=2), or with pilocarpine for 3 (n=4) or 12 hours (n=2). Cells were pretreated with 
the agonists indicated (1 mM) for the specified times in FD + 10% calf serum, followed by 
second messenger assays using the agonist carbachol. Curves were derived from a least-
squares fit as described in (Bulseco and Schimerlik, 1996).  Average values are 
summarized in Table 4.3. The fitted parameters were estimated to be 1050 = 0.23 ± 0.16 
p.M, EC50 = 22.0 ± 11.0 gM, 54.1 ± 8.4 % inhibition; 1050 = 3.56 ± 2.42 1.1M, EC50 = 
91.2 ± 14.411M, 57.6 ± 34.3 % inhibition; 1050 = 2.53 ± 1.73 pM, EC50 = 210 ± 35 pM, 
46.7 ± 17.4 % inhibition; 1050 = 0.59 ± 0.26 pM, EC50 = 100.3 ± 19.6 gM, 56.9 ± 16.8 
% inhibition and 1050 = 0.54 ± 0.47 pM, EC50 = 21.7 ± 12.4 p.M, 76.0 ± 25.8 % 
inhibition for control, 3 hour carbachol treatment, 12 hour carbachol treatment, 3 hour 
pilocarpine treatment and 12 hour pilocarpine treatment respectively. 148 
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Figure 4.16: Desensitization of PI hydrolysis for low expression wild-type pm2 
mAchR. 
The data are presented as fold stimulation of PI hydrolysis over basal levels of 
inositol monophosphate for control cells and are from representative experiments for 
pretreatment with carbachol for 3 (n=10) or 12 hours (n=3), or with pilocarpine for 3 
(n=4) or 12 hours (n=2). Cells were pretreated with the agonists indicated (1 mM) for the 
specified times in FD + 10% calf serum, followed by assays for PI metabolism using the 
agonist, carbachol. Curves were derived from a least-squares fit of equation 1. Fitted 
parameters were estimated to be EC50 = 1.9 ± 0.7 ilM, 1.9 ± 0.3 fold stimulation; EC50 = 
1.3 ± 0.5 1.1M, 1.7 ± 0.3 fold stimulation and EC50 = 0.3 ± 0.1 pM, 1.7 ± 0.3 fold 
stimulation for control, 3 hour pilocarpine and 12 hour pilocarpine treatments respectively. 
Carbachol treatments resulted in small responses and poorly determined fits. 149 
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Figure 4.17: Desensitization of PI hydrolysis for high expression wild-type pmt 
mAchR. 
The data are presented as fold stimulation of PI hydrolysis over basal levels of 
inositol monophosphate for control cells and are from representative experiments for 
pretreatment with carbachol for 3 (n=4) or 12 hours (n=2), or with pilocarpine for 3 (n=2) 
or 12 hours (n=2). Cells were pretreated with the agonists indicated (1 mM) for the 
specified times in FD +  10% calf serum, followed by assays for PI metabolism using the 
agonist, carbachol. Curves were derived from a least-squares fit of equation 1. Fitted 
parameters were estimated to be EC50 = 1.1 ± 0.3 ptM, 1.6 ± 0.1 fold stimulation; EC50 = 
1.4 ± 0.6 gM, 1.5 ± 0.2 fold stimulation and EC50 = 0.8 ± 0.4  1.5 ± 0.2 fold 
stimulation for control, 3 hour pilocarpine and 12 hour pilocarpine treatments respectively. 
Carbachol treatments resulted in small responses and poorly determined fits. 150 
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Figure 4.18: Desensitization of wild-type pm2 mAchR in the absence of calf serum. 
Data are presented as cAMP generated relative to forskolin-stimulated levels and 
are from representative experiments. Cells were pretreated with 1 mM carbachol for 3 
hours in FD media without calf serum, followed by second messenger assays using the 
agonist carbachol. Curves were derived from a least-squares fit as described in (Bulseco 
and Schimerlik, 1996). The fitted parameters were estimated to be 1050 = 0.37 ± 0.10 
iiM, EC50 = 30.0 ± 10.0 JAM, 71.0 ± 6.8 % inhibition and 1050 = 1.5 ± 1.111M, EC50 = 
10.2 ± 2.8 p.M, 57.2 ± 5.2 % inhibition for control and carbachol treated cells respectively. 151 
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Figure 4.19: Carbachol competition binding curves after agonist treatment of c1.5. 
Data are from a representative experiment presented as specifically bound 
(M) for untreated CHO cells expressing approximately 1.0 x 106 receptors per 
cell, or for cells previously treated with 1 mM carbachol (n=4), oxotremorine M (n=2), 
pilocarpine (n=2) or 50 I.LM forskolin (n=2). Curves were derived from a least-squares fit 
to equation 5 as described in (Vogel et al., 1995) with Lo fixed at 2.5 nM, Kd at 0.4 nM, 
with K1 and K2 shared across all data. The fitted parameters were estimated to be K1 = 
0.09 ± 0.0511M, K2 = 36.1 ± 4.4 AM with associated sites R1 = 12.7 ± 7.6 pM (7.2 ± 4.3 
%), R2 = 164.5 ± 6.2 pM (92.8 ± 3.5 %) for untreated cells; R1 = 40.1 ± 7.2 pM (41.0 ± 
7.4 %), R2 = 57.8 ± 6.3 pM (59.0 ± 6.4 %) for carbachol treated cells; R1 = 25.8 ± 7.1 
pM (27.8 ± 7.7 %), R2 = 66.8 ± 5.9 pM (72.2 ± 6.3 %) for oxo M treated cells; R1 = 30.3 
± 7.6 pM (16.7 ± 4.2 %), R2 = 150.7 ± 6.5 pM (83.3 ± 3.6 %) for pilocarpine treated 
cells; and R1 = 10.7 ± 7.4 pM (6.0 ± 4.2 %), R2 = 165.8 ± 6.2 pM ( 94.0 ± 3.5 %) for 
forskolin treated cells. 152 
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Figure 4.20: Carbachol competition binding curves after agonist treatment of &I. 
Data are from a representative experiment (n=2) presented as specifically bound 
[31{]11MS (M) for untreated CHO cells expressing greater than 2.0 x 106 receptors per 
cell, or for cells previously treated with 1 mM carbachol, oxotremorine M, pilocarpine or 
501.1M forskolin. Curves were derived from a least-squares fit to equation 5 as described 
in (Vogel et al., 1995) with Lo fixed at 2.5 nM, Kd at 0.4 nM, with K1 and K2 shared 
across all data. The fitted parameters were estimated to be K1 = 4.1 ± 2.9 µM, K2 = 
159.2 ± 25.3 pM with associated sites R1 = 57.7 ± 24.8 pM (15.1 ± 6.5 %), R2 = 323.9 ± 
24.7 pM (84.9 ± 6.5 %) for untreated cells; R1 = 92.2 ± 24.3 pM (33.8 ± 8.9 %), R2 = 
180.6 ± 24.4 pM (66.2 ± 9.0 %) for carbachol treated cells; R1 = 52.9 ± 21.5 pM (19.1 ± 
7.8 %), R2 = 223.5 ± 20.9 pM (80.9 ± 7.6 %) for oxo M treated cells; R1 = 61.2 ± 22.2 
pM (21.6 ± 7.8 %), R2 = 223.7 ± 21.9 pM (78.4 ± 7.7 %) for pilocarpine treated cells; 
and R1 = 33.8 ± 23.6 pM (8.5 ± 5.9 %), R2 = 363.8 ± 23.3 pM (91.5 ± 5.9 %) for 
forskolin treated cells. 153 
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Figure 4.21: Carbachol competition binding curves after agonist treatment of D69N. 
Data are from a representative experiment (n=2) presented as specifically bound 
j3HINMS (M) per 106 cells, for untreated CHO cells expressing greater than 2.0 x 106 
D69N mutant receptors per cell, or for cells previously treated with 1 mM carbachol, 
oxotremorine M, or pilocarpine. Curves were derived from a least-squares fit to equation 
5 as described in (Vogel et al., 1995) with Lo fixed at 2.5 nM, Kd at 0.4 nM, with K1 and 
K2 shared across all data. The fitted parameters were estimated to be K1 = 0.09 ± 0.01 
1.1M, K2 = 22.8 ± 3.0 p.M with associated sites Ri = 93.7 ± 22.7 pM (16.9 ± 4.1 %), R2 = 
461.1 ± 19.1 pM (83.1 ± 3.4 %) for untreated cells; R1 = 24.0 ± 21.5 pM (8.2 ± 7.4 %), 
R2 = 267.8 ± 15.6 pM (91.8 ± 5.3 %) for carbachol treated cells; Ri = 24.7 ±21.6 pM 
(7.5 ± 6.6 %), R2 = 302.8 ± 15.8 pM (92.5 ± 4.8 %) for oxo M treated cells; and R1 = 
52.2 ± 21.8 pM (14.5 ± 6.0 %), R2 = 308.6 ± 16.4 pM (85.5 ± 4.5 %) for pilocarpine 
treated cells. 154 
Table 4.1: Summary of internalization and recycling rate constants 
Summary of the rate constants determined by nonlinear curve fitting as described 
in "Materials and Methods" and shown in Figures 4.4, 4.5 and 4.6. Rates are presented as 
% receptors/cell per minute, and Re0 in % receptors. Rates for new receptor synthesis 
(10 were determined as shown in figures 4.11, 4.12 and 4.13 and were treated as 
constants throughout the rest of the analysis. 
Treatment  k1  k2  k3  1(4  Re° I I I  I 
c1.5 
0.002 ± 0.001  0.012 ± 0.003  0.0026 ± 0.0005  0.031 ± 0.069  23.41 ± 1.94 Control 
0.002 ± 0.001  0.054 ± 0.014  0.074 ± 0.005  0.276 ± 0.093  47.15 ± 3.86 Carbachol 
Pilocarpine  0.002 ± 0.001  0.019 ± 0.008  0.005 ± 0.001  0.054 ± 0.013  39.79 ± 7.45 
c1.1 
0.003 ± 0.001  0.011 ± 0.003  0.003 ± 0.001  0.014 ± 0.066  21.34 ± 1.26 Control 
0.003 ± 0.001  0.043 ± 0.013  0.059 ± 0.011  0.375 ± 0.237  26.83 ± 2.72  Carbachol 
Pilocarpine  0.003 ± 0.001  0.027 ± 0.009  0.043 ± 0.008  0.090 ± 0.029  29.55 ± 4.10 
D69N 
0.069 ± 0.026  0.0595 ± 0.013  0.007 ± 0.001  0.081 ± 0.034  10.37 ± 4.97 Control 
0.069 ± 0.026  0.044 ± 0.007  0.109 ± 0.011  0.090 ± 0.020  28.72 ± 1.60 Carbachol 
Pilocarpine  0.069 ± 0.026  0.043 ± 0.007  0.100 ± 0.019  0.001 ± 0.003  30.39 ± 1.68 155 
Table 4.2: Ratios of the rate constants are altered in response to agonist treatment 
Ratios of the rate constants (k2/k3 and k, /k4) reported in Table 4.1 for CHO cells 
expressing about 1.0 x 106 receptors per cell (c1.5, low expression), greater than 2.0 x 106 
receptors per cell (c1.1, high expression) or the D69N mutant mAchR expressing greater 
than 2.0 x 106 receptors per cell. 
Low Ex s ression c1.5 
k2/k1  kilki 
Ex i ression c1.1 
k Ikl  kfica 
D69N 
kik  kilka 
Control  4.62  0.07  3.67  0.21  8.50  0.85 
Carbachol  0.73  0.01  0.73  0.01  0.40  0.77 
Pilocarpine  3.80  0.04  0.63  0.03  0.43  69.00 156 
Table 4.3: Desensitization of wild-type pmt mAchR to inhibition of adenylyl 
cyclase. 
Assays were conducted as described in "Materials and Methods", and analyzed as 
described in (Bulseco and Schimerlik, 1996). Values are the mean ± SD of n experiments, 
each done in duplicate. CHO cells expressing - 1.0 x 106 m2 AchR per cell (low 
expression) or greater than 2.0 x 106 receptors per cell (high expression) were exposed to 
saturating concentrations of agonists (1 mM) for either 3 or 12 hours and assays for 
inhibition of forskolin-stimulated adenylyl cyclase were conducted. 
Low expression  High Expression 
IC50  Max  n  IC50  Max  n 
(pm)  Inhibition 
% 
(pM)  Inhibition 
OA 
Untreated'  0.25 ± 0.02  70.8 ± 1.8  12  0.6 ± 0.2  60.2 ± 2.6  5 
(3 hours) 
Carbachol  4.7 ± 1.1  35.4 ± 2.7  10  3.9 ± 0.6  48.2 ± 4.8  4 
Pilocarpine  0.61 ± 0.21  62.6 ± 3.0  4  0.3 ± 0.1  64.5 ± 2.7  4 
(12 hours) 
Carbachol  4.3 ± 0.3  37.2 ± 2.2  2  3.3 ± 0.8  43.1 ± 3.6  2 
Pilocarpine  0.54 ± 0.39  75 ± 3  2  0.4 ± 0.2  73.0 ± 3.0  2 157 
Table 4.4: Desensitization of wild-type pm2 mAchR to stimulation of PI 
metabolism. 
Assays were conducted as described in "Materials and Methods", and analyzed as 
described in (Bulseco and Schimerlik, 1996). Values are the mean ± SD of n experiments, 
each done in duplicate. CHO cells expressing - 1.0 x 106 m2 mAchR per cell (low 
expression) or greater than 2.0 x 106 receptors per cell (high expression) were exposed to 
saturating concentrations of agonists (1 mM) for either 3 or 12 hours and assays for 
stimulation of PI hydrolysis conducted. 
Low expression  High Expression 
EC50  Max  n  EC50  Max  n 
(iiM)  Stimulation  (IIM)  Stimulation 
%  % 
Untreated'  2.5 ± 0.5  1.66 ± 0.05  10  2.8 ± 0.5  1.56 ± 0.02  4 
(3 hours) 
Carbachol  a  1.10 ± 0.03  10  a  1.14 ± 0.02  4 
Pilocarpine  2.9 ± 0.6  1.58 ± 0.05  4  2.0 ± 0.6  1.48 ± 0.03  2 
(12 hours) 
Carbachol  a  1.10 ± 0.05  2  a  1.14 ± 0.05  2 
Pilocarpine  1.3  ± 0.6  1.62 ± 0.10  3  2.1 ± 1.3  1.45 ± 0.05  2 
a Small response resulted in poorly determined fit for EC50. 158 
Agonist binding properties after receptor internalization 
Ligand binding properties of wild-type and D69N mutant AchR were difficult to 
characterize after long exposure to saturating concentrations of agonists. Surface receptor 
sites were reduced by this treatment, but agonist binding affinities of the receptor that 
remained was not altered in any obvious way. For this reason, competition binding 
experiments were analyzed by sharing parameters for high (KH) and low (KO affinity 
binding sites for all treatments. The fractions of receptor in each affinity state were fit, 
and are presented as both concentration of sites and percent sites in the legends for 
Figures 4.19, 4.20 and 4.21. 
Treatment of CHO cells expressing low and high wild-type m2 mAchR numbers 
resulted in a 45% and 48% loss of surface receptor sites for carbachol and oxo M 
treatments, and 29%, 28% and 26% reduction for carbachol, oxo M and pilocarpine 
treatments respectively. Treatment with 50 µM forskolin, a concentration sufficient to 
elevate intracellular cAMP levels, had no effect on surface receptor expression of wild-
type m2 mAchR, consistent with findings presented in Chapter 3. Treatment of CHO cells 
expressing D69N mutant AchR resulted in 47%, 41% and 35% reduction of surface 
receptor numbers for carbachol, oxo M and pilocarpine respectively. Agonist treatment 
also appeared to alter the fraction of receptors in low and high affinity states, but not in 
any consistent way. This may be explained by insufficient data for the kind of analysis 
applied in these experiments. 159 
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Figure 4.22: Model for receptor internalization and recycling 
G-protein coupled receptors are internalized, recycled and degraded in response to 
persistent agonist treatment. The respective rates of internalization and recycling appear 
to be agonist and receptor density dependent, and are independent of effector coupling. 
The rate of receptor degradation also appears to be agonist-dependent, but may be 
independent of receptor density. In addition, effector coupling may be necessary to 
increase the rate of receptor degradation in response to binding of agonists. 160 
Discussion 
Role of receptor internalization and recycling 
Trafficking of membrane receptors is a dynamic process. This report as well as 
other studies on muscarinic AchRs (Koenig and Edwardson, 1996; Koenig and 
Edwardson, 1994) demonstrate that receptors are being rapidly turned over even if net 
loss of surface receptors are not observed. When CHO cells expressing low receptor 
levels were exposed to pilocarpine, there was no measurable loss in surface receptor sites, 
although an increase in receptor trafficking was observed. Assuming initial surface 
receptors sites of 106 receptors per cell, receptor internalization was increased from 2,600 
receptors/cell/minute to 5000 receptors/cell/minute after pilocarpine treatment. Using 
initial endosomal receptor numbers of 234,500 and 397,790 receptors/cell for untreated 
and pilocarpine treated cells respectively, receptor recycling was also increased from 2,809 
to 7,560 receptors/cell/minute. Exposure to pilocarpine resulted in a net increase in 
receptor movement from 5,409 to 12,560 receptors/cell/minute, even if no measurable 
change in surface receptor numbers was observed. 
The role of receptor internalization and recycling is not well understood, but it has 
been suggested that recycling is necessary for dephosphorylation and resensitization 
(Fonseca et al., 1995; Pippig et al., 1995; Yu et al., 1993) of G-protein coupled receptors. 
Although our results show agonist-dependent changes in recycling and internalization 
rates, it appears that desensitization may be in part due to recycled receptors that are 161 
refractory to coupling. For wild-type receptor, the full agonist carbachol increases the 
rate of recycling to a greater extent than does pilocarpine at both low and high receptor 
expression levels. Since only the full agonist results in receptor desensitization, a period 
of refractoriness may be necessary to allow the recycled receptor to "reassociate" with G-
proteins or other signal transduction proteins. 
Pilocarpine leads to a reduction in surface receptors available for ligand binding in 
CHO cells with high m2 receptor densities and not in cells with low receptor numbers, but 
this partial agonist does not lead to desensitization. This may be explained by different 
fates of internalized receptor (i.e. differences in efficiency of phosphorylation or 
dephosphorylation) or possibly that pilocarpine leads to fewer refractory receptors in the 
plasma membrane than does carbachol. This is supported by the observation that 
stimulation of PI metabolism for wild-type m2 AchR is slightly reduced relative to control 
cells after treatment with pilocarpine, but is completely abolished after treatment with 
carbachol. If receptors that remain are refractory to stimulation after carbachol treatment 
but not after pilocarpine treatment, the results observed would be expected. Furthermore, 
carbachol treatment reduces surface receptor numbers by 50%, leaving at least 106 
receptors per cell for the high expression cell line and 105 receptors for the low expression 
cell lines. Reduction of surface receptor to these levels with the slowly dissociating 
antagonist l -QNB resulted in a measurable coupling to PI metabolism for wild-type pm2 
mAchR (Vogel et al., 1995). Clearly, the fate of receptors after antagonist treatment is 
different than after exposure to agonists. 162 
Acionist-promoted internalization is dependent on receptor density 
Receptor density appears to play an important role in properties of signal 
transduction (Vogel et al., 1995; Whaley et al., 1995; Whaley et al., 1994). In support of 
these findings, we are reporting that receptor density determines the internalization 
properties of wild-type pm2 mAchR when expressed in CHO cells. Rates of receptor 
internalization and recycling are similar for untreated CHO cells expressing low and high 
receptor numbers. For the low expression cell line, carbachol leads to an increase in both 
recycling and internalization rates, while pilocarpine stimulates a slight increase in rate of 
recycling. The rate for receptor internalization is unaffected by pilocarpine treatment at 
low receptor densities. Pilocarpine may promote a receptor conformation that interacts 
differently with available G-proteins which prevents receptor internalization. This is 
consistent with the finding that agonist regulates an early step in 132 adrenergic receptor 
endocytosis (von Zastrow and Kobilka, 1994), specifically the redistribution of receptors 
to microdomains of the plasma membrane, from which endocytosis and receptor recycling 
can occur passively. It is not clear if pilocarpine and carbachol result in differences in 
plasma membrane distribution of the pm2 mAchR, but it is clear that more receptor 
movement, as measured by receptor internalization and recycling, occurs following 
treatment with carbachol. CHO cells expressing low receptor numbers internalize 74,000 
receptors/minute following carbachol treatment, while pilocarpine leads to internalization 
of about 5,000 receptors/minute. In addition, about 25,461 receptors are recycled per 
minute after carbachol treatment while pilocarpine leads to recycling of 7,560 
receptors/minute. These observations provide indirect support for agonist-dependent 163 
differences in receptor redistribution, although the mechanisms regulating this receptor 
movement is not yet characterized. 
Interestingly, when pm2 mAchR is expressed at high levels in CHO cells, both 
carbachol and pilocarpine result in a reduction of surface receptor. Treatment with 
carbachol, and to a lesser extent pilocarpine, results in increased rates of receptor 
internalization and recycling. Receptor movement may be modulated by other proteins, 
perhaps G-proteins, located in the plasma membrane of CHO cells. If receptor is in large 
excess over this modulatory factor, receptor movement may not be regulated, and agonist-
promoted internalization may occur for both full and partial agonists. Alternatively, 
excess receptor may lead to a pattern of receptor distribution predisposed to agonist-
mediated endocytosis, and redistribution to specific microdomains may be unnecessary. It 
is not clear if receptor distribution is different at low and high receptor densities, and 
specific experiments with epitope tagged receptors are needed to answer this question. 
Both receptor distribution and the effects of specific agonists may also contribute 
to receptor internalization via two pathways. Studies conducted on the cholecystokinin 
receptor, a peptide G-protein coupled receptor, demonstrated that both coated and 
smooth pits are utilized during agonist-mediated receptor endocytosis (Roettger et al., 
1995). Smooth vesicles appear to remain closer to the plasma membrane, and may be 
responsible for receptor dephosphorylation and recycling, while clathrin-coated vesicles 
may be responsible for receptor down-regulation and degradation. This model suggests 
that at least two specific microdomains exist in the plasma membranes of CHO cells. This 
agrees well with our observations that carbachol increases the rate of receptor degradation 164 
to a much greater extent than does pilocarpine. For wild-type receptor, the observed rate 
constant is increased by 9 and 27 fold for low and high receptor expression respectively. 
When initial endosomal receptor is taken into account for the specific cell lines, this 
translates into 130,134 and 201,255 receptors degraded per minute after exposure to 
carbachol, while basal levels observed in untreated cells are 2,600 and 5,975 
receptors/minute respectively. The pathway taken by pm2 mAchRs may be determined in 
part by the agonist used in the experiments, with carbachol exposure resulting in receptor 
internalization by coated pits (Maloteaux and Hermans, 1994) and pilocarpine 
predominately by non-coated pits (Roettger et al., 1995). If further experiments 
demonstrate that agonist-dependent trafficking does occur, this may help explain the 
finding that the full agonist carbachol but not the partial agonist pilocarpine results in 
desensitization of the pm2 AchR. 
Desensitization 
Assessment of desensitization is difficult since measured response is dependent on 
receptor density. As surface receptor number is decreased, coupling properties of the pmt 
mAchR is altered as indicated by a rightward shift in IC50 for inhibition of adenylyl 
cyclase and a reduction in maximal response for PI hydrolysis while maximal percent 
inhibition of adenylyl cyclase and EC50 for PI hydrolysis remains unchanged (Vogel et al., 
1995). 
Exposing CHO cells expressing wild-type pm2 mAchR to carbachol results in both 
a rightward shift in IC50 for inhibition of AC and a reduction in maximal stimulation of PI 
hydrolysis. Although a reduction in total surface receptor number would lead to the same 165 
results, this cannot explain all of the observations we have made. Exposing these cells to 
pilocarpine, cGMP or SNP (Chapter 3) also results in significant reduction in surface 
receptor sites without a measurable change in effector coupling properties. These findings 
imply that receptor internalization alone is not sufficient for receptor desensitization. 
Desensitization is observed only after treatment with full agonists carbachol and 
oxo M. The D69N mutant mAchR clearly demonstrates that receptor internalization does 
not require receptor-effector coupling. In addition, desensitization can be promoted by 
full agonists that do not activate receptor-effector coupling for this mutant (Chapter 3). 
This implies that desensitization is also independent of effector activation, or is dependent 
on activation of effector systems that we have not measured. Both of these observations 
may also be explained by receptor internalization and recycling properties that are 
promoted by full and partial agonists. 
Model 
G-protein coupled receptors are internalized, recycled and degraded in response to 
persistent agonist treatment. The rate constants for each of these steps are shown in 
Figure 4.22. Agonist-promoted receptor internalization (k3) and recycling (k2) rates 
appear to be agonist and receptor density dependent and independent of effector coupling. 
The rate of receptor degradation (k4) also appears to be agonist dependent, but may be 
independent of receptor density. Furthermore, effector coupling may be necessary before 
an increase in receptor degradation occurs in response to agonist binding. The model is 
discussed in greater detail below. 166 
This model suggests that receptor internalization and recycling properties are 
independent of receptor desensitization. It is clear that different ligands possess different 
properties when bound to their receptors. While antagonists inhibit physiological 
responses, agonists may stimulate full or partial responses. In addition, full agonists 
appear to promote different receptor conformations which affect the ability of the receptor 
to activate effectors (Chapters 2 and 3). These examples support a model in which 
different receptor internalization and recycling properties are dependent on agonists 
agonists may simply lead to slightly different receptor conformations that affect the fate of 
a liganded receptor. In addition, other factors may modulate these properties,  and high 
receptor density may have an impact on the effectiveness of these modulators. G-proteins 
are down-regulated with receptors (Dell'Acqua et al., 1993; Wise et al., 1995), presumably 
as RG complexes, and may be limiting when receptor is in large excess. Furthermore, 
desensitization may be regulated by numerous events that include receptor internalization 
and recycling as well as receptor phosphorylation and rapid uncoupling. 
The fate of internalized receptor may depend both on the bound ligand as well as 
coupling to effector systems. It is not clear where internalized receptors are stored, and 
the model proposed in Figure 4.22 combines all of these internal compartments into 
endosomes or lysosomes. This oversimplification may not be adequate to explain the fate 
of internalized receptors. For example, it is not understood how receptors stored in 
endosomes are targeted for degradation via lysosomes.  Perhaps the more important 
questions are how are receptors targeted for recycling and what are the roles of specific 
agonists on these processes? 167 
The specific pathways taken by receptors into the intracellular compartments may 
determine the fate of the receptors. Characterization of cholecystokinin receptor 
internalization demonstrates that the receptor can take two paths into the cell (Roettger et 
al., 1995). Agonist treatment promoted receptor internalization by both coated and non-
coated endocytotic pits, presumably clathrin-coated and caveolin associated respectively. 
Furthermore, receptor phosphorylation appears to occur when the receptor is localized to 
the plasma membrane while dephosphorylation occurs in intracellular compartments. 
They have proposed that endocytosis via smooth vesicles results in receptor resensitization 
and recycling while clathrin mediated endocytosis results in receptor degradation and 
down regulation. A more complete model should therefore include internalization via two 
distinct pathways, with specific fates of the receptor determined by the pathway taken. 
Desensitization of responses are much more difficult to assess for the pmt mAchR 
expressed in CHO cells.  It is not clear if loss of response occurs due to depletion of other 
proteins necessary for signal transduction, or an apparent loss of response is merely a 
passive result of reduced receptor density. The full agonist carbachol appears to promote 
desensitization while the partial agonist pilocarpine does not. Since both agonists will 
promote net receptor internalization by affecting both k2 and k3, desensitization must not 
be dependent solely on receptor movement. Cabachol treatment results in a four to five 
fold greater increase in receptor degradation rate (k4) than is induced by the partial agonist 
pilocarpine for both low and high expression CHO cell lines.  It is not clear how these 
agonists would promote different fates for internalized receptor. It is possible that both 
agonist used and receptor density affects trafficking properties of internalized receptor. 168 
One additional possibility is that the fate of these receptors are also dependent on 
receptor-effector coupling. Receptor degradation rate is not increased after treatment 
with carbachol or pilocarpine for the D69N mutant mAchR. Since these agonists do not 
activate effector systems, degradation of the internalized receptor may not be stimulated, 
consistent with our results (Table 4.1). Desensitization cannot be dependent on 
degradation though, since carbachol will promote desensitization of D69N to both 
inhibition of adenylyl cyclase and stimulation of PI hydrolysis by the agonist oxo M 
(Chapter 3) even if it does not promote an increase in (k4). This suggests that a full 
agonist promotes a unique series of events while receptors are being internalized and 
recycled, perhaps in endosomes, or that much of the desensitization observed is due to 
depletion of other factors required for signal transduction. 
Summary 
In summary, we have shown that the pm2 mAchR expressed in CHO cells 
undergoes rapid receptor internalization and recycling following prolonged treatment with 
agonists. This response is both agonist and receptor density dependent, and apparently 
independent of effector coupling. Studying the relative rates of agonist-promoted 
receptor internalization and recycling indicate that this process is regulated by mechanisms 
distinct from receptor desensitization. Finally, the components of this process appears to 
possess agonist and receptor density dependent and independent steps. Further studies 
should provide insight into the specific mechanisms regulating the many steps in receptor 
internalization and desensitization. 169 
Chapter 5 
Conclusions 
m2 muscarinic receptor structure-function relationship 
The primary objective of this research is to investigate the relationship between m2 
muscarinic receptor structure and functional coupling to effector systems using site-
directed mutagenesis. Specific amino acids in the third intracellular loop were mutated 
with two primary criteriaalter the charge in a particular position, or convert m2/m4 
conserved amino acids to those conserved in the ml /m3 /m5 family. Unfortunately, there 
are no available methods to follow alterations in receptor structure after mutagenesis, and 
data collected is limited to bioassays that are several steps removed from an agonist-
promoted conformational change. 
Analysis and interpretation of "structural" changes are therefore limited by our 
ability to assess structural changes, or the changes in agonist-promoted conformation after 
mutating the receptor. Studies on secondary structure have been attempted in our 
laboratory (Peterson et al., 1995), but information gained from circular dichroism studies 
fail to answer the most important questions. How are the agonist-promoted 
conformational changes affected by site-directed mutants? Are receptor/G-protein 170 
interactions altered even if agonist-promoted conformational events are unchanged by the 
mutants? Experiments conducted using second messenger assays provide information on 
effector coupling efficiency and potency. Although an indirect measure of structural 
changes, or more precisely, a reasonably good measure of mutations that do not affect 
coupling properties and presumably structural properties, there are other factors that 
affect the observed responses in whole cells which greatly complicate analysis of these 
mutant receptors. 
In general, the context in which the receptors are expressed appear to have a large 
effect on their functional properties. Since we must rely on their functional properties to 
draw inferences on changes in structure, it is important to characterize these effects 
thoroughly. Some of the more obvious factors include receptor density, co-expression of 
other proteins in the signal transduction pathway and expression of other as yet 
unidentified factors that modulate functioning of the receptor. 
Finally, questions relating to organization of receptors, and receptor/G-protein 
effector systems in the plasma membrane may in addition play a large role in our ability to 
interpret functional coupling studies. Evidence indicates that certain G-proteins are 
localized in caveolae, non-coated pits in the plasma membranes of mammalian cells, as are 
specific receptor proteins (including G-protein coupled receptors) (Anderson, 1993; Chun 
et al., 1994; Roettger et al., 1995).  Agonist-promoted diffusion of the (32 adrenergic 
receptor appears to terminate at specific locations in the plasma membrane of Chinese 
hamster ovary cells (von Zastrow and Kobilka, 1994).  Cholecystokinin receptors (a G-
protein coupled receptor) appear to be protected from the effects of acid washing after 171 
agonist treatment (Roettger et al., 1995a; Roettger et al., 1995b), presumably via 
insulation in membrane invaginations such as caveolae or clathrin coated pits. In addition, 
receptor organization in the plasma membrane may be dependent on receptor density. 
Receptor-density dependence 
Functional coupling of the m2 AchR to effector systems is receptor density 
dependent. Increasing receptor density results in greater maximal stimulation of PI 
metabolism for the pmt mAchR, with no apparent change in EC50. For coupling to 
inhibition of forskolin-stimulated adenylyl cyclase activity, IC50 is inversely related to 
receptor density, while maximal percent inhibition is unchanged until very low receptor 
densities are achieved (Vogel et al., 1995). 
This finding requires that mutant receptors be assessed after expression of wild-
type receptor at comparable receptor densities, or after reduction in wild-type receptor 
density using the slowly dissociating antagonist, / -QNB. Antagonist knock-out of 
receptor sites is a common method used to address this, but may have inherent problems 
that further complicate analysis. For example, reduction of sites with l -QNB results in 
receptor-effector coupling properties that are different than reduction in sites following 
agonist treatment (Vogel et al., 1995). Others have normalized functional coupling after 
deriving mathematical relationships between receptor density, EC50, maximal response 
and Kd for agonist (Whaley et al., 1995; Whaley et al., 1994). The importance of 
considering receptor density has only recently been appreciated, and some of the 172 
conclusions drawn by researchers regarding the functional effect of site-directed 
mutagenesis may be tenuous, pending more thorough investigation and analysis. 
Assessment of functional coupling in transient transfection systems may lead to 
misleading results. Since receptor density plays a large role in coupling properties, results 
obtained with transiently transfected systems, where the average receptor density is known 
for the population of cells, but the distribution of the receptors throughout these cells is 
uncharacterized, may lead to incorrect conclusions. In addition, subtle effects on 
receptor-effector coupling may only be detectable after thorough study with multiple full 
and partial agonists. 
Similar observations were made with respect to agonist-promoted receptor 
internalization and desensitization. The rates of receptor internalization and recycling 
appears to be dependent on initial receptor density as well as the agonist used in the 
experiment. In our studies, the differences between agonists were reduced with increasing 
receptor concentration, consistent with results on functional coupling. 
Agonist dependence 
The ligands used in these experiments can be classified as full and partial agonists 
as well as antagonists.  While antagonists competitively bind receptor sites and either have 
no effect or an inhibitory effect, agonists function to activate coupling of the receptor to 
effector systems. Of these agonists, some are capable of "full" activation (full agonists) 
and some only partially activate the system (partial agonists)--i.e. elicit a less than 
maximal response at saturating concentrations of agonist. 173 
We have found that full agonists are equal in their ability to activate coupling. 
While oxo M is a full agonist for wild-type receptor, it appears to have properties different 
from another full agonist, carbachol. For the mutant A212E, oxo M becomes a partial 
agonist for coupling to PI metabolism relative to wild-type receptor, while it maximally 
activates inhibition of adenylyl cyclase. The latter finding can be explained by the 
observation that there are "spare receptors" for coupling to adenylyl cyclase. The 
observation with the PI response is not as easily explained, and implies that oxo M is 
capable of promoting a receptor conformation different than carbachol. 
This observation is also supported by the finding that effector coupling for the 
mutant D69N is only mediated by the agonist oxo M. Carbachol, acetylcholine and 
pilocarpine are incapable of activating the receptor/G-protein complex to promote effector 
activation. This implies that oxo M is uniquely capable of promoting a receptor 
conformation that can activate G-proteins, while the other full agonists carbachol and 
acetylcholine, and the partial agonist, pilocarpine cannot. 
When characterizing coupling of hml mAchR to PI metabolism in CHO cells, the 
dose-response curves have very different appearances for oxo M and carbachol. Although 
both stimulate PI metabolism approximately 15 fold, and are considered full agonists for 
hml, the slope factor for the two agonists are clearly different. Data obtained with the 
agonist carbachol is best fit with a slope factor of 1, while data for oxo M is often best fit 
with a slope factor closer to 0.5. Although the functional significance of these 
observations are unclear, it may be explained by cooperativity for oxo M binding and 
activation and lack of cooperativity for carbachol. These findings do point out that oxo M 174 
appears to promote activation of effector systems with characteristics different from 
carbachol. 
The same observation is made with agonist-promoted internalization of surface 
receptor. The agonist dependence appears to also depend on receptor density. At high 
receptor densities, all agonists appeared to have similar effects on internalization and 
recycling rates. At low receptor densities, the partial agonist pilocapine elicited a response 
different from the full agonist carbachol. It is not clear how these observations relate to 
receptor density. 
High receptor density may result in different receptor organization in the plasma 
membrane. Increased interactions between receptors may result in dimers or multimers 
that have an impact on the functioning of the mAchR. The mAchR may be normally 
distributed or localized to particular areas of the plasma membrane, perhaps in close 
proximity with other proteins in the signal transduction pathway. High receptor density 
may result in distribution of receptors into areas of the cell membrane in which they would 
not normally be found. Alternatively, if another protein or factor that normally interacts 
with the receptor is in limited supply, removal of a constraint may also have an impact on 
how the receptor functions and may modulate the effects of full and partial agonists. 
Finally, agonist rates of dissociation and association may depend on the receptor 
organization in the plasma membrane. The observed responses may be a function of this 
organization and its effects of receptor interaction with agonists as well as G-proteins and 
effector systems. 175 
One additional problem encountered when comparing different clonal cell lines is 
the possibility that selection of clones also resulted in selection of other properties. It is 
not clear if clonal lines achieve different receptor levels because metabolic rates of 
internalization and recycling are inherently different, or if the measured rates are different 
because of different receptor levels. For example, different clonal cell lines appear to 
possess different levels of forskolin-stimulated adenylyl cyclase. Although this potential 
problem is a concern, we do not think that it is very likely since baseline rates (untreated 
cells) of receptor internalization, recycling and degradation are very similar for the three 
clonal cell lines studied (Table 4.1). 
Expression system dependence 
Muscarinic acetylcholine receptors couple to inhibition of adenylyl cyclase or 
stimulation of PI metabolism, depending on the receptor subtype being characterized. The 
m2/m4 subtype family couples to inhibition of adenylyl cyclase activity while the 
ml/m3/m5 subtypes couples to stimulation of PI metabolism. When expressed in Chinese 
hamster ovary cells, the pmt muscarinic acetylcholine receptor couples to both inhibition 
of adenylyl cyclase and stimulation of PI metabolism. Although it is unlikely that this 
occurs in normal tissue expressing pm2 AchR, it does illustrate that the receptor 
interaction with effector systems may be somewhat promiscuous. It is entirely possible 
that the m2 mAchR will preferentially interact with a specific subtype of Gi, but will also 
interact with other available G-proteins if receptor is in large excess. 176 
Furthermore, some of the properties reported for G-protein coupled receptors are 
specific only for the expression system selected. Different tissues expressing endogenous 
muscarinic receptors, as well as different exogenous expression systems often lead to 
different results. This emphasizes that the context in which these receptors are expressed 
is also an important consideration when studying G-protein coupled receptors. 
Summary 
Regulation of signal transduction is a complex cellular process. Co-evolution of 
signaling ligands, receptors and signal transduction machinery has resulted in an elegant 
system of precise responses. Studying G-protein coupled receptors in an exogenous 
expression system places them in a cellular environment that may or may not be 
appropriate. In order to accurately assess the functioning of these receptors in expression 
systems, many things must be considered. First, the context of expression is important. 
Studying G-protein coupled receptors expressed in a variety of cellular environments may 
be necessary to gain a clear understanding of the basic mechanisms underlying function. 
Second, the level of receptor expression must be considered when studying the interaction 
of receptors with other signal transduction machinery. Since the context of receptor 
expression is important, overexpression may lead to artifactual interactions between the 
receptor being studied and signal transduction components that are part of the appropriate 
context. If excess receptor results in altered interactions, studying the basic properties of 
receptor function will be difficult. Third, full characterization requires that more than one 
agonist is studied. This approach will reduce the likelihood that subtle differences in 
receptor function will be overlooked. Finally, more refined methods of experimentation 177 
and data analysis are required to uncover subtle interactions between components of a 
signal transduction system designed for precise interactions and cellular responses. 178 
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Introduction 
Model of receptor activation of G-proteins 
Muscarinic agonists mediate receptor-effector coupling through G-proteins. The 
effector system that specific muscarinic receptor subtypes couples to is determined by G-
protein interactions. While receptors of the ml/m3/m5 family interact with PTX 
insensitive G-proteins, the m2 AchRs appear to primarily interact with PTX sensitive Gi 
alpha subunits. This simplified view of receptor-G-protein specificity is clearly inadequate, 
and many other factors must be considered when studying G-protein activation 
(Gudermann et al., 1996). 
The guanine nucleotide binding proteins are heterotrimers comprised of a, (3 and y 
subunits. Agonist binding to a G-protein coupled receptor is thought to promote the 
exchange of bound GDP for GTP. The binding of GTP leads to an uncoupling of the 
receptor and the heterotrimeric G-protein, as well as dissociation of the heterotrimer into 
a and 13y subunits. Intrinsic GTPase activity converts GTP bound to the a subunit to 
GDP, which then reassociates with the 13y subunit (Simon et al., 1991). 
Principle steps in the activation process 
Activation of G-proteins requires that agonist binding leads to the appropriate 
receptor conformation. This conformational change is the activation signal that leads to 
changes in state of the heterotrimeric G-protein. In order to better characterize the steps 
following agonist binding, each of these principle steps in the activation process must be 191 
well characterized. This can be accomplished by characterizing the exchange of GDP and 
GTP using a variety of experimental approaches as well as agonist-promoted GTPase 
activity. 
Materials and Methods 
Materials 
Radioactive ligands ([3H] l -QNB, 52.3 Ci/mmol; [3H]NMS, 84 Ci/mmol; y32P-
GTP; 30 Ci/mmol; 35GTPYS,  1156 Ci/mmol) were purchased from New England Nuclear. 
N- methyl -3' -O- anthranoyl (MANT) GTP analog was synthesized as described (Remmers 
et al., 1994). Unlabeled agonist and antagonists were from Research Biochemicals 
International. Cell culture reagents were from GIBCO-Bethesda Research Laboratories or 
Sigma. 
Membrane preparation 
Cells were grown as described (Bulseco and Schimerlik, 1996), harvested and the 
pellet resuspended in two volumes of homogenization buffer (250 mM sucrose, 50 mM 
EDTA, 25 mM imidazole buffer, pH 7.4) containing benzamidine, soybean trypsin 
inhibitor, and pepstatin A at final concentrations of 1 mg/ml. The cell suspension was 
homogenized with a polytron homogenizer for 2x30 sec at 4°C and cell membranes were 
prepared by sucrose gradient centrifugation as previously described (Peterson and 
Schimerlik, 1984). In some cases, 5 mM sodium butyrate was added 24 hours before 
harvesting cells to further enhance receptor expression. Untreated and butyrate-treated 192 
cultures resulted in membrane preparations with specific activities of 20 to 300 pmol NMS 
sites/mg protein. 
Liciand binding 
All ligand binding experiments were conducted in buffer containing 100 mM NaC1, 
10 mM HEPES, 10 mM MgC12, 1 mM EDTA, 1 mM EGTA, pH 7.4 at 25°C by 
displacement of either [3H] / -QNB or [3H]NMS. Samples were filtered through glass 
fiber filters and washed with 3X 4 ml of ice cold 50 mM Na phosphate buffer pH 7.4. 
When [3H]NMS was used, the glass fiber filters were treated with 0.1% (w/v) PEI before 
use. Nonspecific binding was determined in the presence of 10-4 M / -hyoscyamine and 
was less than 10% of the total radiolabel bound. 
Assays for GTPase activity 
GTPase activity was examined in membranes prepared from both fresh and frozen 
CHO cells expressing wild-type mAchR at low (pSVE pm2 c1.5) and high (pSVE pm2 
short c1.1) expression levels as well as KDKKE(219-223)ELAAL and A212E mutant 
AchRs. Assays were conducted in 100 mM NaC1, 10 mM HEPES, 10 mM MgC12, 1 mM 
EDTA, 1 mM EGTA, 1 mM ATP, pH 7.4 at 30°C. Approximately 5 lig of total plasma 
membrane protein were used per data point. Reactions were initiated by addition of 
membrane to tubes containing buffer, saturating concentrations of agonist and 30 nM 
?2P -GTP (S.A. 30 Ci/mmol). Reactions were stopped by addition of ice cold 0.75 ml 
slurry of activated charcoal. The reaction tubes were stored on ice until ready for 193 
centrifugation. Tubes were centrifuged at top speed in an Eppendorf Microcentrifuge, and 
a 500 pi aliquot removed for Cerenkov counting. 
Kinetics of GTPYS binding 
Agonist-promoted 35GTPyS binding was examined in CHO cell membranes 
prepared from cells expressing wild-type (pSVE pm2 c1.5 and pKNEO pmt c1.1) pm2 
AchR. Assays were done in 100 mM NaC1, 50 nM GDP, 100 nM DTT, 10 mM HEPES, 
10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, pH 7.4 at 25°C. Membranes were 
equilibrated with saturating concentrations of carbachol, then assays initiated with the 
addition of 50 nM 35GTPyS (23.7 Ci/mmol). Aliquots were removed at specific time 
points and filtered through glass fiber filters. 
Kinetics of agonist-promoted MANT-GTP binding 
Kinetics of agonist-promoted MANT-GTP binding was studied in CHO cell 
membranes prepared from cells expressing wild-type receptors (pSVE pm2 c1.5 and 
pKNEO pm2 c1.1). Assays were conducted in 100 mM NaC1, 10 mM HEPES, 10 mM 
MgC12, 1 mM EDTA, 1 mM EGTA, pH 7.4 at 25°C using a Dionex Stopped Flow 
apparatus. Assays were initiated by combining membrane suspension in binding buffer 
with MANT-GTP at a final concentration of 0.1 mM. 
Data analysis 
GTPyS and MANT-GTP association kinetics were analyzed using least squares 
nonlinear curve fitting in Origin (MicroCal Software, Inc.) to Equation 1. Y is the 194 
association signal being measured, with y0 the background signal. Al is the signal 
amplitude; "C, the relaxation time; and x, time. 
y = y0 + Al *(1 - exp( -xh))  (Eq. 1) 
GTPase experiments were analyzed by determining the linear initial rate in the 
presence and absence of the agonist, carbachol. 
Results and Discussion 
Liciand binding 
Ligand binding properties were examined in normal binding buffer (10 mM 
HEPES, 10 mM MgC12, 1 mM EDTA, 1 mM EGTA, pH 7.4) supplemented with 100 mM 
NaC1, at 25°C. Independent experiments determined that 100 mM NaCl was required to 
be able to measure agonist-promoted G-protein activation in CHO cell membranes. Table 
A.1 summarizes the dissociation constants for agonists and antagonists of the pm2 AchR. 
Antagonist binding affinities were very similar to wild-type receptor membranes 
characterized in normal binding buffer. Agonist binding affinities were similar for 
carbachol, oxotremorine M and pilocarpine, but not acetylcholine. All of the agonist 
affinities were within 2 fold of wild-type receptor membranes characterized in normal 
binding buffer. Acetylcholine on the other hand displayed between 10 and 100 fold higher 
affinity for K1 and K2, and about 5 fold for K3. 195 
Table A.1: Dissociation constants for ligands in high salt buffer. 
Membranes were prepared from CHO cells expressing wild-type pm2 mAchR. 
Data are presented as the mean ± S.D. of n determinations. Carbachol, acetylcholine and 
oxotremorine M were best fit to three classes of binding sites while pilocarpine was best fit 
to two. 
Kl (nM)  K2 (nM)  K3 (PM)  n 
Carbachol  0.39 ± 0.15  71.0 ± 17  7.6 ± 2.8  2 
Acetylcholine  1.8 ± 1.6  137.6 ± 80.6  I  4.0 ± 1.3  4 
Oxotremorine M  2.2 ± 1.2  65.3 ± 23.3  2.8 ± 0.1  3 
Pilocarpine  2107 ± 1438  6.1 ± 0.4  3 
Kd (nM)  n 
NMS  0.38 ± 0.09  2 
1-QNB  0.017 ± 0.003  3 
/-Hyoscyamine  1.6 ± 0.3  2 
Pirenzipine  652 ± 28  2 196 
GTPase 
Agonist-promoted GTPase activity was studied in membranes prepared from CHO 
cells expressing between 5 pmol/mg and 35 pmol/mg m2 AchR. Figure A.1 shows 
carbachol promoted increase in GTPase activity. The initial rates were determined to be 
12.7 ± 27.0 for untreated membranes, and 300.0 ± 41.7 for membranes pre-incubated with 
carbachol. Figure A.2 shows the effect of different agonists on the production of 32P from 
32PyGTP. The reaction velocity is assumed to be linear over the time course of the 
experiment. Acetylcholine, carbachol and oxo M stimulated GTPase activity, while the 
hydrophilic antagonist NMS did not. Both of these results are in support of agonist-
mediated activation of G-proteins, and may be used to study the effects of mutant AchR 
on agonist-stimulated GTPase activity. 197 
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Figure A.1: Agonist-promoted GTPase activity for c1.5 wild-type pm2 AchR. 
GTPase experiments were conducted as described in "Materials and Methods". 
Membranes were equilibrated with 1 mM carbachol prior to addition of 32PyGTP to 
initiate reaction. The rates were estimated to be 12.7 ± 27.0 and 299.9 ± 41.7 for control 
and carbachol-treated cells. 198 
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Figure A.2: Agonist-stimulated GTPase activity of c1.5 wild-type pm2 AchR. 
GTPase activation was studied as described in "Materials and Methods". Data is 
presented as the mean ± S.D. from a single experiment done in duplicate. Membranes 
were equilibrated with agonists or the antagonist NMS prior to initiating the experiment 
with 32PyGTP. The reaction was allowed to proceed for 30 minutes.  The reaction 
velocity is assumed to be linear over this period of time. 199 
GTPyS 
Agonist-promoted association of GTP was studied using the non-hydrolyzable 
analog, 35GTPyS. Association kinetics were rapid, and difficult to characterize. Figure 
A.3 shows carbachol stimulated association of GTPyS in membranes with about 25 
pmolimg m2 mAchR. The relaxation times obtained by nonlinear curve fitting to equation 
1 were 36.9 ± 13.1 and 10.0 ± 1.6 sec-1 for control and carbachol-stimulated membranes 
respectively. The half time for this reaction was reduced from about 26 to 7 seconds by 
the agonist carbachol. Figure A.4 shows carbachol-stimulated association of GTPyS to 
membranes with a specific activity of about 7 pmoVmg m2 AchR. The observed 
relaxation times were 214 ± 37 and 44 ± 27 sec-1 for control and carbachol stimulated 
membranes respectively. It is not clear if the amplitudes observed in these experiments 
have any significance. Carbachol stimulation did not alter amplitude by more than about 2 
fold. 
The rapid association of GTPyS is not unexpected, since agonist-mediated 
activation of G-proteins are expected to occur rapidly. In order to follow the time course 
of these rapid events, we attempted to study MANT-GTP association to endogenous G-
proteins in CHO cell membranes using stopped-flow rapid kinetics fluorescence 
spectroscopy. 200 
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Figure A.3: 35GTPyS binding to c1.5 wild-type pm2 mAchR membranes 
GTPyS binding was conducted as described in "Materials and Methods". 
Membranes were equilibrated with carbachol before addition of 35GTPyS to initiate the 
reaction. The amplitudes were estimated to be 1054 ± 110 and 2120 ± 73 for control and 
carbachol treated cells, with relaxation times of 36.9 ± 13.1 and 10.0 ± 1.6 sec"' 
respectively. 201 
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Figure A.4: 35GTPyS binding to c1.1 wild-type pkneo pm2 mAchR membranes 
GTPyS binding was conducted as described in "Materials and Methods". 
Membranes were equilibrated with carbachol before addition of 35GTPyS to initiate the 
reaction. The amplitudes were estimated to be 867 ± 94 and 817 ± 205 for control and 
carbachol treated cells, with reciprocal relaxation times of 214 ± 37 and 44 ± 27 sec-1 
respectively. 202 
MANT-GTP binding 
The binding of the fluorescently labeled analog of GTP, MANT-GTP was followed 
using a stopped flow rapid kinetic fluorometer. These experiments were technically 
difficult, and large quantities of membranes were required to see small signal changes. 
Other problems associated with turbidity of the suspension used, as well as non-
homogenous distribution of membranes in this suspension led to many experiments with 
uninterpretable results. Figure A.5 shows one such experiment. Parameter estimation 
resulted in amplitudes of 0.036 ± 0.001 and 0.101 ± 0.001 for control and carbachol 
treated cells, with relaxation times of 34.3 ± 2.0 and 81.7 ± 2.5 msec respectively. This 
particular result was unexpected, and is not consistent with other results described in this 
appendix. The half time for association was actually increased by exposure to carbachol, 
from 24 to 56 msec, while amplitude was increased. It is likely that the data collected 
during these experiments will not yield any interpretable results. 203 
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Figure A.5: MANT-GTP association to c1.1 pkneo wild-type pm2 mAchR 
membranes. 
MANT-GTP binding was studied as described in "Materials and Methods". Data 
is from a single experiment, and is the average of 3 shots (12,288 data points) on the 
Dionex Stopped Flow apparatus. All data points were used in the data analysis, but only 
409 points used for plotting purposes. The amplitudes were estimated to be 0.036 ± 
0.001 and 0.101 ± 0.001 for control and carbachol treated cells, with relaxation times of 
34.3 ± 2.0 and 81.7 ± 2.5 msec respectively. 204 
Summary 
The ability to measure agonist-promoted interactions between receptor and G-
proteins will provide useful tools to assess the effects of receptor mutations. Questions 
regarding the affinity of liganded receptor for G-proteins, the specificity of these 
interactions and the efficiency with which agonist-bound receptors can activate G-proteins 
remains to be answered. Although the approaches described above allows one to begin to 
address these questions, they are inadequate. More refined methods for experimentation 
as well as data analysis are needed before these questions will be satisfactorily answered. 